



## CURRICULUM VITAE

Updated: 2024-10-02

### BIOGRAPHICAL DATA

Name: Man-Chiu POON(潘文釗)

Addresses:

Citizenship: Canadian

Office: University of Calgary  
Foothills Hospital  
1403 - 29th Street N.W.  
Calgary, Alberta, Canada. T2N 2T9

Mobile phone: +1 (403) 671-9185  
e-mail: mcpoon@ucalgary.ca

### PRESENT APPOINTMENTS

Professor Emeritus  
Departments of Medicine, Pediatrics, Oncology  
University of Calgary, Cumming School of Medicine  
Calgary, Alberta, Canada

University of Calgary Institute/Research Group Affiliations:  
Arnie Charbonneau Cancer Institute

Honorary Professor  
Institute of Hematology and Blood Diseases Hospital,  
Chinese Academy of Medical Sciences & Peking Union Medical College  
Tianjin, China

### ACADEMIC RECORD

M.D., 1968; University of British Columbia, Vancouver, British Columbia, Canada  
M.Sc. (Experimental Pathology), 1970; University of Toronto, Toronto, Ontario, Canada  
F.R.C.P.(C), 1973  
FACP, 1979

Secondary School: Queen Elizabeth School (1956-61)  
Hong Kong

Undergraduate: San Jose City College (1961-63)  
San Jose, California, U.S.A.  
  
San Francisco State College (1963-64)  
San Francisco, California, U.S.A.

Medical School: University of British Columbia (1964-68; M.D. 1968)  
Vancouver, British Columbia, Canada

Clinical Internship/Residency/Fellowship:

Junior rotating internship (1968-69)  
Royal Victoria Hospital

Montreal, Quebec, Canada

Resident in Internal Medicine (1970-72)  
Toronto Western Hospital  
Toronto, Ontario, Canada

Resident (Fellow) in Hematology (1972-74)  
University of Toronto Program  
Toronto, Ontario, Canada

Research Fellowship:

Research fellow (Medical Research Council of Canada, 1969-70)  
University of Toronto, Department of Pathology (M.Sc. 1970)  
Toronto, Ontario, Canada  
(Supervisor: Dr. Henry Z. Movat)

Centennial Research Fellow (Medical Research Council of Canada, 1974-76)  
Case Western Reserve University (Department of Medicine)  
Cleveland, Ohio, U.S.A.  
(Supervisor: Dr. Oscar D. Ratnoff)

Licensure:	Province of Alberta, Canada	(1983-present)
Boards:	Medical Council of Canada	(Licentiate, 1969)
	National Board of Medical Examiners	(Diplomate, 1969)
	Royal College of Physicians and Surgeons of Canada	
	Internal Medicine	(Certificant: 1973)
	Hematology	(Certificant: 1974)
	American Board of Internal Medicine	
	Internal Medicine	(Diplomate: 1974)
	Hematology	(Diplomate: 1974)
Medical Oncology	(Diplomate: 1975)	
American Board of Pathology		
Hematology	(Diplomate: 1979)	

**ACADEMIC APPOINTMENTS**

University of Alabama at Birmingham,  
Birmingham, Alabama U.S.A. (1976-1983)

1976-80: Assistant Professor of Medicine  
1979-83: Assistant Professor of Pathology  
1980-83: Associate Professor of Medicine  
1976-83: Chief, Hematology Service, and  
Chief, Coagulation Research,  
Veterans Administration Hospital

University of Calgary, Faculty of Medicine, Calgary, Alberta, Canada (1983-present)

1983-88: Associate Professor of Medicine  
1985-88: Associate Professor of Pediatrics  
1988-2015: Professor of Medicine  
1988-2015: Professor of Pediatrics  
1994-2015: Professor of Oncology

2015-2022: Clinical Professor, Departments of Medicine, Pediatrics and Oncology

2015- : Professor Emeritus, Departments of Medicine, Pediatrics and Oncology

1993-2001: Chief, Division of Hematology and Hematologic Malignancies  
Department of Medicine

1983-1997: Director, Coagulation Laboratories, Foothills Hospital

1987-1997: Chief, Division of Hematology, Department of Laboratory Medicine, Foothills Hospital

1987-2007: Director, Southern Alberta Hemophilia Clinic (Alberta Children's Hospital, Calgary Health Region)

2007-2019: Director, Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program (Foothills Medical Centre, Alberta Health Services)

University of Calgary Institute/Research Group Affiliations:

1983-2008: Immunology Research Group

2009-2014: Institute of Infection, Immunity and Inflammation /  
Snyder Institute of Chronic Diseases

2019- : Arnie Charbonneau Cancer Institute

Canadian Blood Services (formerly Canadian Red Cross Blood Transfusion Services. CRC-BTS), Calgary Centre, Alberta, Canada

1984 - 2005: Associate Medical Officer/Deputy Medical Director

Calgary Laboratory Services

2007 - 2019: Consultant (Special Coagulation, Molecular Hematology, Special Hematology)

Honorary Professorship

1998 - present: Honorary Professor: Tianjin Institute of Hematology, Peking Union Medical College  
and Chinese Academy of Medical Sciences, Tianjin, China

2005 - 2020: Honorary Professor: Department of Pathology, University of Hong Kong, Li Ka Shing Faculty of Medicine, Hong Kong, Special Administrative Region (SAR), China

Sabbatical Leave: at Tianjin Institute of Hematology, Tianjin, China

August 2005-July 2006

Project: promotion of hemophilia care, education and research in China

Sabbatical Leave: in Canada

Sept 2014 – Aug 2015.

Project - History of Hemophilia Care in Canada

AWARDS AND DISTINCTIONS

- Walter Stewart Baird Memorial Prize for M.D. Thesis (1968)  
University of British Columbia, Vancouver, B.C., Canada
- Elton Hoyt II Memorial Fund Award (1975)  
Citation: "for Distinction in Research by Residents/Fellows"  
University Hospital of Cleveland  
Case Western Reserve University  
Cleveland, Ohio, U.S.A.
- Distinguished Service Award (1982)  
Citation: "for valuable contributions of time and knowledge devoted to the improvement of patient care in Alabama"  
Medical Information Service via Telephone, University of Alabama Medical Center
- Dr. Cecil Harris Award (1993)  
Citation: "In recognition of distinguished contributions to the hemophilia community in the areas of research, care of patients, and personal service"  
Canadian Hemophilia Society  
Montreal, Canada
- Certificate of Excellence (1993)  
Citation: "In recognition of achievement in the subject area Recombinant DNA Technology; for outstanding performance and educational leadership"  
XIVth International Congress on Thrombosis and Hemostasis, New York
- Dedicated Service Award (1996)  
Citation: "In recognition of dedicated service"  
Heart and Stroke Foundation of Canada
- World Federation of Hemophilia Twinning Program (Calgary-Tianjin) (2000)  
Twin of the year 1999 Award – Citation: "for successful and impressive cooperation between the Division of Hematology in Foothills Hospital in the University of Calgary and the Institute of Hematology in Tianjin in promoting efficient hemophilia care and organization")
- Queen Elizabeth II Golden Jubilee Medal (2003)  
Citation: "For those persons who have made a significant contribution to Canada, to their community or to their fellow Canadians"  
[For hemophilia work]
- Nomination for Immigrant of Distinction Award 2003 (2003)  
Calgary Immigrant Aid Society
- World Federation of Hemophilia - Inga Marie Nilsson Award 2004 (2004)  
Citation: "In recognition of your commitment and effort in assisting the World Federation of Hemophilia in China, thus improving the lives of people with hemophilia worldwide"
- Guenter Distinguished Achievement Award – University of Calgary (2005)  
Citation: "For outstanding contributions in international health"
- Alberta Centennial Medallion Award with Certificate of Alberta Centennial Recognition – Province of Alberta, Canada (2005)  
Citation: "For outstanding work, achievements and volunteering efforts for

the people, communities and province of Alberta.’

- Nomination for University of Calgary President’s Internationalization Award (2007)
- Canadian Hemophilia Society International Contribution Award for year 2006 (2007)  
(For international hemophilia volunteer work)
- American Society of Hematology Distinguished Emeritus Member (2008)  
Voted by the Executive Committee  
Citation: “To recognize individuals whose exemplary service and efforts in the advancement of the field of hematology have significantly advanced the interests of the Society and the field, as a whole”
- World Federation of Hemophilia – 2008 International Healthcare Volunteer Award (2008)  
Citation: “To honor a volunteer healthcare professional who has contributed significantly to further the mission and goals of the WFH with an impact to global hemophilia care. This includes doctors, nurses, physiotherapists, psychologists, social workers, dentists, and other professionals who provide care and treatment for people with hemophilia”  
(For hemophilia volunteer work in China)
- The Dr. John Dawson Award for Clinical Excellence (2009)  
Department of Medicine, Foothills Hospital and University of Calgary  
Citation: “Nominations provided by members within the Department of Medicine, including resident physicians, for recognized clinical expertise, diagnostic acumen, great respect by colleagues, caring and empathy, and an individual who has served as a role model as a clinician.”
- Canadian Hemophilia Society, Calgary Chapter – volunteer recognition (2009)
- City of Calgary Friends of Canada Award (2009)  
Citation: “For efforts in promoting haemophilia care within Calgary, Canada and to the rest of the world”
- Department of Medicine – Division of Hematology and Hematologic Malignancies (2010)  
University of Calgary and Alberta Health Services – recognition for mentorship
- Hong Kong Haemophilia Society Certificate of Appreciation (2010)
- Canadian Hemophilia Society Alberta Chapter - Southern Alberta Region (2011)  
2010 - Lifetime Achievement Award.  
Citation: “In grateful recognition of your enduring compassion, caring & support of our community”
- Queen Elizabeth School, Hong Kong (2014)  
Citation: Alumni with Outstanding Achievements in Science and Technology
- Department of Medicine Mentorship Excellence Award (for 2013-2015) (2015)  
Department of Medicine, University of Calgary
- Foothills Hospital Medical Staff Association Service Recognition Award (2016)
- Canadian Academy of Medical Sciences, elected fellow (2024)

Listed as “Top 2% Scientist in the World”, Stanford University database (science-wide author databases of standardized citation indicators””, Elsevier Data Repository);

- Listed in each of Versions 1 – 6 (published serially 2019 – 2023)  
[Version 6: Ioannidis, John P.A. (2023), “October 2023 data-update for "Updated science-wide author databases of standardized citation indicators””, Elsevier Data Repository, V6, doi: 10.17632/btchxktzyw.6] URL: <https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/6>

#### HONORARY AND VISITING PROFESSORSHIP/HONOARY APPOINTMENTS

Honorary Professorship: Tianjin Institute of Hematology, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China	(1998-present)
Honorary Professorship: Department of Pathology, University of Hong Kong, Li Ka Shing Faculty of Medicine, Hong Kong, Special Administrative Region (SAR), China	(2005-2020)
Visiting Professorship: Institute of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.	(2005 December and 2018 December)
Visiting Professorship: Anhui Provincial Hospital, Hefei, Anhui, China	(2006 March/April)
Visiting Professorship: Peking Union Medical College Hospital, Beijing, China	(2007 – 2010)
Honorary Senior Advisor, Hemophilia Program, Nanfang Hospital, Southern Medical University/the First Military University, Guangzhou, China	(2000 – present)

TEACHING AWARDS (for Undergraduate Medical Education):	Award Year
Gold Star Letter Award for Excellence in Teaching (Blood Course) University of Calgary -- M.D. Class of 1996	1993
Gold Star Letter Award for Excellence in Teaching (Blood Course) University of Calgary -- M.D. Class of 1997	1994
Gold Star Letter Award for Excellence in Teaching (Blood Course) University of Calgary -- M.D. Class of 1998	1995
Gold Star Letter Award for Excellence in Teaching (Blood Course) University of Calgary -- M.D. Class of 1999	1996
Gold Star Letter Awards for Excellence in Teaching (Blood Course, Lectures) University of Calgary -- M.D. Class of 2000	1997
Gold Star Letter Awards for Excellence in Teaching (Blood Course, Small Group Teaching) University of Calgary -- M.D. Class of 2000	1997
Associate Dean’s Letter for Teaching Excellence in Undergraduate Curriculum (Blood Course) University of Calgary – M.D. Class of 2000	1997
Gold Star Letter Award for Excellence in Teaching (Blood Course, Lectures) University of Calgary -- M.D. Class of 2001	1998
Gold Star Letter Award for Excellence in Teaching (Blood Course, Lectures) University of Calgary – M.D. Class of 2002	1999
Gold Star Letter Award for Excellence in Teaching (Blood Course, Lectures) University of Calgary – M.D. Class of 2003	2000
Gold Star Letter Award for Excellence in Teaching (Blood Course, Lectures) University of Calgary – M.D. Class of 2004	2001
CMSA letter of Excellence in Teaching (Blood Course, Small Group Teaching) University of Calgary – M.D. Class of 2004	2001
Gold Star Letter Award for Excellence in Teaching (Blood Course, Lectures) University of Calgary – M.D. Class of 2005	2002

CMSA letter of Excellence in Teaching (Blood Course, Lectures) University of Calgary – M.D. Class of 2006	2003
CMSA letter of Excellence in Teaching (Blood Course, Lectures) University of Calgary – M.D. Class of 2007	2004
Associate Dean’s letter of Excellence in Teaching (Blood Course) University of Calgary – M.D. Class of 2013	2011
Assistant Dean’s Letter of Commendation in Teaching (Silver Award, Blood Course) University of Calgary – M.D. Class of 2013	2011
Assistant Dean’s Letter of Commendation in Teaching (Silver Award, Blood Course) University of Calgary – M.D. Class of 2014	2012
Assistant Dean’s Letter of Commendation in Teaching (Silver Award, Blood Course) University of Calgary – M.D. Class of 2015	2013
Hellbender Honour Roll for excellent teaching in lectures, small group and bedside setting (Blood Course) University of Calgary – M.D. Class of 2014	2013
Assistant Dean’s Letter of Commendation in Teaching (Silver Award, Blood Course) University of Calgary – M.D. Class of 2016	2014
Honour Roll for excellent teaching in lectures, small group and bedside setting (Blood Course) University of Calgary – M.D. Class of 2016	2015
Associate Dean’s letter of Excellence for Clinical Core Teaching (Blood Course) University of Calgary – M.D. Class of 2018	2016
Assistant Dean’s Letter of Commendation in Teaching (bronze Award, Blood Course) University of Calgary – M.D. Class of 2018	2016
Honour Roll for excellent in Teaching (Blood Course) University of Calgary Cuming School of Medicine	2017
Associate Dean’s Letter of Excellence for Clinical Core Teaching (Blood Course) University of Calgary – M.D. Class of 2019	2017
Assistant Dean’s Letter of Commendation in Teaching (silver Award, Blood Course) University of Calgary – M.D. Class of 2019	2017
Associate Dean’s Letter of Excellence for Clinical Core Teaching (Blood Course) University of Calgary – M.D. Class of 2020	2018
Assistant Dean’s Letter of Commendation in Teaching (Bronze Award, Blood Course) University of Calgary – M.D. Class of 2020	2018
Assistant Dean’s Letter of Commendation in Teaching (silver Award, Blood Course) University of Calgary – M.D. Class of 2021	2019
Assistant Dean’s Letter of Commendation in Teaching (silver Award, Blood Course) University of Calgary – M.D. Class of 2022	2020
Associate Dean’s Letter of Excellence for Clinical Core Teaching (Blood Course). University of Calgary – M.D. Class of 2022	2020
Associate Dean’s Letter of Excellence for Small Group Teaching (Blood Course) University of Calgary – M.D. Class of 2023	2021
Assistant Dean’s Letter of Commendation in Teaching (Bronze Award, Blood Course) University of Calgary – M.D. Class of 2023	2021
Associate Dean’s Letter of Excellence for Clinical Core Teaching (Blood Course). University of Calgary – M.D. Class of 2024	2022
Associate Dean’s Letter of Commendation in Teaching (Bronze Award, Blood Course) University of Calgary – M.D. Class of 2024	2022
Associate Dean’s Letter of Commendation in Teaching (Silver Award) University of Calgary – M.D. Classes of 2024 and 2025	2023
Associate Dean’s Letter of Commendation in Teaching (Silver Award) University of Calgary – M.D. Classes of 2025 and 2026	2024

## EDUCATIONAL (TEACHING) ACTIVITIES (1983-present)

### Undergraduate Medical Education

#### Medicine 308 (Blood Course)

- Member, Curriculum Committee (1984-2011)
- Manager, Easy Bruising, and Bleeding Unit (1984-2014)
- Manager, Venous Thrombosis and Hypercoagulable State Unit (1984-2014)

#### Medicine 340/440 (1st and 2nd year medical students research supervision)

- Bobby Jain (1993-1995): Antithrombin III, protein C, protein S deficiency and activated protein C resistance: a retrospective review of Foothills Hospital experience. (Canadian Hematology Society award for abstract presentation at the Royal College Meeting – 1995)
- Leslie Shuman (1997-1999); Incidence of HLA antibody formation by bone marrow transplant patients) (Canadian Hematology Society Award for abstract presentation at the Royal College of Physicians Meeting – 1999)
- Julie Jarand (1998-2000); Lupus-type inhibitor: relationship with clinical indications and aPTT) (Canadian Hematology Society award for abstract presentation at the International Society of Hematology Meeting – 2000)
- Anthony Wong (2015-2017): von Willebrand disease: our current practice is to provide no hemostatic coverage for delivery if clotting factors at the third trimester is 50% or higher – is this practice safe? (QI/QA project) (Presented at the Association of Hemophilia Clinic Directors of Canada meeting – 2017)

#### Medicine 340 (Research Method and Evidence Based Medicine) supervisor

- Yen Ling Chong (2001-2)
- Ron Robins (2001-2)

#### Medicine 440 (AEBM – Applied Evidence-Based Medicine) supervisor

- Anthony Wong (2015-17)

#### Faculty Advisor [Undergraduate Medical Education] for

- Alandra Quayle [class of 2002] (1999-2002)
- Min Yi Ngae [class of 2005] (2002-2005)

#### Career Exploration Program Coach for

- Daniel Ghods-Esfahani [class of 2022] (2019)
- Nadia Narendan [class of 2023] (2020 & 2021)

#### Member, International Health Exchange Student Electives Committee (1999-2009)

#### Member, Students Academic Review Committee (2007-2012)

### Graduate Course

- MDSC 641.02 Immunologic basis of disease
- MDSC 639.04 Immunopathogenesis of Disease
- MDSC 755-1 “Procoagulant Membrane Dynamics Study – A Novel Laboratory Analysis to Examine Thrombosis in Health and Disease” Directed study course for Lisa Yamaura, PhD candidate (Spring, 2021)

### Post-doctoral Associate Supervision



Fedir Rasumenko, PhD

O'Brien Institute and Charbonneau Scholar

Department of Community Health Sciences and Department of History

Research Topic

Cancer Clinical Trials in Canada and the Ethics of Human Dignity Framework, 1971-1998

Funding

2019-2020

O'Brien Institute of Community Health Scholarship

Arnie Charbonneau Cancer Institute Scholarship

2020-2021

Associated Medical Services Postdoctoral Fellowship in the History of Medicine and Health Care

Graduate Student Co-supervision:

Barbara M. Fraser (M.Sc. 1990, principal supervisor : Dr. David Hoar)

Michael Motyer (M.Sc. 2002, principal supervisor : Dr. Kenneth Wong)

Hemophilia/Hemostasis subspecialty Fellowship (Clinical and Research) Supervision

Shannon Jackson (2007-2009, supported by Bayer International Hemophilia Award, US\$140,000)

Dawn Goodyear (2010-2012, supported by Bayer International Hemophilia Award, US\$180,000)

Adrienne Lee (2012-2014, supported by Bayer International Hemophilia Award, US\$160,000)

Hematology Residency/Fellowship Training Program

Director of Program (1990-1993)

Member of Committee (1983-2022)

Coordinator of Research (2008-2022)

(Participated in mentoring of many residents and hematology fellows not necessarily listed in this CV over the years)

Hematology Residents/Fellows Research mentoring

Shannon Jackson (2004-2007)

Topic: Effect of H. pylori eradication therapy on ITP

Adrienne Lee (2010-2012)

Topic: In vivo assessment of bone microarchitecture using HR-pQCT in hemophilia patients: Insight into etiology of decreased BMD in this patient population

Deepa Suryanarayan (2012-2014) [co-mentor with Dr. Dawn Goodyear]

Topic: DDAVP and cardiovascular outcomes in patients with bleeding disorders undergoing invasive procedures

Leslie Skeith (2013-2015)

Topic: Pregnancy complications in von Willebrand disease

Gwynivere Davies (2014-2017) [co-mentoring with Dr. Dawn Goodyear]

Topic: Attitudes toward Prenatal Diagnosis and Pregnancy Management in Carriers of Hemophilia: A Qualitative Analysis exploring the views of Carriers in Southern Alberta

Ellen Cusano (2021- 2024) [co-mentoring with Dr. Dawn Goodyear]

Topic: Clinical and economic outcome analysis of rituximab-based immunosuppression as first-line inhibitor eradication in acquired hemophilia A

Department of Internal Medicine Resident Research Mentoring

Nicole Schneider-MacRae (2008-2012)

Topic: Thrombophilia screening practices in the community: an impact assessment for family physicians in the Calgary Health Region (CHR)

Archana Vijay (2015-2018)

Topic: Comparison of hemophilia care in a developed and developing country

Priya Chandrakumaran (2020- )

Topic: Desmopressin in von Willebrand disease: Test-response and clinical outcomes in a single Canadian centre

Summer Student Research Supervision

Kwai-Shan Chow:	1986 (Alberta Heritage Foundation of Medical Research [AHFMR] Summer Studentship Award)
Winnie Low:	1987
Ken Kuhn:	1989
Tracy Wong:	1993
	1994- (Canadian Hemophilia Society Summer Studentship Award)
	1995
Jaswinda Kaur:	1994
Diane Angela Yee:	1995
June Ma:	1997
	1998 (Canadian Hemophilia Society Summer Studentship)
	2000
	2001 (The Chamberlain-Heaslip Summer Scholarship Award, University of Toronto Faculty of Medicine)
Amy Yoo:	1999
	2000 (Canadian Hemophilia Society Summer Studentship Award)

International Scholars preceptorship – hematology (most for hemophilia care and implementation of multidisciplinary comprehensive care) \*non-hemophilia related

Ms. Boxia MA	September/October 1998
	Nurse, Institute of Hematology and Blood Diseases Hospital, Tianjin, China) (sponsored by Lilly)
Dr. Tiejun QIN	April/May 1999
	Hematologist, Institute of Hematology and Blood Diseases Hospital, Tianjin, China) (sponsored by the World Federation of Hemophilia Fellowship)
Dr. Ruifeng ZHOU	January-March, 2000
	Hematologist, Institute of Hematology and Blood Diseases Hospital, Tianjin, China (sponsored by the World Federation of Hemophilia Fellowship)
Dr. Lixia CHEN	April/May 2003
	Physiatrist, Peking Union Medical College Hospital, Beijing, China (sponsored by the World Federation of Hemophilia Fellowship)
*Dr. Linhua YANG	March-August 2004
	Hematologist, Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China (Senior scholar sponsored by Chinese National Exchange Scholarship Program, China)
*Dr. Zhaoxia DUAN	October 2006 – September 2007 [for research training]
	Hematologist, People’s Hospital of Shanxi Province, Shanxi Medical University, Taiyuan, Shanxi Province, China (sponsored by Shanxi Provincial Exchange Scholarship Program, China)
*Dr. Yun LI	November 2007 – April 2008 [for hematologic malignancy care]
	Hematologist, Daqing Oilfield Hospital, Daqing, Heilongjiang Province, China (sponsored by Daqing Oilfield Hospital, Daqing, China)
Dr. Runhui WU	March 9-13, 2009
	Pediatric Hematologist, Beijing Children’s Hospital, Beijing, China (sponsored by World Federation of Hemophilia Short-term Fellowship)
Ms. Crystal Yun FENG	November 18-December 26, 2010
	Hemophilia Nurse Coordinator, Institute of Hematology, Union Hospital and Hubei Treatment and Diagnosis Center of Hemophilia, Tonji Medical College, Huazhong University of Science and technology, Wuhan, China (sponsored by World Federation of Hemophilia – Bayer Nursing Fellowship)
Ms. Kuixing (Jessica) LI	August 17, 2012-January 30, 2013

- Hemophilia Nurse Coordinator, Peking Union Medical College Hospital Hemophilia Center  
Beijing, China  
(sponsored by Novo Nordisk Haemophilia Foundation International Fellowship)
- Dr. Yunhai FANG July 15 – 26, 2013  
Hematologist, Shangdong Blood Center, Jinan, Shandong Province, China  
(sponsored by the Peking Union Medical Foundation, China)
- Dr. Guo AI July 15 – 26, 2013  
Hematologist, Qinghai Provincial People's Hospital, Xining, Qinghai Province, China  
(sponsored by the Peking Union Medical Foundation, China)
- Dr. Huacong CAI Sept 9-25, 2013  
Hematologist, Peking Union Medical College Hospital, Beijing, China  
(sponsored by the Peking Union Medical Foundation, China)
- Dr. Yanhui LIU Sept 10-25, 2013  
Hematologist, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China  
(sponsored by the Peking Union Medical Foundation, China)
- Ms. Ho Ki (Cendy) SUM March 10-21, 2014  
Hemophilia Nurse coordinator, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China  
(sponsored by Pamela Youde Nethersole Eastern Hospital, Hong Kong Health Authority, Hong Kong)
- Dr. Jian JIANG Nov 8-21, 2014  
Hematologist, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China  
(sponsored by the Peking Union Medical Foundation, China)
- Dr. Ying SUN Nov 8-21, 2014  
Hematologist, Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Liaoning Province, China  
(sponsored by the Peking Union Medical Foundation, China)
- Dr. Changgang LI January 8-23, 2015  
Professor and Head, Hematology/Oncology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China  
(sponsored by educational grant, CSL-Behring Canada)
- Dr. Hongxia YAO January 8-23, 2015  
Director of Hematology, Hainan Provincial People's Hospital, Hainan Province, China.  
(sponsored by educational grant, CSL-Behring Canada)
- Dr. Shih-Chiang LIN Jun 8-19, 2015  
Director, Hematology/Oncology, Far Eastern Memorial Hospital, New Taipei City, Taiwan  
(supported by Novo Nordisk Taiwan)
- Dr. Yongjun FANG Nov 24-Dec 4, 2015  
Associate Professor and Director, Department of Hematology & Oncology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China PR  
(sponsored by the Peking Union Medical Foundation, China)
- Dr. Mei ZHANG Nov 24-Dec 4, 2015  
Professor and Director, Department of Hematology. The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China  
(sponsored by the Peking Union Medical Foundation, China)
- Dr. Zhongjin XU Dec 4-Dec 18, 2015  
Jiangxi Children's Hospital. Nanchang City. Jiangxi Province, China  
(sponsored by the Peking Union Medical Foundation, China)
- Dr. Zhenyu YAN Dec 4-Dec 23, 2015  
Hematology Department, Affiliated Hospital of North China University of Science & Technology, Tangshan City, Hebei Province, China  
(sponsored by the Peking Union Medical Foundation, China)
- Dr. Vijayakumar Narayana Pillai, July 4 – August 29, 2016  
Director Aluva Hemophilia Clinic and Medical Officer in Charge, Regional Blood Transfusion Centre and Regional Dialysis Centre, District Hospital, Aluva, Kerala, India
- Dr. Baolai HUA Sept 10-Sept 25, 2016  
Hematology Department, Peking Union Medical College Hospital, Beijing China

- (sponsored by educational grant, CSL-Behring Canada)  
Dr. Jian GU Sept 10-Sept 25, 2016  
Professor and Director, Yangzhou Institute of Hematology, Northern Jiangsu People's Hospital, Yangzhou, China
- (sponsored by educational grant, CSL-Behring Canada)  
Dr. Shujie WANG Sept 17-Sept 28, 2018  
Professor and Director, Adult Hemophilia Center of the Peking Union Medical College Hospital, Beijing, China
- (sponsored by educational grant, CSL-Behring Canada)  
Dr. Juan XIAO Sept 17-Sept 28, 2018  
Professor and Director, Pediatric Hemophilia Center of the Peking Union Medical College Hospital, Beijing, China
- (sponsored by educational grant, CSL-Behring Canada)

For official exchange we also send our staff and trainees for 2-week observership at the Peking Union Medical College Hospital Hemophilia Treatment Centre.

Calgary exchange observers (all sponsored by educational grant, CSL-Behring Canada) include:

- Dr. Adrienne Lee (hematology fellow/then staff) 2012
  - She was then also supported by the World Federation of Hemophilia (WFH) as WFH volunteer in the promotion of hemophilia care in China, visiting various Chinese centers yearly 2012-2016
- Dr. Oksana Prokopchuk-Gauk (hematology resident/fellow) Nov 2013
- Dr. Natalia Rydz (hematology staff), Feb 2015
- Dr. Leslie Skeith (hematology resident/fellow) Feb 2015
- Dr. Dawn Goodyear (hematology staff) March 2017
- Dr. Ninada Ganta (hematology resident/fellow) March 2017

#### DIVISION OF HEMATOLOGY AND HEMATOLOGIC MALIGNANCIES MENTORSHIP PROGRAM (established 2009)

##### Hematology Faculty – mentee

Dr. Farzana Sayani	2009-2012
Dr. Dawn Goodyear	2012-2019
Dr. Natalia Rydz	2013-2019
Dr. Adrienne Lee	2014-2019

#### ADMINISTRATIVE RESPONSIBILITIES

##### Faculty of Medicine and Department of Medicine, University of Calgary

- Member, Acquired Immune Deficiency Syndrome (AIDS) Committee (1983-1987)
- Member, Ad Hoc Committee for Hematology/Oncology Division Head Review (1987)
- Member, Executive Committee, Department of Medicine (1993-2001)
- Member, Ad Hoc Committee for Alberta Cancer Board, Tom Baker Cancer Center Medical Oncology Department Head Review (1995)
- Member, Search Committee for Head, Division of Hematology & Hematologic Malignancies, Department of Medicine (2003-2005)
- Member, Division of Hematology & Hematologic Malignancies Research Committee (2006-2019)
- Member, Division of Hematology & Hematologic Malignancies – Non-Malignant Hematology Clinical Advisory Committee (2006-2019)
- Member, Division of Hematology & Hematologic Malignancies – Search and Selection Committee (2008-2019, 2021)
- Member, Division of Hematology & Hematologic Malignancies – Thrombosis Program Advisory Committee (2009-2015)

Member, Department of Medicine Anti-racism taskforce (2020-2023)

Calgary Health Region/Alberta Health Services

Member, Executive Council, Regional Department of Medicine (1997-2001)  
Member, Laboratory Coordinating Committee, Foothills Hospital (1987-1995)  
Chairman, Flow Cytometry Users Subcommittee (1988-1993)  
Chairman, Molecular Diagnostic Subcommittee (1992)  
Member, Bone Marrow Transplantation Review Committee (1984-2001)  
Member, Ad Hoc Committee for Pediatric Bone Marrow Transplantation Review (1990)  
Member, Ad Hoc Committee for Anticoagulant Review, Foothills Hospital (1986-1989)  
Member, Blood Utilization Committee, Alberta Children's Hospital (1992-1995)

Alberta Provincial Health

Member, Alberta Provincial Molecular Diagnostic Committee. (1995)  
Member, Provincial Blood Co-ordinating Program Advisory Committee (2016-2018)  
Member, Alberta Blood Operational Collaborative Committee (ABOC) (2018-2022)

Canadian Red Cross Society Blood Services, Calgary Centre

Member, Management Committee (1984-1998)  
Chairman, Library Committee (1989-1998)

Calgary Laboratory Services

Member, Research and Development Steering Committee (1997-2003)  
Member, Liaison Committee for Hematopathology Services in Calgary Health Region (2008-2019)

University of Alabama in Birmingham

Member, Graduate Program Advisory Committee for Blood Bank Specialist (SBB) Education Program, Department of Pathology and School of Allied Health Sciences (1981-1983)

PROFESSIONAL ACTIVITIES

Membership in professional and learned societies

Fellow, Royal College of Physicians of Canada  
Fellow, American College of Physicians  
(Senior active member as of 2008)  
Fellow, International Society of Hematology  
(Councilor 1998-2012) (retired)

Life Member, World Federation of Hemophilia  
Life Member, Society of Chinese Bioscientists in America

Distinguished Emeritus Member (conferred), American Society of Hematology, 2008-present  
(regular member 1974-2008)

Member, International Society on Thrombosis and Haemostasis  
Member, Canadian Medical Association (and Alberta Medical Association)  
Member, Canadian Hemophilia Clinic Directors Group (CHCDG) (transitioned to AHCDC 1994)  
(Secretary 1988-90, Founding member 1988)  
Member, Association of Hemophilia Clinic Directors of Canada (AHCDC)  
(President 1997-1999, Founding member 1994; Vice President 1994-1997)

Full member 1994-2002, Associate member 2022-present)  
Member, Canadian Hematology Society  
(President 1998-2000, Vice President 1996-1998) (Emeritus member as of 2016)  
Member, Chinese Medical Society of Calgary  
(President 1989-1990, Founding member 1988; Board of Directors, 2002-2012)  
Member, Hemophilia & Thrombosis Research Society of North America  
(Member, Board of Directors, 2000-2002) (Emeritus member as of 2008)  
Member, Central Society for Clinical Research (Emeritus member as of 2008)

Member, American Heart Association (Council on Thrombosis) (retired)  
Member, American Association for the Advancement of Sciences (retired)  
Member, British Society for Haematology (retired)  
Member, International Society of Blood Transfusion (retired)  
Member, Canadian Society for Clinical Investigation (retired)

#### Professional services

##### Grant panels

Canadian Hemophilia Society (1990)  
Canadian Heart and Stroke Foundation  
Committee VI (1993, 1994), Committee VII (1995)  
Canadian Medical Research Council (invited member- Experimental Medicine) (1994)  
Calgary Laboratory Services Research Fund (2003)

##### Editorships

International Monitor on Hemophilia (Review Editor, 1996-2018)  
Clinical and Applied Thrombosis/Hemostasis (Senior Editor, 2009-2015)  
Haemophilia Forum (Member, Editorial Board, 1999-2008)  
Psychosocial Issues in Hemophilia: A Canadian Bulletin (Co-editor, 1987-90)

##### Reviewer

Ad Hoc Reviewer for various medical/scientific journals

Reviewer For "Hematology section, Calgary Guide to Understanding Disease (Blue Book)  
[www.thecalgaryguide.com](http://www.thecalgaryguide.com) " edited by University of Calgary Medical students (2012-  
present)

Ad Hoc grant reviewer:

CIHR  
Heart and Stroke Foundation of Canada  
Canadian Hemophilia Society  
Association of Hemophilia Clinic Directors of Canada  
Hong Kong Research Foundation  
the French National Research Agency  
P.S.I Foundation  
University of Calgary (Scientific Merit Review Panel, Division of Hematology and  
Hematologic Malignancies)

#### International Hemophilia Care Promotion Activities

1. China – promotion of hemophilia care, education and research (1993- present)



Adobe Acrobat  
Document

For background information:  
*Haemophilia* 2008;14:879-888 **PMID: 18637966**



Adobe Acrobat  
Document

For recent achievement information:  
*Blood Advances* 2019;3(suppl 1):34-37 **PMID 32666580**



Adobe Acrobat  
Document

*Haemophilia* 2020;26(3):759-67 **PMID 32666580**

- a. 1993-1997 consultation and education activities with Tianjin Institute of Hematology and Blood Diseases Hospital
- b. World Federation of Hemophilia (WFH) center twinning activities
  - a. Calgary with Tianjin Institute of Hematology (1997-2004)
  - b. Calgary/Ottawa (with Dr. Brian Luke) with Shanghai Ruijin Hospital (2002-2007)
  - c. Introduced Ottawa to twin with Guangzhou Nanfang Hospital (2000-2006)

*Emphasis: collaboration between the twins – all projects were developed for participation for all three twins with benefits for all three*

- c. Helped formation of HTCCNC (Hemophilia Treatment Center Collaborative Network of China) initially with 6 core centers (Tianjin, Beijing, Shanghai, Guangzhou, Hefei, Jinan) 2004
  - a. Establish WFH Hemophilia Training Center for China (2010) the 6 core centers collectively became the Training Center
    1. To train hematologist, nurses, physiotherapist, laboratory scientists – using the train-the-trainer model
    2. Each core center developed its outreach care/education network

*Emphasis again was collaboration for participation of the 6 core-centers and other clinics joining HTCCNC – emphasis was benefits for all.*

- b. Established 5 working groups (registry, nursing, physiotherapy, laboratory diagnosis, pediatrics) each developed collaborative projects.
- c. Education meetings: HTCCNC has biannual national education meetings; and annual education meetings for nurses, psychiatrists/physiotherapists, and pediatrics
- d. Volunteer consultant for WFH projects to increase diagnosis, infrastructure/treatment center and patient engagement, helped patient organization development and education in China (since 2000)
- e. Over the year, helped the WFH to develop these programs in China to further hemophilia care in China
  - a. WFH country program (2002)
  - b. Pre-GAP (Global Alliance for Progress) (2007-2009)
  - c. GAP program (2009-2013)
  - d. GAP II program (2016-2019)
  - e. Post GAP country program (2019-2022)
  - f. Upcoming PACT (Path to Access to Care and Treatment) Program (2022-2025)  
(additional activities planned in this program:
    - i. development of collaborative 3-tier care clinics [a) basic care clinic, b) diagnosis/management clinic, c) multidiscipline comprehensive care clinic],

ii. clinic accreditation

*Emphasis was on collaboration between the core centers, working groups and other participating new centers while each center developed its strengths and expertise*

- f. Developed Canada (Toronto Hospital for Sick kids, Ottawa, Calgary)-China collaborative projects on joint health, quality of life instruments, individualized prophylaxis trial
- g. Volunteer consultant (2006-2008) for Novo Nordisk Haemophilia Foundation (NNHF) China Program to initiate projects in China (2006) and to assist in Strategic planning (NNHF and the 6 core centers of HTCCNC) (2017).
- h. Developed exchange observership between Calgary and Chinese centers
  - a. Calgary hosted observership/preceptorship to 24 hematologists, 1 physiatrist and 4 nurses from China (see section on International Mentoring p10-12
  - b. Calgary also sent 6 hematologists to Beijing clinic for observership (see page 12) to encourage participation in international health initiatives
- i. Major achievement (see embed pdf articles at beginning of this section) Outcomes
  - a. Improved insurance coverage for treatment products through collaborative advocacy of clinics with patient groups – insurance from local governments. Coverage currently varied (50%-95% coverage depending on the local economy).
  - b. Capacity building - Growth:
    - 1 clinic in 1993
    - 6 centers in 2004
    - 19 centers in 2009
    - 50 centers in 2015
    - 120 centers in 2019
    - 315 centers in 2023 (315 centers of various capacities, at least one in each province, including Tibet)
  - c. Multidisciplinary comprehensive care centers developed in major cities
    - i. Management guidelines (consensus medical guidelines, including nursing, physio/exercise manuals) in place
    - ii. Center accreditation/certification ongoing to ensure standards of care
    - iii. Development of 3-tier clinics system planned to bring hemophilia care to patients in all parts of China including the more underdeveloped and rural areas
  - d. Improved diagnosis. Reference laboratories (Tianjin, Beijing, Shanghai) and external quality assurance program established
  - e. Improved management:
    - i. Popularization of affordable/beneficial low-dose prophylaxis for children and adults; individualized prophylaxis being developed; protocols for the management of inhibitor patients under development
    - ii. Changed physiotherapy concept from being contraindicated in hemophilia (prior to 2004) to being an essential component of hemophilia care; also promotion of exercise for hemophilia patients
  - f. Academic achievement of Chinese hemophilia healthcare professionals and recognition–
    - i. Government now regularly consulted HTCCNC on hemophilia/bleeding disorders issues
    - ii. participation in clinical, basic and translational investigations as well as hemophilia related clinical trials, participation in international learned societies and conferences. Notable accomplishments include (but not limited to) (a) demonstration of benefits of low-dose factor prophylaxis now practiced, now recommended by the WFH, not only in China, but also in



- many other countries with economic constraint, (b) development of hemophilia B gene therapy with use of prophylactic corticosteroid to prevent liver enzyme surge that could result in the loss of transgene expression (Lancet Hematology 2022), (c) randomized clinical trial to show single dose rituximab+steroid was non-inferior to cyclophosphamide+steroid for acquired hemophilia A with potential to decrease infection morbidity/mortality risk of inhibitor-eradication immunosuppressive therapy (Am J Hematol 2023) (d) efficacy of low-dose immune-tolerance induction therapy for factor VIII inhibitor.
- iii. The improvement in hemophilia care has also inspired the Chinese manufacturers/investors to develop and manufacture recombinant factors VIII and IX for Chinese patients and for patients elsewhere
  - iv. I continue to help a number of students from the Beijing Children's Hospital and the Tianjin Institute of Hematology to help with their research activity, data analysis and manuscript development
- g. **THE CURRENT PHASE (2022-2025):** helping to implement the WFH-PACT (Path to Access to Care and Treatment) Program; with the following planned initiatives to further promote/modernize hemophilia care to all Chinese patients in all regions of China.
- i. Development of a collaborative/consultative network of a 3-tiers-care clinics system
    1. Tier-1, Hemophilia Treatment Centers: basic care clinics (with at least 20 patients) in rural/economically disadvantaged areas,
    2. Tier-2, Hemophilia Diagnostic and Management Centers: Diagnosis/Management Centers (with at least 100 patients) in urban areas
    3. Tier-3, Hemophilia Comprehensive Care Centers: multidiscipline comprehensive care clinics in major cities (with at least 500 patients).Each clinic is to be developed based on local economy and expertise available and each will become a member of the collaborative consultative HTCCNC network (*collaboration between all clinics of all levels is emphasized*).  
Aims: to bring basic hemophilia care to all parts of China, including the rural/economically disadvantaged areas. Clinics in the underserved area will be supported by more advanced care centers within the HTCCNC network.
  - ii. Accreditation of clinics within the 3-tiers clinic system to maintain the standards of hemophilia care throughout the country (planned ~140 accredited by 2025)
  - iii. They also strives to reach the required WFH metrics by 2025 of new patient diagnosis (aim: ~5000), new training (using the train-to trainer model) of nurses (~100), lab scientists (~ 50) and physiotherapist-musculoskeletal experts (~ 50), etc.

HTCCNC Centers Audit/Accreditation progress as of September 2023 (initiated 2022),

- i. HTCCNC has now been joined by 315 centers of various capacity.
- ii. Data are available from 265 centers
- iii. Applications received for audit: 169 centers
- iv. Audited and certified - 108 centers as of September 2024 including:
  - 110 Hemophilia Treatment Centers (Tier 1) [each must regularly follow at least 20 patients for management]
  - 37 Hemophilia Diagnostic and Management Centers (Tier 2) [each must regularly follow at least 100 patients in addition to having capacity to diagnose and manage hemophilia and bleeding disorders patients]

- 8 Multidisciplinary comprehensive Care Centers (Tier 3) [each must regularly follow at least 500 patients and practice multidisciplinary comprehensive hemophilia care]
2. I also had Informal consultation to the Aluva Hemophilia Care Center in Aluva, Kerala Province, India (contact: Dr. Vijayakumar Narayana Pillai who spent an observership in Calgary in 2016) (2016-2020)  
This center now has WFH twinning relationship with the UK New Castle upon Tyne center

#### National and international committees

##### World Federation of Hemophilia

Member, Medical Advisory Board (1996-2000)

Faculty member, World Federation of Hemophilia International Hemophilia Training Centre Workshop at Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China (May 11-14, 1993)

Member, Scientific Advisory Committee, WFH 2000 Congress, Montreal, Canada (1998-2000)

##### World Federation of Hemophilia – Hemophilia Treatment Center Collaborative Network, China

Planning Committee and Faculty Member:

WFH-China National Hemophilia Conference (2005, 2006, bi-yearly 2007-present)

WFH-China Workshops for nurses, physiotherapist and pediatricians (yearly 2005-present)

##### World Federation of Hemophilia Guidelines development Committee

Member: International Hemophilia Management Guidelines (ed 1) (2002-2005)

Member: International Hemophilia Management Guidelines (ed 2) (2009-2013)

##### Royal College of Physicians and Surgeons of Canada

Scientific Program Committee member (1996-1998)

Specialty Committee in Hematology Corresponding member (Jan 1990-Dec 1991)

##### Canadian Hematology Society

President (1998-2000)

Vice president (1996-1998)

##### Association of Hemophilia Clinic Directors of Canada (AHCDC) (formerly Canadian Hemophilia Clinic Directors' Group)

President (1997-1999)

Vice President (1994-97)

Secretary (1988-1990)

Member, Board of Directors (1994-2001)

Member, Executive Committee (1993-2001)

Factor IX Subcommittee (chair: 1993-2006; member 1993-2010, 2013-2016)

Member, von Willebrand Disease Subcommittee (1997-2013)

Member, Rare Bleeding Disorders Subcommittee (Co-chair 2002-2004; member 2002-present)

Member, Research Subcommittee (2003-2005)

Chair, Organizing Committee for meeting on "Legal aspects of hemophilia care" (Toronto ON, March 1, 1993)

Member, Adhoc Committee for Review and Recommendation of Blood Products (1993)

Chair, Committee for Clinical Practice Guidelines for the Management of Hemophilia and von Willebrand disease (1994-2001)  
Co-chair, History of Hemophilia Care in Canada – book development

Canadian Hemophilia Society (National)

Medical and Scientific Advisory Committee (MSAC).

Chair (1990-1994)

Member (1984, 1986-2005)

Hemophilia Research Fund

Member, Board of Directors (1990-1994)

Research Subcommittee

Chairman (1987-1990)

Member (1987-1993)

Patient Care Subcommittee

Member (1990-1993)

Center and Standards Classification Subcommittee

Member (1984-1988)

International Projects Committee

Member (2007-2018)

Annual Rendez Vous Scientific meeting

Chair, organizing committee for

1986 meeting (Calgary)

2011 meeting (Calgary)

International Society on Thrombosis and Haemostasis

1999-Congress (Washington, DC, USA), Member, Scientific Advisory Committee (1997-1999)

2015-Congress (Toronto, ON, Canada), Member, Hemorrhagic Disorders Subcommittee (2013-2015)

International Society of Hematology

Councilor (1998-2012)

2000-Congress (Toronto, Canada), Member, Scientific Advisory Committee (1998-2000)

International Society of Blood Transfusion

2002-Congress, Member, Scientific Advisory Committee (2000-2002)

Hemophilia Research Society of North America

Member, Board of Directors (1999-2002)

Hemophilia care Enhancement And Learning INitiative Group (HEALING) – a forum for promoting hemophilia research for young hemophilia treaters

Organizer, co-chair, senior advisor (2010-2017)

This initiative is being revived under the aegis of the Association of Hemophilia Clinic Directors of Canada by Dr. Adrienne Lee, a mentee of mine and previous cochair.

Chinese Medical Society of Calgary

President (1989-1990)

Secretary (1987-1989)

Member, Board of Directors (1987-1992; 2002-2013)

National Advisory Committee on Blood and Blood Products (Canadian Blood Services)

Member, rFVIIa Working Group (2006-2008)

Member, Prothrombin Complex Concentrates (Octaplex/Periplex) Working Group (2008-2022)

Canadian Hemophilia Physicians Update meeting (2015 Jun 20-21)  
Chair, Organizing Committee (2014-2015)

AIDS Calgary Awareness Association  
Member, Advisory Committee (1986-1992)

Clinical Trials/studies Committees (incomplete list, participation of trials not included)  
Genetics Institute recombinant human factor IX International Clinical Trials  
Canadian Coordinator (1995-2001)

IMMUNO Factor IX International Clinical Trial  
Chairman, Steering Committee (1991-1995)

IMMUNO European Immunate von Willebrand Disease Trial  
Member, Oversight Committee (1997-1999)

Canadian Multi-Center Study on the Immune Status of Hemophiliacs  
Member, Executive Committee (1984-1991)

International Registry on rFVIIa in congenital platelet disorders  
Coordinator (with Roseline d'Oiron, France) (1998-2004)

Novo Nordisk – Glanzmann Thrombasthenia Registry  
(Prospective Observational Registry On The Use Of Recombinant Human Activated  
Factor VII (rFVIIa) And Other Hemostatic Agents)  
Chair, Expert Panel (2005-2014)  
Member, Expert Panel (2004-2014)

Stem Cell Therapeutics Corp – REGENESIS-LED trial  
(A Phase IIb prospective, randomized, double-blind, placebo controlled, dose  
escalation study of NTx<sup>®</sup>265: human chorionic gonadotropin (hCG) and epoetin alfa  
(EPO) in acute ischemic stroke patients)  
Member, Data Safety Monitoring Board (2008-2010)

Stem Cell Therapeutics Corp – REGENESIS-LED trial  
for "A Phase IIa Single Centre, Open Label Study to Characterize the Safety of  
human chorionic gonadotropin (hCG) and epoetin alfa (EPO) in Traumatic Brain  
Injury- Dosing Tier 1", Stem Cell Therapeutics Regensis-LED study  
Member, Data Safety Monitoring Board (DSMB) (2011-2016)

SPARK Therapeutics Hematology Program (SPK-9001-101 hemophilia B gene  
therapy)  
Canadian Medical Officer (2016-2017)

## RESEARCH AND GRANT SUPPORT

(Principal/co-principal investigator denoted by \*, others as co-investigator)

## CURRENT GRANT SUPPORT

\*\*History of Hemophilia Care in Canada\*\*

Association of Hemophilia Clinic Directors of Canada

\$24,000 (2012- present)

Previous Grant Supports

Between 1976-1983

\*"Coagulation Research" U.S. Veterans Administration R and D Fund

From 1983-present

Hemostasis Fellowship Training Grants

\*"Evaluating the Risk of Ischemic Heart Disease in Hemophiliacs: A Long-Term Case-Control Study"  
(Clinical Scholarship and research operating funding for Dr. Shannon Jackson – Hemostasis Fellow"  
Bayer International Hemophilia Award US\$140,000 (2007-2009)

\*"Barriers to Health Care Delivery to Patients with Mild Hemophilia A"  
(Clinical Scholarship and research operating funding for Dr. Dawn Goodyear – Hemostasis Fellow)  
Bayer International Hemophilia Award US\$180,000 (2010-2012)

\*"In vivo assessment of bone microarchitecture using HR-pQCT in hemophilia patients: Insight into  
etiology of decreased BMD in this patient population"  
(Clinical Scholarship and research operating funding for Dr. Adrienne Lee – Hemostasis Fellow)  
Bayer International Hemophilia Award US\$160,000 (2012-14)

\*"In vivo assessment of bone microarchitecture using HR-pQCT in hemophilia patients: Insight into  
etiology of decreased BMD in this patient population"  
Canadian Hemophilia Society-Association of Hemophilia Clinic Directors of Canada – CSL-  
Behring Hemostasis Fellowship for Dr. Adrienne Lee (*declined*) \$75,000 (2012-13)

Post-doctoral Associate Training Grants

"Cancer Clinical Trials in Canada and the Ethics of Human Dignity Framework, 1978-1998"  
Associated Medical Services (AMS) History of Medicine and Healthcare Grant  
\$47,500 (2020-2021)  
Postdoctoral fellowship for Dr. Fedir Razumenko (Poon as principal supervisor)

"Cancer Clinical Trials in Canada and the Ethics of Human Dignity Framework"  
Uof Calgary O'Brien Institute of Public Health and Arnie Charbonneau Cancer Institute  
\$50,000 (2019-2021)  
Postdoctoral scholarship for Dr. Fedir Razumenko (Poon as Principal supervisor)

Operating Grants

\*"Development of mouse monoclonal antibodies for structural and functional studies of factor VIII  
coagulant protein" \$1,200 (1983)  
University of Calgary Research Fund

\*"Characterization of VIII:C protein" \$13,000 (Oct 83-Jun 84)  
Foothills Hospital Research and Development Foundation

\*"Immunology and molecular biology of acquired immune deficiency syndrome"  
University of Calgary AIDS Research Fund \$10,000 (Oct 83-Sep 84)

\*"Characterization of VIII:C protein" \$155,000 (Jul 84-Dec 87)  
Canadian Red Cross Society Blood Services Research and Development fund

\*"Hemophilia carrier detection by gene probing techniques"

Alberta MSI Foundation	\$83,250	(Jan 86-Dec 88)
"CMV markers in blood donors" Canadian Red Cross Society Blood Services Research and Development fund	(PI. Dr. S. Cassol) \$151,355	(Jul 86-Jun 89)
"Basic and applied studies on cell surface marker expression in AIDS" Japan Immuno-Research Laboratories	(PI. Dr. T. Tamioki) \$50,000	(Aug 87-Dec 88)
*"von Willebrand disease: diagnosis and carrier detection by gene probing techniques" Alberta MSI Foundation	\$92,168	(Jun 88-Jun 90)
*"Molecular analysis of factor IX variants" Canadian Red Cross Society Blood Services Research and Development fund	\$60,350	(Jul 88-Jun 90)
*"Heterosexual transmission of HIV: a multi-centre study of the hemophilia/blood recipient population" National Health Research Development Program (NHRDP), Health and Welfare Canada	\$725,886	(Oct 88-Sep 91)
*"Analysis of variant factor IX gene expression" Canadian Hemophilia Society	\$92,520	(Jul 91-Dec 93)
"HIV positive blood transfused population identification and impact assessment: feasibility study" (PI. Dr. J. McDonald) National Health Research Development Program (NHRDP), Health and Welfare Canada	\$13,860	(Jul 89-Apr 91)
*"Development of an accurate, rapid screening method for point mutations using hemophilia B as a model system" Alberta Children's Hospital Foundation	\$38,900	(Jan 91-Dec 91)
*"Molecular diagnosis of hemophilias" Canadian Red Cross Blood Transfusion Service Research and Development fund	\$103,435	(Jan 93-Dec 94)
*"Chimerism in bone marrow transplantation" Canadian Red Cross Society Blood Services Research and Development fund	\$109,560	(Jan 91-Dec 92)
Alberta Cancer Board	\$45,894	(Jul 93-Sept 94)
	\$19,800	(Jan 93-Jun 93)
"Active immunization of patients with HIV infection: a study of the effect of VaxSyn® on progression of immunodeficiency" Canadian HIV Trial Network Calgary funding:	(Calgary PI. Dr. J. Gill) \$1,1009,140	(Mar 92-Dec 95)
*"Molecular studies of factor IX variants" Canadian Hemophilia Society	\$90,000	(Jul 94-Jun 96)
*"Activated protein C resistance mutations" Heart and Stroke Foundation of Canada, Alberta Chapter	\$40,000	(Jul 95-Jun 97)
*Safety and Efficacy of recombinant Factor IX Genetics Institute (clinical trial: safety and efficacy of recombinant factor IX in previously treated and untreated hemophilia B patients)	\$50,000	(1998-2000)
*Inherited risk factors for venous thrombosis MSI Foundation	\$25,000	(1999-2000)

- \*Protease activated receptors (PAR) mediated secretion of von Willebrand factor from endothelial cells \$128,400 (1998-2001)  
Canadian Red Cross Society Blood Services/Canadian Blood Services
- Von Willebrand's disease in women with objectively proven menorrhagia \$25,000 (2000-2001)  
Calgary Laboratory Services Health Services Research Fund (PI. Dr. Gary Sinclair)
- \*Recombinant Factor IX: Pharmacokinetics, Efficacy and Safety monitoring \$321,100 (1998-2001)  
Canadian Blood Services and Genetics Institute
- \*Type 2N Mutations in Type 1 von Willebrand Disease \$26,500 (2000-2002)  
Aventis Research and Development Fund
- Heparin induced thrombocytopenia and platelet factor 4/heparin complex antibodies in patients receiving unfractionated or low molecular weight heparins (PI: Dr. Gary Sinclair)  
Calgary Laboratory Services Health Services Research Fund \$10,000 (2001-2003)
- Effect of Extended Thaw Periods on Coagulation Factors in Fresh Frozen Plasma (PI:Burkart)  
Canadian Blood Services \$15,000 (2002-2003)
- Aminoglycoside Antibiotic Treatment to Suppress Nonsense Mutations in Severe Hemophilia  
Canadian Hemophilia Society (PI: Dr. D. Lillicrap) \$43,696 per year (2002-2004)
- Phenotypic heterogeneity in severe Hemophilia A: analysis of low levels of clotting factor activity by a novel thrombin generation assay" (PI: Dr. Gary Sinclair)  
Calgary Laboratory Services Research & Development Fund \$8,000 (2004-2005)
- \*Treatment of immune thrombocytopenic purpura with helicobacter pylori eradication therapy – a pilot study.  
Calgary Laboratory Services Research & Development Fund \$7,996 (2003-2006)
- “Development of Hemophilia Physiotherapy Education” (PI. Lixia CHEN, PUMCH, Beijing, China)  
Canadian Hemophilia Society International Project Grant \$15,000 (2005-2007)
- “Development of Hemophilia Nursing Guidelines” (PI. Jing SUN, Nanfang Hospital, Guangzhou, China)  
Canadian Hemophilia Society International Project Grant \$15,000 (2005-2007)  
Bayer International Research and Development Fund US\$15,000 (2005-2007)
- “Development of Hemophilia Physiotherapy Education, phase 2: Train-the-trainer program development” (PI. Lixia CHEN, PUMCH, Beijing, China)  
Canadian Hemophilia Society International Project Grant \$15,000 (2008-2010)
- “A Priority Project to Develop Hemophilia Nursing Training and Care in Rural Communities in China” (PI Jie ZHAO, Nanfang Hospital, Guangzou, China)  
Bayer International Hemophilia Award US\$15,000 (2008-2010)
- \*“Thrombophilia screening practices in the community: an impact assessment for family physicians in the Calgary Health Region (CHR)”  
Calgary Laboratory Services Research and Development Fund \$8070 (2008-2010)

- \*"Investigation of Clotting Activity Heterogeneity in Severe Hemophilia A"  
 Canadian Hemophilia Society \$100,000 (2005-2007)  
 Association of Hemophilia Clinic Directors of Canada  
 (AHCDC Research Fund) \$211,973 (2006-2011)
- "Risk of Ischemic Heart Disease in Hemophilia: Evaluating endothelial function and the Development of atherosclerotic vascular disease in hemophilia" (PI. Shannon Jackson)  
 Canadian Hemophilia Society \$50,000 (2009-2010)
- \*\*"Evaluating the Risk of Ischemic Heart Disease in Hemophiliacs and Carriers of Hemophilia: A Case Study"  
 Division of Hematology Clitheroe Endowment Research Fund \$32,550 (2007-2012)
- "Development of hemophilia Physiotherapy Manual in China" (PI. Lixia CHEN, PUMCH, Beijing, China)  
 Bayer International Hemophilia Award US\$25,000 (2010-2012)
- \*\*"Barriers to Health Care Delivery to Patients with Mild Hemophilia A" (PI Dawn Goodyear, Poon Co-PI)  
 Pfizer Hemophilia Award \$50,974 (2011-2014)
- "A Genome Wide Association Study (GWAS) to Determine Factors that Contribute to Mucocutaneous Bleeding"  
 Association of Hemophilia Clinic Directors of Canada – Baxter Canadian Hemophilia  
 Epidemiological Research Program (P.I. Paul JAMES, Queen's Univ) \$75,000/yr (2010-14)
- "Multicentre Canadian Study of Prophylaxis in Older Adults with Severe Hemophilia"  
 Association of Hemophilia Clinic Directors of Canada – Baxter Canadian Hemophilia  
 Epidemiological Research Program (P.I. Shannon JACKSON, UBC ) \$75,000/yr (2011-13)
- "Age Related Cardiovascular Disease in Hemophilia Epidemiological Research – The ARCHER Study"  
 Association of Hemophilia Clinic Directors of Canada – Baxter Canadian Hemophilia  
 Epidemiological Research Program (P.I. Leonard Minuk, Univ of Western Ontario, London,  
 ON) \$40,000/yr (2012-13)
- \*\*"In vivo assessment of bone microarchitecture using HR-pQCT in hemophilia patients: Insight into etiology of decreased BMD in this patient population" (PI Adrienne Lee, Poon co-PI)  
 Calgary Health Trust Hematology Education and Research Fund \$16,056.10 (2011-12)
- "HR-pQCT: a novel imaging technology detects microarchitectural skeletal pathology in hemophilia patients" (PI Adrienne Lee, Poon co-PI) Canadian Hemophilia Society \$124,810.00 (2014-2016)
- \*\*"Potential role of thromboelastography (TEG) in DDAVP response monitoring for von Willebrand disease and mild hemophilia A"  
 Calgary Laboratory Services (PI Adrienne Lee, Poon co-PI) \$9520 (2013-2016)
- "Developing interdisciplinary knowledge exchange capacity between Canada and China on imaging outcomes for hemophic joints"  
 Canadian Institute for Health Research (CIHR) (P.I. Andrea Doria, Hospital for Sick Kids, Toronto, ON) \$25,000 (2014-2016)
- \*\*"Southern Alberta Rare Blood & Bleeding Disorder Comprehensive Care Program Strategic Planning"



Bayer (Canada) Inc.	\$25,818.00 (2017)
*"Rare Bleeding Disorders Care and Education Improvement" Bayer (Canada) Inc. QI/QA grant	\$75,401.00 (2016-2018)
**"Pregnancy loss in von Willebrand disease: A multi-centre cohort study" (Co-PI Leslie Skeith, Poon) CSL-Behring Canada	\$45,500.00 (2015-17)
**"Pregnancy loss in von Willebrand disease: A multi-centre cohort study" (Co-PI Leslie Skeith, Poon) Calgary Health Trust Hematology Education and Research Fund	\$14,557.14 (2014-17)
"The role of factor VIII and joint arthropathy in bone density, microarchitecture, and bone strength in adolescent severe hemophilia A" (PI Adrienne Lee, Poon co-investigator/Mentor) Bayer Hemophilia Award Program (Early Career Investigator Grant for Dr. A Lee)	US\$185,957.50 (2017-19)
**"A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects with Congenital Fibrinogen Deficiency with a Prospective Followup Component" CSL-Behring	\$67,450.50 (2015-2017)
"Patient-Oriented Research in Alberta and its Origins in Oncological Clinical Trials, 1990-2010. Alberta Medical Foundation Program Grant	\$10,000 (2020-2021)
"Personalized medicine for Canadians with hemophilia: a pragmatic evaluation of the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo) tailored dosing: the PMCH study" (PI: Alfonso Iorio, McMaster University, CoI: Poon, Adrienne Lee and others) CIHR	Total project \$256,274 (2019-2021)
"Adult Canadians with hemophilia living with inhibitors study (ACHILLES)" (PI: Natalia Rydz, CoI Poon, Linda Sun) Canadian Hemophilia Society Bayer ADVANCE grant	\$49,800 (2019-2021)
"Improving the use of hydroxyurea in the sickle cell disease population within the Southern Alberta Rare Blood and Bleeding Disorders (SARBBDD) comprehensive care program" (PT: Natalia Rydz, CoI Poon, Lee, Goodyear) Sickled cell diseases Association of Canada	\$14,020 (2019-2020)
"A national prospective case series of patients with congenital FXIII deficiency" (PI Natalia Rydz, Co-PI Poon, Linda Sun) Association of Hemophilia Clinic Directors of Canada SCHERP grant	\$76,390 (2018-2020)
**"A prospective, multi-national, non-interventional study in haemophilia A and B patients with or without inhibitors treated according to routine clinical treatment practice" (local PI: Poon) Novo Nordisk	\$29,568 (2019-2021)
"The role of platelet procoagulant membrane dynamics in DDAVP mediated mechanisms of coagulation enhancement" (PI Adrienne Lee, Co-PI Poon, Ejaife Agabani, Morley Hollenberg) Canadian Hemophilia Society Care Until Cure Research Program	\$140,675 (2019-2021)
"Incidence and burden of bone fracture in patients with hemophilia" (PI Adrienne Lee, Co-PI Poon, Linda Sun, Chatree Chai-Adisaksopha) Canadian Hemophilia Society Bayer ADVANCE Research Program	\$15,000 (2018-2020)

“Interrogating archives of Canadian clinical cancer research and interviewing its investigators as living sources, 1965-2011”

Associated Medical Services (AMS) History of Medicine and Healthcare Grant \$9,995 (2022)

A Canadian, multi-center, retrospective, non-interventional study of the clinical and economic outcomes from early use of Rebinyn® in the prevention and treatment of bleeding episodes in patients with hemophilia B in a real-world setting (national PI: Poon, Coordination: Alfonso Iorio, McMaster University)

Novo Nordisk Total project \$337,292 (2019-2022)

\*”Hematologist Exchange Program (between the Southern Alberta Rare Blood and and Bleeding Disorders Comprehensive Care Program in Calgary and Chinese Hemophilia Care Centres”

CSL-Behring \$59,866.66 (2014-2022)

\*” Southern Alberta Rare Blood & Bleeding Disorder Comprehensive Care Program Hemostasis Centre of Excellence Program”

Bayer (Canada) Inc \$300,000 (2018-2022)

#### Conference/Lectureship Grants

\*”Canadian Hemophilia Society 1986 Biannual Medical Scientific Meeting (Calgary, May 1986)  
Alberta Heritage Foundation for Medical Research (1986) \$6,000

\*”AFHMR Visiting Lecturers Grant  
Dr. John Semple, University of Toronto, Toronto, ON, Feb 23-25, 2005,  
Alberta Heritage Foundation for Medical Research/University of Calgary \$1520

\*”AHFMR Visiting Lecturers Grant  
Dr. Alan Lazarus, University of Toronto, Toronto, ON, March 3-4, 2008  
Alberta Heritage Foundation for Medical Research/University of Calgary \$1400

\*”AHFMR Visiting Lecturers Grant  
Dr. Paula James, Queen’s University, Kingston, ON, Sept 8-9, 2008  
Alberta Heritage Foundation for Medical Research/University of Calgary \$1750

\*”AHFMR Visiting Lecturers Grant  
Dr. David Lillicrap, Queen’s University, Kingston, ON, April 6-7, 2009  
Alberta Heritage Foundation for Medical Research/University of Calgary \$1750

#### Equipment Grant

\*”Flow cytometer” \$110,000 (1987)  
National Health Research and Development Program (NHRDP), Health and Welfare Canada

## INVITED PRESENTATIONS/ADDRESSES

(1983-present, Calgary regional hospital rounds and presentations not included)

Calgary Immunoematology Club, Calgary, AB (Oct, 1983)

"Blood transfusion and AIDS"

Canadian Red Cross, Calgary, AB. (Sept 1984)

"Management of hemophilia"

IVth International Symposium on Hemophilia Treatment, Tokyo, Japan (Nov 8-9, 1984)

"Symptomatology, diagnosis, laboratory examinations and treatment of acquired immune deficiency syndrome (AIDS)"

"Present status of acquired immune deficiency syndrome (AIDS)"

"Assessment of self-infusion therapy of hemophiliacs in Canada"

Calgary Immunoematology Club, Calgary, AB (March 1985)

"Management of hemophilia: recent development"

U.S. National Hemophilia Foundation - Canadian Hemophilia Society Joint Meeting Houston, TX (Nov 1-2, 1985)

"Status of comprehensive hemophilia care in Canada"

Canadian Society of Medical Technologist, Calgary, AB (Mar 1986)

"Coagulation for the blood bankers"

Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL (Apr 4, 1986)

"Hemophilia B carrier detection by gene probes"

Welmark Symposium, Calgary, AB. (May 1986)

"Molecular genetics of hemophilia"

Alberta Society of Medical Technologists, Calgary, AB. (Oct 1986)

"Molecular diagnostic techniques for coagulation disorders"

AIDS, Hemophilia and Psychosocial Issue: Dialogue Days for the Canadian Health Care Professionals, Calgary, AB. (Jan 25-26, 1987)

"AIDS Today"

AIDS Calgary: AIDS Education and awareness Week (Mar 27, 1987)

"AIDS overview for health practitioners"

Canadian Hemophilia Clinic Directors' Group Meeting, Toronto, ON (May 1, 1987)

"Current status of AIDS among persons with hemophilia in Canada"

American College of Physicians/Royal College of Physicians and Surgeons of Canada Course: Advances in Internal Medicine, Banff, AB (Jun 15-19, 1987)

Workshop: "Investigation and management of patients with mild bleeding disorders"

Canadian Hospital Pharmacist Association (Alberta Chapter) Meeting, Calgary, AB (Sept 23, 1987)

"Recent advances in anticoagulant therapy"

Canadian Hemophilia Society/AIDS and Hemophilia Project Conference: Renewing our energies - new and changing realities in hemophilia care. Calgary, AB (Oct 1-2, 1987)

Workshop: "HIV and AIDS related issues on blood products"

Workshop: "Re-energizing the hemophilia comprehensive care"

AIDS and BM-1 Meeting, Calgary, AB (Apr 15, 1988)  
"Hemophilia, AIDS and BM-1"

First Canada-Japan Joint AIDS Meeting, Tokyo, Japan (Dec 8, 1988)  
"HIV infection and hemophilia in Canada"

American College of Physicians/Royal College of Physicians and Surgeons of Canada Course: Advances in Internal Medicine, Banff, AB (Jun 27, 1989)  
Workshop: "ITP and hemolytic anemia"

Baxter-Dade Hemostasis Seminar, Calgary, AB (May 29, 1990)  
"Recent advances in hemostasis"

Saskatchewan Hemophilia Society Annual Meeting, Waskesiu, SK (Sept 27, 1990)  
"Update on hemophilia therapy"

Alberta Hemophilia Society Annual Meeting, Deer Valley Meadow, AB (Oct 10, 1990)  
"Recombinant factor VIII, where are we?"

Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL (Feb 26-27, 1991)  
"Laboratory evaluation of thrombosis"  
"Hemophilia carrier detection"

Royal College of Physicians and Surgeons of Canada Annual Meeting Symposium: New Concepts in Blood Product Usage, Quebec City, PQ (Sept 20-23, 1991)  
"Evaluation and clinical application of recombinant factor VIII"

International Symposium on Recombinant Factor VIII, Montreal, PQ, (Oct 16-17, 1991)  
Symposium chair

Canadian Society of Laboratory Technologists Congress, Calgary, AB (Jun 15-19, 1992)  
"Molecular diagnosis of coagulation disorders"  
"Panel discussion on coagulation disorders" Panel chair  
"DNA recombinant technology in future transfusion medicine"

International Symposium on the Impact of Biotechnology on Hemophilia Care, Cannes, France (Apr 2-4, 1993)  
"Recombinant factor VIII: impact on the immune and other systems"

World Federation of Hemophilia International Hemophilia Training Centre Workshop, at Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China (May 11-14, 1993)

"Hemophilia and von Willebrand disease: general diagnosis and management"  
"Use of blood products"  
"Cryoprecipitate: uses and alternatives"  
"Clinical aspects of hemophilia: hematoma and neurovascular complications"

Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, B.C. (September 11, 1993)

Symposium co-chair: "Diagnosis and Treatment of Inhibitors of Coagulation"

University of Calgary Regional Conference Program, Mineral Spring Hospital, Banff, AB (October 18, 1993)  
"Investigations, Management and Treatment of Anemia"

University of Alabama at Birmingham, Birmingham, Alabama (April 8, 1994)  
"Carrier determination in Hemophilia: Recent Advances"

The Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong (August 21, 1996)  
“von Willebrand Disease: Recent Advances”

Royal College of Physicians and Surgeons of Canada Annual Meeting, Halifax, N.S. (September 28, 1996)  
Symposium co-chair: "Hemophilia Management: State-of-the-Art"

Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, B.C. (September 25-28, 1997)  
Canadian Hematology Society Scientific Program Chair

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union College February 23-26, 1998

1. “Recent Advances in Hemophilia Management”
2. “Recent Advances in von Willebrand Disease”

World Federation of Hemophilia Congress, The Hague, The Netherlands (May 17-20)  
Symposium: World Federation of Hemophilia (WFH) Center Twinning Symposium  
Lecture: “Calgary, Canada - Tianjin, China Twinning” (May 18, 1998)

Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, B.C. (September 25-27, 1998)  
Canadian Hematology Society Scientific Program Chair

Medical Symposium “New Dimensions in Treating Inhibitor Patients” Toronto, ON (October 16-18, 1998)  
1. Symposium Co-chair  
2. Symposium lecture “Approaches to Immune Tolerance”

Hong Kong Society of Blood Transfusion and Haematology, Hong Kong (November 7, 1998)  
Annual General Meeting Lecture: “Low molecular Heparins: Role in Thrombotic Disorders and New Indications”

Hong Kong Paediatric Haematology and Oncology Study Group, Hong Kong (November 9, 1998)  
“Recent advances in Haemophilia Management”

The 5th Novo Nordisk Symposium on the Treatment of Bleeding and Thrombotic Disorders. Use of NovoSeven (rFVIIa) and rFVIIai (Copenhagen, Denmark, May 7-8, 1999)  
“Recombinant factor VIIa (NovoSeven) treatment of platelet related bleeding disorders”

Symposium: Infectious Disease Update in Hemophilia, Banff, AB, February 4-5, 2000, Invited Speaker:  
Managing platelet disorders

44<sup>th</sup> Annual meeting of the German Society of Thrombosis and Hematology Research (Gesellschaft für Thrombose- und Hämostaseforschung), Freiburg, Germany, February 16-29, 2000  
Seminar on Cell-based hemostasis: new aspects for thrombosis and hemostasis, Invited Speaker:  
“New aspects in the treatment of platelet related bleeding disorders”

23<sup>rd</sup> International Congress of the World Federation of Hemophilia, Montreal, July 16-21, 2000  
Symposium on Ethical issues surrounding equity of care in developed versus developing countries  
Invited Speaker: “Supporting treatment access: Examples of China”  
Chair of scientific session: Clotting Factor Concentrates

The 2<sup>nd</sup> National Workshop on Hemophilia, Tianjin, China, September 22-24, 2000  
Invited faculty/speaker:  
“Treatment of hemophilia: blood products and alternative agents”

Nanfeng Hospital, Guangzhou, China, November 20, 2000  
“Hemophilia: Diagnosis and Management”

World Federation of Hemophilia Workshop, Hong Kong, SAR, China, November 22-24, 2000

Invited faculty/speaker:

1. "Contribution of WFH in haemophilia care, with specific reference to the Tianjin-Calgary twinning programme"
2. "The development of national guidelines of haemophilia management: The Canadian experience"

American Society of Hematology Meeting , San Francisco, December 1, 2000

Satellite Symposium speaker "Advances in Hemostasis for Patients with Bleeding Disorders"

Invited speaker: "recent developments in the management of platelet disorders"

The 6<sup>th</sup> NovoSeven Symposium on the Treatment of Bleeding and Thrombotic Disorders (Copenhagen, Denmark, May 3-4, 2001)

"Use of Recombinant factor VIIa (NovoSeven) in Patients with Glanzmann's Thrombasthenia"

International Society of Thrombosis and Hemostasis, Paris, July 6, 2001

Satellite Symposium "Recombinant Factor IX: Seven Years of Clinical Use – The Global Experience"

Invited speaker: "Recombinant Human Factor IX: The Canadian Postmarketing Surveillance"

Vancouver General Hospital, Vancouver, BC, Oct 23, 2001

Invited discussant, conjoint hematology residents education round: "Circulating Anticoagulants"

University of Calgary 19<sup>th</sup> Annual Therapeutic Course, Calgary, AB, March 14-15, 2002

Faculty workshop speaker: "Long term platelet inhibition"

XXV<sup>th</sup> World Federation of Hemophilia Congress, Seville, Spain, May 19, 2002

Satellite Symposium "Recombinant Factor IX: Eight Years of Clinical Use, the Global Experience"

Invited speaker: "Recombinant Human Factor IX: The Canadian Postmarketing Surveillance: an Update"

Symposium, Taiwan Hemophilia Society, Taipei, Taiwan, August 19, 2002:

"Recombinant factor IX recovery and inhibitor formation" (invited speaker – lecture given in Calgary via audio-link)

Symposium, Ontario Hemophilia Nurses Meeting, Niagara-on-the-Lake, ON, Nov 10, 2002:

"Recombinant factor IX efficacy and safety"

Anhui Provincial Hospital Hemophilia Program, Hefei, Anhui, China Nov 29, 2002:

"Comprehensive Hemophilia Care"

University of Calgary 19<sup>th</sup> Annual Therapeutic Course, Calgary, AB, April 11, 2003

Faculty workshop speaker: "update on LMW heparins in the community. Current indications"

Hemophilia Forum, St. Louis, MO, April 26, 2003

"Basic and Clinical Perspective on Factor IX Recovery"

Canadian Hemophilia Society von Willebrand disease symposium, Montreal, PQ May 8, 2003.

workshop facilitator: "forum on treatment"

National Technical Working Group meeting, Montreal, PQ. June 6, 2003-10-29

"Clinical use of recombinant factor VIIa"

ICH (Intracranial Hemorrhage) Advisory Board meeting, Calgary, AB, June 29, 2003

Invited Speaker: "Niastase Mechanism of Action"

Association of Hemophilia Clinic Directors of Canada/Novo Nordisk Symposium on The Evolving Role of rFVIIa in Hemostasis and Blood Conservation. Montreal, PQ. September 29, 2003.

“Safety Overview of rFVIIa”

American Society of Hematology 45<sup>th</sup> Annual Meeting, San Diego, CA, Dec 4-9, 2003  
Faculty, Meet the Expert session on “Hemophilia and Inherited Bleeding Disorders”

WFH (World Federation of Hemophilia) Hemophilia Conference, Jinan, Shangdong Province, China. March 25-27, 2004  
Co-Chair of sessions and Summary Remarks

Prince of Wales Hospital, Department of Pediatrics, Chinese University of Hong Kong., Hong Kong, SAR, China. April 1, 2004  
:“Progress in Hemophilia Care, China Perspective”

University of Toronto Hematology Training Program J. G. Scott Day, London, ON, June 1, 2004.  
“Practical tips on Hemophilia Management and Prophylaxis

XXVIth World Federation of Hemophilia Congress, Bangkok, Thailand, October 21, 2004  
Meet the Expert Session “Bleeding management and prevention in patients with Glanzmann thrombasthenia”

WFH (World Federation of Hemophilia) Nursing Workshop, Guangzhou, China. October 22-24, 2004  
Co-organizer and Co-chair of sessions.  
Lecture: “Hemophilia Diagnosis”

University of Calgary Rural/Regional CME Program – Fort MacLeod General Hospital, Fort MacLeod, Alberta, November 17, 2004  
“Anticoagulant Guidelines”

Constellation CME Program, Caribbean Sea, Jan 30, 2005  
“Anticoagulant Guidelines”

Royal University Hospital & University of Saskatchewan, Dept of Medicine, Visiting lecturer/Grand round presentation March 2, 2005  
“Inhibitor management in hemophilia”

Chinese Medical Society of Calgary CME lecture, Calgary, AB. March 22, 2005  
“ITP (Immune Thrombocytopenic Purpura), to treat or not to treat”

WFH Hemophilia Conference and Coagulation Workshop, Shanghai, China , April 22-24, 2005.  
1. “Thrombin generation – studies and clinical applications”  
2. “Inhibitors of coagulation and in hemophilia “

Anhui Provincial General Hospital, Hefei, China, May 25, 2005  
“Inhibitors in hemophilia”

8<sup>th</sup> Novo Norkisk Symposium on Haemostasis Management. Copenhagen, Denmark, May 12-13, 2005  
1. “Update on the Registry for Glanzmann’s thrombasthenia”  
2. “Hemophilia Care in China”

State of the Art International Symposium on Pharmacokinetics of Factor Concentrates in Hemophilia – challenges and relevance to clinical practice, Toronto, Canada, Sept 29-30, 2005  
“Pharmacokinetics of Fator IX and other factor concentrates”

Tianjin Institute of Hematology and Blood Diseases Hospital Lecture series. Tianjin, China. September 20, 2005.  
“Inhibitors in congenital and acquired hemophilia”

Regional Hemophilia Nursing Conference (Joint: Hefei/Shanghai Hemophilia Centers), Anhui Provincial Hospital, Hefei, Anhui, China. November 25, 2005  
“Complications of Hemophilia”

Regional Hemophilia Nursing/Physiotherapy Conference (Joint Beijing/Tianjin Hemophilia Centers), Beijing, China. November 27-28, 2005  
“Complications of Hemophilia”

Regional Hemophilia Nursing Conference, Jinan People’s Provincial Hospital, Jinan, Shangdong, China. November 30, 2005  
“Complications of Hemophilia”

Symposium – Recent Developments in Hemophilia Management, Beijing, China. December 6, 2005  
“Management of Acquired Inhibitors”

Datong Fifth People’s Hospital, Datong, Shanxi Province, China. December 17, 2005  
“Hemostatic mechanism, hemophilia and von Willebrand’s disease”

Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. December 19, 2005 (Visiting Professorship lecture)  
“Hemostatic mechanism, hemophilia and von Willebrand’s disease”

2nd Hospital affiliated with the Harbin Medical University, Harbin, China. January 6, 2006 (visiting scholar)  
“Heparin induced thrombocytopenia” discussion on research program and meet with Graduate students.

Hong Kong Society of Hematology Scientific meeting, Lecture Hall, 4/F, Duke of Windsor Social ServicenBuilding, 15 Hennessy Road, Hong Kong, Feb 23, 2006.  
“Inhibitors of coagulation and their management”

Anhui Provincial Hospital, Hefei, Anhui, China March 27-April 7, 2006 (Visiting Professorship lectures).  
“Acquired Hemophilia” (March 29, 2006)  
“Anticoagulation Guidelines (April 5, 2006)  
“Hemophilia and von Willebrand’s disease (April 6, 2006)

Hemophilia Society of Guangzhou, Guangzhou, Guangdong Province, China April 17, 2006.  
“Congenital Coagulation Disorders and Complications”.

Ruijin Hospital, Shanghai, China, April 25, 2006 .  
“Hemophilia and Inhibitors – pathogenesis and management”

Chinese Medical Society Continuing Education Conference and Anhui Hematology Society 9<sup>th</sup> Annual Scientific Meeting, Taiping Hu, Huangshan, Anhui Province, China (June 15, 2006). .  
“Anticoagulant therapy for venous thrombotic diseases”

Anhui Provincial Medical Genetics Society Meeting, Wuhu City, Anhui Province, China (June 17, 2006) .  
“Hemophilia: Genetics and Applications”

World Federation of Hemophilia and Chinese Hemophilia Center Collaborative Network Conference, Huangshan City, Anhui Province, China (June 19-20, 2006) – co-organizer and chair of sessions.  
“Management of hemophilia patients with inhibitors”

Bayer Summit Conference on Hemostasis and Thrombosis, Toronto Sept 27-28, 2006.  
“Hemophilia prophylaxis: a global perspective”

Calgary Family Physicians Group, Calgary, AB (Nov 15, 2006). .  
“Thrombophilia screening”



- American Society of Hematology 49<sup>th</sup> Annual Meeting, Orlando, FL. Dec 9-12, 2006  
Faculty, Meet the Expert session on “Recombinant coagulation factors” (Dec 10, 2006)  
Novo Nordisk symposium on WFH Canadian Hemophilia Twinning “Ten years Twinning Activity in China” (Dec 10, 2006)
- Hemophilia Nursing Conference and Hemophilia Nursing Workshop, Guangzhou, China Jan 19-21, 2007
1. Conference co-chair
  2. Presentation: “Hemophilia management, the basics and the future”
- Hemostasis/Hemophilia Forum, Shantou University First Affiliated Hospital, Shantou, China. Jan 21-23, 2007  
Presentation: “Hemostasis and Hemophilia Management”
- Canada-China Hemophilia Collaboration Workshop. Hospital for Sick Children, Toronto, Canada, March 9-10, 2007
1. “Chinese Hemophilia Collaboration: New Opportunities and Challenges – 2007 and Beyond”
  2. “Chinese Hemophilia collaborating center characteristics and staffing”
- Grandround, Department of Anesthesiology, Calgary, AB, Mar 2, 2007  
“Recombinant activated factor VIIa (rFVIIa) as an Universal Hemostatic Agent. How does it measure up clinically”
- Canadian Society of Transfusion Medicine Annual Meeting, Calgary, AB, May 3-6, 2007  
Invited speaker: “Recombinant activated factor VIIa (rFVIIa) as an Universal Hemostatic Agent. How does it measure up in clinical trials” (May 5, 2007)
- World Federation of Hemophilia – Hemophilia Treatment Centers Collaborative Network of China “Physiotherapy Workshop”, Beijing, China May 22-23, 2007  
Invited speaker: “Hemophilia: Basic Management” (May 24, 2007)
- World Federation of Hemophilia – Hemophilia Treatment Centers Collaborative Network of China “Hemophilia Conference”, Beijing, China May 26-27, 2007  
Invited speaker: “Management of Coagulation Disorders” (May 26, 2007)
- Anhui Province Combined Symposia on Clinical Advances in Genetics and Advances in Hemophilia Care, Hefei City, Anhui Province, China. September 22-24, 2007  
Invited speaker: “Challenges and Advances in Hemophilia Care” (Sept 23, 2007)
- Southern Medical University/Nanfang Hospital (Guangzhou, Guangdong Province) Hemophilia Outreach Symposium (World Federation of Hemophilia and Hemophilia Treatment Centers Collaborative Network of China), Guiyang City, Guizhou Province, China. September 24, 2007  
Invited speaker: 1. “Complication of Hemophilia”  
2. “Challenges and Advances in Hemophilia Care”
- Chinese Society of Thrombosis and Hemostasis Annual Meeting, Taiyuan City, Shanxi Province, China. September 27-30, 2007  
Invited speaker – Education Session: “Venous Thromboembolism: Diagnosis and Therapy” (Sept 27, 2007)
- International Prophylaxis Study Group Symposium, Toronto, ON (October 14-16, 2007)  
Invited speaker: Hemophilia Care in China – Challenges and Opportunities (Oct 15, 2007)
- Seasonal Combined Conference of Hematology Society of Taiwan and Taiwan Society of Blood and Marrow Transplantation., Kaohsiung, Taiwan (Dec 15, 2007)  
Keynote Lecture: “Challenges of the past, and evolution of recombinant FVIII therapies.
- Hemophilia Conference, Kaosiung, Taiwan (Dec 15, 2007)  
Invited speaker: “Evolution of recombinant Factor VIII treatment”

- Hemophilia NW China Outreach Education Conference, Lanzhou, Gansu Province, China (April 12-13, 2008)  
Invited speaker: "Hemophilia Overview: Clinical Manifestations and Diagnosis"
- Hemophilia SE China Outreach Education Conference, Zhongshan, Guangdong Province, China (April 16, 2008)  
Invited speaker: "Hemophilia Overview: Clinical Manifestations and Diagnosis"
- Canadian Hemophilia Physician Update 2008, Niagara-on-the-Lake (06-21, 2008)  
Session moderator: "Interactive Case Discussion"
- Asia Regional Hemostasis Update, Bangkok, Thailand (July 26-27, 2008)  
Invite speaker: "Management of bleeding in refractory platelet function disorders"
- Asia Pacific Society of Thrombosis and Haemostasis Meeting, Singapore (Sept 17-20, 2008)  
Invite speaker: "Prophylaxis prevents joint disabilities: evidence and challenges"
- Global Hemostasis tests, Toronto, ON (Oct 4, 2008)  
Speaker: "Canadian multicenter severe hemophilia FVIII heterogeneity study: preliminary analysis"
- Outreach Hemophilia Nursing Conference, Haikou, Hainan Province, China (Nov 8, 2008)  
Invited speaker: "Hemophilia complications and management"
- World Federation of Hemophilia Conference, Tianjin, China (Nov 15, 2008)  
Invited speaker: "Women with congenital bleeding disorders"
- Glanzmann's Thrombasthenia Registry Expert Panel Meeting, Copenhagen, Denmark (Jan 26, 2009)  
Invited speaker: "Glanzmann Thrombasthenia Registry 2009 Update"
- Glanzmann's Thrombasthenia Registry Investigators Meeting, Zürich, Switzerland (Feb 20, 2009)  
Keynote Speaker: "Modern Insights and Treatment of Glanzmann's Thrombasthenia"
- Hanoi Society of Transfusion Medicine and Hematology - World Federation of Hemophilia Conference, Hanoi, Vietnam (April 10-11, 2009)  
Keynote speaker: (1) "Hemostasis: Activation and Control"  
Invited speaker: (1) "Inhibitors in Hemophilia and non-hemophilia"  
(2) "von Willebrand's disease"
- World Federation of Hemophilia and Hemophilia Treatment Centers Collaborative Network of China  
Physiotherapy Workshop, Beijing, China (April 13, 2009)  
Invited speaker: "Hemophilia Therapy"
- World Federation of Hemophilia and Hemophilia Treatment Centers Collaborative Network of China SE  
Outreach Education Conference Nanning, China (April 15, 2009)  
Invited speaker: "Hemophilia Complications and Management"
- Malaysian Society of Hematology and Malaysian Society of Transfusion Medicine 3<sup>rd</sup> Asia Regional Hemostasis  
Update, Kuala Lumpur, Malaysia (April 18-19, 2009)  
Invite speaker: "Management of patients with refractory platelet function disorders"
- Association of Clinic Directors of Canada Annual Meeting, Ottawa (May 9, 2009)  
Speaker: "Does heterogeneity in measured calibrated thrombin generation assay or FVIII activity (<1%)  
explain clinical heterogeneity in severe hemophilia A?"
- Chinese Medical Association (Guangdong Province Branch) Hematology Meeting, Guangzhou, Guangdong,  
China (May 25, 2009)  
Invited speaker: "Hemostasis: Mechanism and Regulation"
- Canadian Society of Transfusion Medicine Annual Meeting, Ottawa (June 7, 2009)

Invited speaker: “Prothrombin complex concentrates (PCC) [e.g. Octaplex®] and vitamin K antagonist reversal”

Dr. Oscar Ratnoff Symposium, Cleveland, OH, USA (October 2, 2009)

Invited speaker: “2B or not to be: the 45-year saga of Montreal Platelet Syndrome (MPS)”

Alberta Hematology Fellows Conference, Banff, AB, Canada (October 4, 2009)

Invited speaker: “Management of interesting Hemostasis cases”

Haemophilia Society of Malaysia and Malaysian National Blood Centre Symposium, Langkawi, Malaysia (October 31, 2009)

Invited speaker: “Recombinant factor IX: review of the latest clinical evidence”

Invited speaker: “Recombinant factor IX: experience from clinical practice”

Workshop Session Co-chair: “Beyond the Bleed – managing haemophilia in an integrated service model”

Workshop Session Co-chair: “Outcome assessment and regimen choice”

University of Hong Kong-Queen Mary Hospital, Department of Pathology Seminar, Hong Kong, China (November 19, 2009)

Invited speaker: “2B or not to be: the 45-year saga of Montreal Platelet Syndrome (MPS)”

Hong Kong Hemophilia Society Conference, Hong Kong, China (November 19, 2009)

Invited speaker: “Development of Hemophilia Care in Canada”

World Federation of Hemophilia (WFH) China Annual Hemophilia Annual Conference, Guangzhou, China (November 21, 2009)

Invited speaker: “Replacement therapy for surgery ”

Session chair: “Session: Hemophilia Comprehensive Care, China”

Third WFH Physiotherapy Conference, China. Guangzhou, China (November 22, 2009)

Invited speaker: “Hemophilia: the basics for physitrists/physiotherapists”

Glanzmann’s Thrombasthena Registry Investigators Meeting, Edinburgh, Scotland, UK (February 3, 2010)

Invited Speaker: “Glanzmann’s thrombasthena: genotype-phenotype correlations”

European Association for Haemophilia and Allied Disorders 3<sup>rd</sup> Annual Congress, Edinburgh, Scotland, UK (February 3-5, 2010)

Invited symposium speaker: “Therapeutic tools for the clinical management of Glanzmann’s Thrombasthena”

Hong Kong Haemophilia Society Forum of Haemophilia Care in Hong Kong, Queen Elizabeth Hospital, Hong Kong, (April 14, 2010)

Invited speaker: “The updated international management of haemophilia

Panel discussion: “The key to transfer the patients with haemophilia (from pediatric to adult care) in Hong Kong” (panel participant Chan G, Ling S, Au WY, Luke KH, **Poon M-C**, So S)

Recombinant Factor IX symposium, Osaka, Japan (July 30, 2010)

Invited speaker: “Evidence of clinical efficacy and safety of recombinant factor IX: 13 years clinical experience in Canada”

VIIth World Federation of Hemophilia Symposium China, Jinan, China (Oct 30, 2010)

Invited speaker: “Rare inherited bleeding disorders.”

IVth China Hemophilia Physiotherapy Forum, Jinan, China (Oct 31, 2010)

Invited speaker: “Hemophilia and low bone mass: role of physiotherapists”

China Hemophilia Pediatric Forum, Jinan, China (Oct 31, 2010)

Invited speaker: “Barriers to Pediatric Hemophilia Care in China: Are there possibilities to overcome?”

Hemophilia Symposium, Institute of Hematology, Union Hospital and Hubei Treatment and Diagnosis Center of Hemophilia, Tonji Medical College, Huazhong University of Science and Technology, Wuhan, China (Nov 2, 2010)

Invited speaker: “Modern management of hemophilia: benefits of a comprehensive care model”

University of Calgary Evening Course Program - Continuing Medical Education, Calgary (Jan 12, 2011)

Invited speaker: “Hematology, Platelet Abnormalities”

Canadian Hemophilia Society/Association of Hemophilia Clinic Directors of Canada Medical and Scientific Symposium “New challenges in the care of people with inherited bleeding disorders” Calgary, AB (May 27, 2011)

1. Section chair: Rare Inherited Bleeding Disorders
2. Invited speaker: “Rare Platelet disorders: Management of Glanzmann’s thrombasthenia”

Association of Hemophilia Clinic Directors of Canada Dinner Presentation, Calgary, AB (May 28, 2011)

Dinner Presentation speaker: “Hemophilia Care in Southern Alberta: A Personal Reminiscence”

World Federation of Hemophilia /Hemophilia Treatment Center Collaborative Network China (HTCCNC) - 5<sup>th</sup> Hemophilia Physiotherapy Workshop, Wenzhou, China (June 5, 2011)

Keynote speaker: “Pain and Pain Management”

World Federation of Hemophilia /Hemophilia Treatment Center Collaborative Network China (HTCCNC) - Hemophilia Pediatric Forum, Tianjin, China (June 10, 2011)

1. Keynote speaker: “Hemophilia and Low Bone Mass: Role of Pediatricians in Prevention”
2. Panel Discussion member: “Development of pediatric Comprehensive Hemophilia Care Centers”
3. Panel Discussion member: “Clinical joint assessment and QoL assessment in Hemophilia”

East Asian Hemophilia Forum, Tianjin, China (June 11, 2011)

Plenary speaker: “Inhibitor development in Hemophilia: Risks, Management and Prevention”

Korean Society of Thrombosis and Hemostasis Symposium, Daejeon, Korea (July 21, 2011)

Invited speaker: “Prophylaxis Improves Joint Outcome: Evidence and Challenges”

Kyung-Hee Univeristy Hospital, Gang Dong, Korea (July 22, 2011)

Orthopedic Surgery Grand Round invited speaker: “Surgical Prophylaxis in Patients with Hemophilia – How I Usually Do it?”

Hemophilia Prevent Symposium, Seoul, Korea (July 22, 2011)

Invited Speaker: “Prophylaxis is a Standard of Care in Hemophilia”

International Society on Thrombosis and Haemostasis, Satellite Symposium. Kyoto, Japan (July 27, 2011)

Symposium on “Managing Haemophilia for Life: Treatment Trend in Haemophilia B”

1. Chair of Symposium
2. Invited speaker: “The Global Haemophilia B Landscape”

China 7<sup>th</sup> WFH/HTCCNC Nursing Workshop/Forum, Yangzhou, China (Sept 27, 2011)

Keynote Speaker: “Home Management of Hemophilia”

Mongolian Association of Hematology, World Federation of Hemophilia Symposium on “Improvement of the Laboratory Diagnosis and Treatment of Bleeding Disorders”, Ulaanbaatar, Mongolia (Sept 29-30, 2011)

Invited Speaker:

1. “Hemophilia Diagnosis and Introduction to Management
2. “Hemophilia Management: principles of hemostatic therapy
3. “Hemophilia Management: comprehensive care and home care”
4. “Hemophilia complications and treatment”

Mongolian Association of Hemophilia. Ulaanbaatar, Mongolia (Sept 30, 2011)

Invited Speaker and Panel Discussant: “Safety of coagulation products”

Hong Kong Hemophilia Society Hemophilia Master Course for Nursing and Physiotherapy , Hong Kong , SAR, China (February 26-28, 2012)

Invited keynote speaker:

1. “Musculoskeletal Complications of Bleeding in Hemophilia
2. “Pain management in Hemophilia
3. “Hemophilia Overview”

Glanzmann’s Thrombasthenia Registry Investigators Meeting, Paris, France (May 21, 2012)

1. Invited Keynote speaker: “Modern insights into the treatment of Glanzmann’s Thrombasthenia (GT)”
2. Invited speaker: “Glanzmann’s Thrombasthenia Registry: Treatment and outcomes in surgical interventions”

VIIIth World Federation of Hemophilia-Hemophilia Treatment Centers Collaborative Network of China Hemophilia Conference and Workshops, Wuhan, China (Oct 19-21, 2012)

Invited speaker:

Main conference

1. “How to write scientific papers in English”

6<sup>th</sup> China Hemophilia Physiotherapy Forum

1. “A Hemophilia Clinic Director’s view on Physiotherapy”

2012 Pediatric Hemophilia Workshop (Oct 21, 2012)

1. “Hemophilia Care: Recent Advances in the Molecular Era”
2. “Inhibitor Management in Hemophilia Children”

Blood Club, Saskatoon, Canada (Jan 16, 2013)

Invited speaker: “Hemophilia Care in China”

Blood Club, Vancouver, BC, Canada (Mar 14, 2013)

Invited speaker: “Hemophilia Care in China”

Canadian Hemophilia Physicians Update, Vancouver, BC, Canada (Jun 15, 2013)

Invited speaker: “Management of cardiovascular issues in hemophilia”

2013 Annual meeting of Taiwan Society of Thrombosis and Hemostasis, Taipei, Taiwan, May 18-19, 2013

Invited speaker:

1. “How to select rFVIII for Hemophilia A patient?”
2. “Managing Hemophilia Through Infancy and into Young Adulthood”

Taiwan Hemophilia KOL Visit & discussion, Kaoshiong, Taiwan, May 20, 2013

1. Invited speaker: “How to select rFVIII for Hemophilia A patient?”

International Society for Thrombosis and Haemostasis Congress, Amsterdam, The Netherlands, July 2, 2013

Oral presentation: “se”

St. Michael’s Hospital Hemophilia Treatment Centre, 30th Anniversary Symposium, Toronto, ON. Sept 23, 2013

Keynote speaker: “History of Comprehensive Hemophilia Care in Canada: A Tribute To the St Michael’s Hospital Program On Its 30<sup>th</sup> Anniversary”

World Federation of Hemophilia-Hemophilia Treatment Centers Collaborative Network of China workshops Nursing Workshop, Chongqing, China (October 19-20, 2013)

Hands-on workshop: “Assessment of muscle and joint bleed”

Pediatric Forum, Chengdu, China (October 26-27, 2013)

Invited speaker: “Inhibitors in hemophilia: diagnosis and risk of development”

Physiotherapy Workshop, Chengdu, China (October 26-27)

Invited speaker: “Hemophilia arthropathy: pain management”

Hereditary Angioedema Canada (HAEC) Western Regional Meeting, Calgary, Alberta (Dec 3, 2013)

Invited speaker: “Hereditary angioedema: An overview”

Calgary History of Medicine Society meeting, Calgary, Alberta (Feb 24, 2014)

Invited speaker: “History of Hemophilia Care in Canada: Triumph and Tragedy”

3<sup>rd</sup> Norman Bethune Symposium, Vancouver, BC, Canada (Apr 9, 2014)

Invited speaker: “Hemophilia in China: New Directions”

Gulf First Rare Bleeding Disorders Symposium, Dubai, UAE (April 11-12, 2014)

Invited co-chair: Plenary Session on “Glanzmann’s Thrombasthaenia”

Invited chair: Workshop on “Management of females with Glanzmann’s Thrombasthaenia”

Invited speaker: “Female with GT: Haematologist’s perspective”

AHCDC Scientific & Educational Symposium, Montreal, PQ, Canada (May 24, 2014)

Speaker (with Dr. Robert Card): AHCDC History Project

Canadian Hemophilia Physician Update, Calgary, AB, Canada (Jun 20-21, 2014)

Chair of the Conference

Moderator, session on “Acquired Hemophilia”

Moderator, session on “Innovation in Hemophilia Care”

Novo Nordisk Hemophilia and Rare Bleeding Disorders Update, Taipei, Taiwan (July 11-13, 2014)

Invited speaker: “Modern management of hemophilia – benefit of a comprehensive care model”

Invited speaker: Glanzmann’s thrombasthenia (GT) – General overview

Biogen Advisory Board meeting, Toronto, ON ( July 19, 2014)

2014 Asia Hemophilia Expert Meeting, Taipei, Taiwan (August 8-9, 2014)

Invited speaker: Plenary lectures

1. “Regional networking and collaboration: sharing best practice for expanding services in hemophilia”
2. “Real-world prophylaxis experience in hemophilia B: perspectives from clinical practice”
3. “Global perspectives on hemophilia care: guideline recommendations”

Discussant, Panel discussion sessions

1. “Developing hemophilia services: networking, collaboration and funding”
2. “Optimizing management strategies for hemophilia”

Workshop coordinator (2 sessions)

1. Individualizing therapy: selecting the right therapy at the right time

2014 Hemophilia Health and Economic Impact Summit (sponsor: Shanghai Fudan University), Beijing, China (Sept 4-6, 2014)

Invited speaker: “Current Treatment Landscape – A Global Perspective”

2014 World Federation of Hemophilia-Hemophilia Treatment Centers Collaborative Network of China biannual Conference, and Annual Pediatric Workshop, Annual Physiotherapy Workshop, Annual Nursing Workshop

Invited speaker:

1. “Real life experience in prophylaxis - recognizing failure risk factors to ensure success” (Pediatric Workshop)
2. “Assessment of musculoskeletal bleeding (with Adrienne Lee) Physiotherapy Workshop

University of Saskatchewan Department of Medicine Medical Grandround, Saskatoon, Canada Nov 19, 2014

Invited speaker: “The Royal Disease – History of Hemophilia Care in Canada: How did we do in Saskatchewan?”

Pan Arabian Hematology Society – European Hematology Association Conference, Abu Dhabi, United Arab Emirate (Feb 5-7, 2015)

Invited speaker: “Updates in Management of Glanzmann’s Thrombasthenia”

Canadian Pediatric Thrombosis and Hemosysis Network symposium , Halifax, NS, Canada May 28, 2015

Invited speaker: “Some investigations inspired by my patients: Glanzmann thrombathenia and Montreal Platelet Syndrome”

History of Medicine Seminar – History Department, College of Arts and Science, University of Saskatchewan, Saskatoon, Saskatchewan October 16, 2015

Speaker with Dr. Robert Card: “History of hemophilia care in Canada: The early years”.

Speaker with Nicole Shedden: “History of hemophilia care in Canada: from Golden to Grim”

Network of Rare blood Disorders Organization biannual conference, Calgary, AB, Oct 17, 2015

Invited speaker “Comprehensive Care: Hemophilia Care as a Model and Introduction to Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program Clinic”

Workshop lead and talk: Hereditary Angioedema

Allied Health Committee of Pathology Commissioned Training Programme 2015/16, Institute of Advanced Allied Health Studies, Hong Kong Hospital Authority, Hong Kong, China, Oct 22-23, 2015

Plenary speaker for theme topic “Diagnosis and Laboratory Studies/Assessment to Support Care for Inherited or Neonatal Disorders”:

1. “Hemophilia: current status”
2. “Inhibitors development in hemophilia”
3. “Von Willebrand disease: diagnosis and classification”
4. “Rare bleeding disorders: odds and ends”

WFH China Workshops (Nursing, Pediatrics, Physiotherapy), Shenzhen, China, Nov 6-8, 2015

Invited speaker

1. “Optimization of Prophylaxis” (with Dr. Adrienne Lee - Plenary session Nov 7, 2015)
2. “How to achieve prophylaxis in a real world: what principles – comments to Case 1” (Pediatrics Workshop Nov 7, 2015)
3. “How to monitor and deal with the inhibitor development in prophylaxis (and problematic differences between FIX and FVIII inhibitors) – comments to Case 2” (Pediatric Workshop, Nov 7, 2015)
4. ”Assessment of Muscle and Joint Bleeds: An Introduction” (with Dr. Adrienne Lee - Nursing workshop, Nov 8, 2015)

Grand Round, Internal Medicine, Queen’s University, Kingston, ON, Nov 12, 2015

“History of Comprehensive Hemophilia Care in Canada (including role of Queen’s in history): *Triumphs and Tragedies*”

Grand Rounds, Hematology, University of Saskatchewan, Saskatoon, SK April 28, 2016

“Hereditary platelet dysfunction: clinical aspects. Mild disorders – OR ARE THEY”

Association of Hemophilia Clinic Directors of Canada Annual Scientific Meeting, Vancouver, BC April 30, 2016

“History of comprehensive hemophilia care in Canada. Triumph and Tragedies”

Canadian Society of Transfusion Medicine Annual Scientific Meeting, Vancouver, BC, May 13, 2016

”Managing hemophilia in China”

4<sup>th</sup> Latin American Hemophilia Summit, Catargena, Colombia, May 16-18, 2016

Invited speaker Plenary lectures

1. “Alternative approaches to hemophilia management in the modern era: lessons from cost-constrained environment.”
2. “Addressing the challenges of prophylaxis: when and how to start?”

Hematology Rounds, Memorial University, St. John’s, NL July 13-14, 2016

1. “Hereditary platelet dysfunction: Diagnosis in non-specialist laboratories and management”
2. “Glanzmann’s thrombasthenia: An overview”

- Asian Pacific Society of Thrombosis and Hemostasis 9<sup>th</sup> Congress, Taipei, Oct 6-9, 2016  
Invited Symposium speaker (Symposium II, Hemophilia I), Oct 7, 2016  
“Individualized Prophylaxis for Optimizing Hemophilia Care: Can We Apply This to Both Developed and Developing Nations?”  
Session moderator: Oral communication 2 (Hemophilia), Oct 7, 2016  
Invited Satellite symposia speaker  
Bayer: “Prophylaxis in adults, is there a benefit?” (Oct 7, 2016)  
Pfizer: “Does circulation FIX activity (in IU) determine efficacy of Hemophilia B product therapy?” (Oct 8, 2016)
- 2016 World Federation of Hemophilia (WFH)-Hemophilia Treatment Centers Collaborative Network of China (HTCCNC) biannual Conference, and Annual Pediatric Workshop, Annual Physiotherapy Workshop, Annual Nursing Workshop, Xi’an, China, Oct 15-16, 2016  
Main conference invited plenary speaker (Oct 15, 2016)  
“Rare Inherited Bleeding Disorders: Clinical Overview”  
Pediatric Workshop (Oct 16, 2016)  
“What is new in hemophilia therapy?”
- 2017 World Federation of Hemophilia (WFH)-Hemophilia Treatment Centers Collaborative Network of China (HTCCNC) Annual Physiotherapy Workshop, Annual Nursing Workshop, Kunming, China, Oct 11-12, Nursing Workshop  
“How do my nurses use Pharmacokinetics (PK) for patient care? What’s new for clotting factors”  
Physiotherapy Workshop  
“Comprehensive care revisited: how our physiotherapists see their roles in the bleeding disorders clinic”
- Hematology Rounds, Division of Hematology and Hematologic Malignancies, Department of Medicine, Calgary, AB. Feb 23, 2017  
“Impact of transfusion medicine on hemophilia care (and vice versa)”
- Hematology Grandround, University of Saskatchewan Royal University Hospital, Saskatoon, SK. May 11, 2017  
“Impact of transfusion medicine on hemophilia care (and vice versa)”
- Peking Union Medical College Hospital, Beijing, China April 16, 2018  
Session moderator: “World Federation of Hemophilia -Hemophilia Day Education Session”
- Peking Union Medical College Hospital Hemophilia Program, Beijing, China, April 17, 2018  
Commentator on “Multidisciplinary comprehensive care in Calgary”
- No.1 Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China April 20, 2018  
Hemophilia Education Session  
“Inhibitors in hemophilia”
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China. April 21, 2018  
Coagulation Workshop  
“Principles of Coagulation testing”  
“Advanced coagulation testing”  
“Pharmacokinetics-guided prophylaxis methods”  
“Quality control (QC) and case reporting”  
“Coagulation case studies”
- Shenzhen Children’s Hospital, Shenzhen, Guangdong Province, China, April 22, 2018  
Regional Thrombosis and Hemostasis Workshop  
“Disseminated intravascular coagulation”  
“Thrombophilia”
- Immune Tolerance Induction (ITI) Therapy for Severe Hemophilia A with FVIII inhibitors The Basics  
Northern Jiangsu People’s Hospital, Yangzhou, Province of Jiangsu, China. April 24, 2018  
Jiangsu Provincial Hemophilia Network meeting on multidisciplinary hemophilia care  
“Multidisciplinary comprehensive hemophilia care in Canada”



- 2018 World Federation of Hemophilia (WFH)-Hemophilia Treatment Centers Collaborative Network of China (HTCCNC) Annual Physiotherapy Workshop, Annual Nursing Workshop, Annual Pediatric Forum, Harbin, China, August 31-Sept 1, 2018
- Nursing Workshop
    - “Mild hemophilia therapy: an old but safe agent that is less expensive and works (focus on DDAVP)”
  - Physiotherapy Workshop
    - “Do hemophilia patient have low bone mineral density? Is it important for physiatrist and Physiotherapist to know?”
  - Pediatric Workshop
    - “Immune Tolerance Induction (ITI) Therapy for Severe Hemophilia A with FVIII inhibitors: the Basics”
- 2018 Canadian Hemophilia Physicians Update. Montreal, Oct 20, 2018
- “DEBATE: Be it resolved, within the next 5 years, non-factor will eclipse factor VIII therapy as the standard of care for patients with hemophilia A (PRO-side)”
- 2019 Pfizer symposium on “Individualized Hemophilia Care” Montreal, May 24, 2019
- Invited speaker “Low dose prophylaxis – what are the benefits and for whom?”
- 2019 European Haematology Association 24<sup>th</sup> Congress, Amsterdam, June 16, 2019
- Scientific working group section on “Thrombocytopenias and platelet function disorders: critical situations in patients with inherited or acquired platelet defects”
  - Invited speaker: “Management of surgery in patients with inherited platelet defect”
- 2019 Korean Hemophilia Symposium, Seoul, South Korea June 28-29, 2019
- Plenary speaker (Jun 28, 2019): “Prophylaxis: global model of personalized prophylaxis in hemophilia B”
  - Plenary speaker (Jun 29, 2019): “New therapies for hemophilia: balancing caution with excitement”
- 2019 World Federation of Hemophilia (WFH)-Hemophilia Treatment Centers Collaborative Network of China (HTCCNC) Annual Physiotherapy Workshop, Annual Nursing Workshop, Xining, Qinghai Province, China, September 14, 2019
- Physiotherapy Workshop
    - “von Willebrand disease – what physiotherapists need to know”
  - Nursing Workshop
    - “von Willebrand disease – what nurses need to know”
- 2020 World Federation of Hemophilia (WFH)-Hemophilia Treatment Centers Collaborative Network of China (HTCCNC) Annual meeting Sept 11-13, 2020
- Nursing Workshop (Sept 13, 2020)
    - “Population Pharmacokinetics (popPK): Important role of the nurses” (virtual by Zoom)
- 2021 Hemophilia PEGylated-rFIX meeting, Taipei, Taiwan, March 13, 2021
- Plenary speaker: “N9-GP: the Canadian experience” (virtual by Zoom)
- 2021 Association of Hemophilia Clinic Directors of Canada (AHCDC) Annual Scientific Meeting (June 5, 2021)
- Card R, Blanchette V, Poon M-C, Teitel J, Israels S. AHCDC History Panel video presentation: “The Whys for AHCDC Formation” (virtual by Zoom)
- 2021 World Federation of Hemophilia (WFH)-Hemophilia Treatment Centers Collaborative Network, China (HTCCNC) Annual Meeting (Sept 25, 2021)
- Pediatrics, Nursing, Physiotherapy Workshops
    - Invited speaker: “An Introduction to Individualized Hemophilia Care” (virtual by Zoom)
- 2022 World Federation of Hemophilia (WFH)-Hemophilia Treatment Centers Collaborative Network, China (HTCCNC) Annual Meeting (Dec 24-25 2022)
- Nursing Workshop
    - Invited speaker: “Old wines in new bottles” (virtual by Zoom)

Pediatric Workshop

Invited speaker: “DDAVP and Tranexamic acid” (virtual by Zoom)

Physiotherapy Workshop

Invited speaker: “not so spontaneous ‘spontaneous bleeds’” (virtual by Zoom)

2023 Vancouver Blood Club meeting (February 2, 2023)

Invited speaker: “Diagnosis and Management of Acquired Hemophilia A (AHA)” (in person)

2023 Association of Hemophilia Clinic Directors of Canada (AHCDC) Annual General Meeting and Annual Scientific Meeting, Niagara Falls, Canada (May 5, 2023)

Invited speaker (with co-speaker Dr. Robert Card of Saskatoon): “Association of Hemophilia Clinic Directors of Canada (AHCDC) History: Background and Evolution”

2023 International Research Forum, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical University, Tianjin, China, (September 21, 2023)

Invited speaker: “Acquired hemophilia A: Diagnosis and Management”

2023 WFH-HTCCNC (Hemophilia Treatment Centers Collaborative Network of China) workshops, Quanzhou, Fujian Province, China (September 22, 2023)

Hemophilia Pediatric Workshop – Invited Master Class speaker: “Why I value my hemophilia physiotherapists”

Hemophilia Nursing Workshop - Invited speaker: “Why I value my hemophilia nurses”

Hemophilia Physiotherapy Workshop - Invited speaker: “Why I value my hemophilia physiotherapists”

2024 Association of Hemophilia Clinic Directors of Canada (AHCDC) Annual Scientific Meeting, Ottawa, Canada (May 4, 2024)

Invited speaker (with co-speaker Dr. Robert Card of Saskatoon): “Association of Hemophilia Clinic Directors of Canada (AHCDC). Part II: Continued Evolution and Moving Forward”

2024 Calgary city wide hemostasis journal club (September 4, 2024)

invited speaker “ISTH 2024. Highlights on Factor VIIIa Mimetics”

2024 WFH-HTCCNC (Hemophilia Treatment Centers Collaborative Network of China) workshops, Shanghai, , China (October 25-27)

Hemophilia Pediatric Workshop – Invited speaker: “What’s next after emicizumab”

Hemophilia Physiotherapy Workshop - Invited speaker: “Keep moving. Hemophilia and Physical Activity””

**PUBLICATIONS/ABSTRACT PRESENTATIONS (\*denotes trainees/graduate students/residents/fellows)**

*In this order: (A) Peer-Reviewed Manuscript, (B) Peer-Reviewed Manuscripts Submitted (C) Electronic Publications (peer-reviewed), (D) Electronic Continuing Medical Education Program, (E) Technology Reports, (F) Books, Chapters, (G) Books and Chapters in press, (H) Non-peer-reviewed Reviews/Invited Manuscripts (I) Theses, (J) Letters to the Editor (non-peer reviewed), (K) Abstracts*

**(A) Peer-Reviewed Manuscripts**

1. Bowen, S.T., Hanson, J., Dowling, P. and **Poon, M-C**. The genetics of *Artemia salina*. VI. Summary of mutations. *Biol.Bull.(Woods Hole)* 131:230-250, 1966.
2. Bowen, S.T., Leberherz, H.G., **Poon, M-C.**, Chow, V.H.S. and Grigliatti, T.A. The hemoglobins of *Artemia salina*. I. Determination of phenotype by genotype and environment. *Comp.Biochem.Physiol.* 31:733-747, 1969.
3. Kiyomoto, R.K., **Poon, M-C.** and Bowen, S.T. Ommochrome pigments of the compound eyes of *Artemia salina*. *Comp.Biochem.Physiol.* 29:975-984, 1969.
4. Waring, G., **Poon, M-C.** and Bowen, S.T. The haemoglobins of *Artemia salina*. II. Isolation of three haemoglobins. *Inter.J.Biochem.* 1:537-545, 1970.
5. Movat, H.Z., **Poon, M-C.** and Takeuchi, Y. The kinin-system of human plasma. I. Isolation of a low molecular weight activator of prekallikrein. *Inter.Arch.Allergy* 40:89-112, 1971.
6. **Poon, M-C.** and Sanders, M.G. Hepatic abscess caused by *Salmonella paratyphi B*. *Canad.Med.Assoc.J.* 102:529-531, 1972.
7. **Poon, M-C.**, Epstein, S.W. and Sepp, H. Immunofluorescent staining of lung biopsy in fibrosing alveolitis. *Canad.Med.Assoc.J.* 108:734-737, 1973.
8. Hubert, C. and **Poon, M-C.** Glutamic-pyruvic transaminase activity related to red cell age. *Canad.J.Biochem.* 53:731-734, 1975.
9. **Poon, M-C.**, Wine, A.C., Ratnoff, O.D. and Bernier, G.M. Heterogeneity of human circulating anticoagulants against antihemophilic factor (factor VIII). *Blood* 46:409-416, 1975.
10. Bowen, S.T., Moise, H.W., Waring, G. and **Poon, M-C.** The hemoglobins of *Artemia salina*. III. Characterization. *Comp.Biochem.Physiol.* 55B:99-103, 1976.
11. **Poon, M-C.** and Ratnoff, O.D. Evidence that functional subunits of antihemophilic factor (factor VIII) are linked by non-covalent bonds. *Blood* 48:87-94, 1976.
12. Ratnoff, O.D., Slover, C.C. and **Poon, M-C.** Immunologic evidence that the properties of human antihemophilic factor (factor VIII) are attributes of a single molecular species. *Blood* 47:657-667, 1976.
13. Saito, H., **Poon, M-C.**, Goldsmith, G.H., Ratnoff, O.D. and Arnason, U. Studies of the blood clotting fibrinolytic system in the plasma of a sei whale. *Proc.Soc.Exp.Biol.Med.* 152:503-507, 1976.
14. **Poon, M-C.** and Ratnoff, O.D. Immunologic evidence that the antihemophilic factor (factor VIII)-like material in hemophilic plasma possesses a nonfunctional low molecular weight subcomponent. *Blood* 50:367-376, 1977.

15. **Poon, M-C.**, Saito, H., Ratnoff, O.D., Forman, W.B. and \*Wiskieski, J. Techniques for demonstration of the specificity of circulating anticoagulants against antihemophilic factor (factor VIII), with studies of two cases possibly related to diphenylhydantoin therapy. *Blood* 49:477-482, 1977.
16. \*Weir, A.B., **Poon, M-C.** and McGowan, E.I. Plasma exchange for idiopathic thrombocytopenia purpura. *Lancet* 2:689, 1978.
17. Saito, H., **Poon, M-C.**, Vicic, W., Goldsmith, G.H. and Menitove, J. Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease. *J.Lab.Clin.Med.* 92:84-95, 1978.
18. Barton, J.C., Conrad, M.E. and **Poon, M-C.** Pseudochloroma: extramedullary hematopoietic nodules complicating early chronic myelocytic leukemia. *Ann.Intern.Med.* 91:735-738, 1979.
19. Parmley, R.T., **Poon, M-C.**, Crist, W.M. and Malluh, T. Giant platelet granules in a child with the Chediak-Higashi syndrome. *Am.J.Hematol.* 6:51-60, 1979.
20. **Poon, M-C.**, Prchal, J.T., Murad, T. and Galbraith, J.G. Multiple myeloma masquerading as chromophobe adenoma. *Cancer* 43:1513-1516, 1979.
21. \*Smith, D.K., **Poon, M-C.** and Flint, A. Inflammatory fibrous histiocytoma: response to non-surgical therapy. A case report. *Med.Pediatr.Oncol* 7:263-267, 1979.
22. \*Moore, M.R. and **Poon, M-C.** Thrombotic thrombocytopenia purpura-like syndrome associated with bacterial endocarditis. *So.Med.J.* 73:541-542, 1980.
23. **Poon, M-C.**, Flint, A. and Miles, G.L. Composite lymphoma - report of a unique case. *Cancer* 46:1676-1682, 1980.
24. \*Weir, A.B., **Poon, M-C.** and McGowan, E.I. Plasma exchange in idiopathic thrombocytopenia purpura. *Arch.Intern.Med.* 140:1101-1103, 1980.
25. \*Weir, A.B., **Poon, M-C.**, Groarke, J.F. and Wilkerson, J.A. Lymphoma simulating Crohn's colitis. *Digest.Dis.Sci.* 25:69-72, 1980.
26. \*Clipson, K.L., Kansal, P.C., **Poon, M-C.** and Boshell, B.R. Hemoglobin A1 in the diagnosis of chemical diabetes mellitus. *Horm.Metab.Res.* 13:129-131, 1981.
27. **Poon, M-C.**, Parmley, R.T., Chang-Poon, V.Y-H., Embry, J. and Austin, R. Non-immune interaction of leukocytes with platelets and megakaryocytes. *Am.J.Hematol.* 10:341-358, 1981.
28. Robinson, A., Mungall, D. and **Poon, M-C.** Quantitation of plasma warfarin concentration by high performance liquid chromatography. *Therapeutic Drug Monitoring* 3:287-290, 1981.
29. \*Floyd, D.M., Huang, S.T. and **Poon, M-C.** Quantitation of ABO mixed cell population by a peroxidase-antiperoxidase immunoenzyme method. *Transfusion* 22:352-354, 1982.
30. Hurst, R.E., Settine, J.M., **Poon, M-C.** and Lurie, A. Chemical heterogeneity in commercial heparins: comparison of anticoagulant potencies and biochemical compositions of anionic density-fractionated heparins. *Thromb.Res* 25:255-265, 1982.
31. \*Moore, M.R., **Poon, M-C.**, Williams, R.B. and McDonald, C.R. Acquired inhibitor to factor VIII (AHF) occurring with squamous cell carcinoma of the tongue. *J.Louisiana State Med.Soc.* 134:23-24, 1982.
32. **Poon, M-C.**, \*Moore, M.R., Castleberry, R.P., Lurie, A., Huang, S.T. and Lehmyer, J. Severe Fletcher factor (plasma prekallikrein) deficiency with partial deficiency of Hageman factor (factor XII). Report of a case with observations on *in vivo* and *in vitro* leukocyte chemotaxis. *Am.J.Hematol.* 12:261-270, 1982.

33. **Poon, M-C.**, Durant, J.R., \*Norgard, M.J. and Chang-Poon, V.Y-H. Inflammatory fibrous histiocytoma: an important variant of malignant fibrous histiocytoma highly responsive to chemotherapy. *Ann.Intern.Med.* 97:858-863, 1982.
34. **Poon, M-C.**, Hurst, R.E. and Rives, M.S. Platelet factor four and protamine sulfate neutralization of heparins fractionated according to anionic charge density. *Thrombos.Haemostas.* 47:162-165, 1982.
35. Rassiga, A.L., Finch, C.A., English, E.C., **Poon, M-C.**, Hartmann, R.C., Bishop, R.C. and Zaino, E.C. The practice of hematology in the People's Republic of China. *Ann.Intern.Med.* 96(4):524-525, 1982.
36. \*Barnes, H.M., **Poon, M-C.**, Huang, S.T., Conrad, M.E., Lin, J. and McGowan, E.I. Febrile transfusion reaction following initial transfusion in a man with immunoblastic lymphadenopathy and granulocyte antibodies. *Am.J.Hematol.* 14:97-100, 1983.
37. Garcia, J.H., Many, W.J.Jr., Alexander, R.W., Fraser, R.G. and **Poon, M-C.** Medical Pathology Conference: respiratory failure in a 54-year-old man with hemophilia A. *Alabama J.Med.Sci.* 20:164-170, 1983.
38. Essex, M., McLane, M.F., Lee, T.H., Tachibana, N., Mullins, J.I., Kreiss, J., Kasper, C.K., **Poon, M-C.**, Landay, A., Francis, D.P., Cabradilla, C., Lawrence, D.N. and Evatt, B.L. Antibodies to human T cell leukemia virus membrane antigens (HTLV-MA) in hemophiliacs. *Science* 221:1061-1064, 1983.
39. Eyster, M.E., Goedert, J.J., **Poon, M-C.** and Preble, O.T. Acid-labile alpha interferon: a possible pre-clinical marker for the acquired immune-deficiency syndrome in hemophiliacs. *N.Engl.J.Med.* 309:583-968, 1983.
40. Hurst, R.E., **Poon, M-C.** and Griffith, M.J. Structure-activity relationships of heparin: independence of heparin charge density and antithrombin-binding domains in thrombin inhibition by antithrombin and heparin cofactor II. *J.Clin.Invest.* 72:1042-1045, 1983.
41. \*Landay, A., **Poon, M-C.**, \*Abo, T., Stagno, S., Lurie, A. and Cooper, M.D. Immunologic studies in asymptomatic hemophilia patients: relationship to acquired immune deficiency syndrome (AIDS). *J.Clin.Invest.* 71:1500-1504, 1983.
42. McDaniel, H.G., Maddox, W.T., **Poon, M-C.**, Rogers, W.J. and Rackley, C.E. Platelet function abnormalities in response to arachidonic acid in the acute phase of myocardial infarction. *Am.J.Cardiol* 52:965-968, 1983.
43. **Poon, M-C.**, Tomana, M. and Niedermeier, W. Detection of serum antibodies against mouse mammary tumor virus-associated antigen nine months before the development of breast carcinoma. *Ann.Intern.Med.* 98:937-938, 1983.
44. **Poon, M-C.**, \*Landay, A., \*Prasthofer, E.F. and Stagno, S. Acquired immunodeficiency syndrome with *Pneumocystis carinii* pneumonia and *Mycobacterium avium-intracellulare* infection in a previously healthy patient with classic hemophilia. Clinical, immunologic and virologic findings. *Ann.Intern.Med.* 98:287-290, 1983. [one of the 100 most cited publications of the year]
45. Carroll, A.J., **Poon, M-C.**, Robinson, N.C. and Finley, W.H. Translocation (9;11)(p21,q23) in a case of acute myeloblastic leukemia (AML-M2). *Cancer Genet.Cytogenet.* 12:329-332, 1984.
46. \*Landay, A., **Poon, M-C.**, Clement, L.T. and Grossi, C.E. A lymphoproliferative disorder of granular lymphocytes with a novel phenotype and suppressor function. *J.Clin.Immunol.* 4:326-334, 1984.
47. Palmer, E.L., Ramsey, R.B., Feorino, P.F., Harrison, A.K., Cabradilla, C., **Poon, M-C.** and Evatt, B.L. Isolation of HTLV from lymphocytes of two hemophiliacs with AIDS. *Ann.Intern.Med.* 101:293-297, 1984.

48. Pontisso, P., **Poon, M-C.**, Tiollais, P. and Brechot, C. Detection of hepatitis B virus DNA in human blood mono-nuclear cells. *Br.Med.J.* 288:1563-1566, 1984.
49. **Poon, M-C.**, Saito, H. and Koopman, W.J. A unique precipitating autoantibody against plasma thromboplastin antecedent (PTA, Factor XI) associated with apparent multiple plasma clotting factor deficiencies in a patient with systemic lupus erythematosus. *Blood* 63:1309-1317, 1984.
50. Chang-Poon, V.Y-H., Hwang, W.S., Wong, A., Berry, J., Klassen, J. and **Poon, M-C.** Pulmonary hemorrhage and angiomatoid vascular changes in mitomycin C associated hemolytic uremic-like syndrome. *Arch.Path.Lab.Med.* 109:877-878, 1985.
51. \*De Braekeleer, M., **Poon, M-C.**, Russell, J. and Lin, C.C. A case of acute lymphoblastic leukemia with t(10;19) (q26;q13). *Cancer Genet.Cytogenet.* 16:369-372, 1985.
52. Hoar, D.I., Bowen, T., Matheson, D. and **Poon, M-C.** Hepatitis B virus DNA is enriched in polymorphonuclear leukocytes. *Blood* 66:1251-1253, 1985.
53. Prchal, J.T., Huang, S.T. and **Poon, M-C.** Immune hemolytic anemia following administration of anti-thymocyte globulin. *Am.J.Hematol.* 19:95-98, 1985.
54. Barton, J.C. and **Poon, M-C.** Coagulation testing of Hickman catheter blood in patients with acute leukemia. *Arch.Intern.Med.* 146:2165-2169, 1986.
55. Carroll, A.J., **Poon, M-C.**, Robinson, N.C. and Crist, W.M. Sideroblastic anemia associated with thrombocytopenia and a No. 3 abnormality. *Cancer Genet.Cytogenet.* 22:183-187, 1986.
56. Chui, D.H.K., Wong, S.C., \*Chung, S-W., Patterson, M., \*Bhargava, S. and **Poon, M-C.** Embryonic  $\alpha$ -globin chains in adults: a marker for  $\alpha$ -thalassemia-1 haplotype due to a >17.5-kb deletion. *N.Engl.J.Med.* 314:76-79, 1986.
57. Matheson, D., Green, B.J., **Poon, M-C.**, Fritzier, M.J., Hoar, D.I. and Bowen, T.J. Natural killer cell activity from hemophiliacs exhibit differential responses to various forms of interferon. *Blood* 67:164-167, 1986.
58. Matheson, D.S., Green, B.J., **Poon, M-C.**, Bowen, T.J., Fritzier, M.J. and Hoar, D.I. T lymphocytes from hemophiliacs proliferates after exposure to factor VIII product. *Vox Sang.* 51:92-95, 1986.
59. \*Moore, M.R., **Poon, M-C.**, Prchal, J.T. and Omura, E.F. Necrotizing vasculitis associated with chronic myelogenous leukemia. *Schumpert Med.Q.* 4:212-217, 1986.
60. Russell, J.A., Houwen, B., Ruether, B.A., Shin, K.H., Jones, A.R., Bowen, T. and **Poon, M-C.** Bone marrow transplantation for acute monocytic leukemia following the treatment of Hodgkin's disease. *Med.Pediatr.Oncol.* 14:319-322, 1986.
61. **Poon, M-C.**, Bowen, T., Cassol, S. and Hoar, D.I. DNA-probing assay in the detection of hepatitis B virus genome in human peripheral blood cells. *Prog.Clin.Biol.Res.* 211:317-331, 1986.
62. Russell, J.A., Berry, J., Blahey, W.B., Geggie, P.H.S., Houwen, B., Jones, A.R., **Poon, M-C.** and Ruether, B.A. Bone marrow transplantation for Hodgkin's disease. *J.Clin.Oncol.* 4:610-611, 1986.
63. Field, S.K. and **Poon, M-C.** Sarcoidosis presenting as chronic thrombocytopenia. *Western J.Med.* 146:481-482, 1987.
64. Kloiber, R., **Poon, M-C.** and Molnar, C.P. Platelet sequestration in a vascular malformation of Klippel-Trenaunay syndrome. *Am.J.Roentgenol* 149:1275-1277, 1987.

65. Matheson, D.S., Green, B.J., Fritzler, M.J., **Poon, M-C.**, Bowen, T.J. and Hoar, D.I. Humoral immune response in patients with hemophilia. *Clin.Immunol.Immunopathol.* 44:41-50, 1987.
66. **Poon, M-C.**, Chui, D.H.K., Patterson, M., Starozik, D.M., Dimnik, L.S. and Hoar, D.I. Hemophilia B (Christmas disease) variants and carrier detection analyzed by DNA probes. *J.Clin.Invest.* 79:1204-1209, 1987.
67. \*Maung, R., Kelly, J.K., \*Schneider, M.P. and **Poon, M-C.** Mesenteric vein thrombosis due to antithrombin III deficiency. *Arch.Path.Lab.Med.* 112:32-37, 1988.
68. **Poon, M-C.** Patients with hemophilia B (Christmas disease) who have anti-factor IX: genetic heterogeneity. *J.Lab.Clin.Med.* 112:283-284, 1988.
69. **Poon, M-C.**, Hall, K., Scott, C.W. and Prchal, J.T. G6PD Viangchan: a new glucose-6-phosphate dehydrogenase variant from Laos. *Hum.Genet.* 78:98-99, 1988.
70. Belenkie, I., Thompson, C.R., Manyari, D., Knudtson, M.L., Duff, H.J., **Poon, M-C.** and Smith, E.R. The importance of effective, early and sustained reperfusion during acute myocardial infarction: a working hypothesis. *Am.J.Cardiol.* 63:912-916, 1989.
71. Cassol, S.A., **Poon, M-C.**, Pal, R., Naylor, M.J., Culver-James, J., Bowen, T.J., Russell, J.A., Krawetz, S.A., Pon, R. and Hoar, D.I. Primer mediated enzymatic amplification of cytomegalovirus (CMV) DNA: application to the early diagnosis of CMV infection in marrow transplantation recipients. *J.Clin.Invest.* 83:1109-1115, 1989.
72. Ching, E.P., Ruether, B.A. and **Poon, M-C.** Rapid thawing of fresh frozen plasma using an unmodified microwave oven. *Immunohematol.Bull.* 10:43-47, 1989.
73. **Poon, M-C.**, Kloiber, R. and Birdsell, D.C. Epsilon aminocaproic acid in the reversal of consumptive coagulopathy with platelet sequestration in a vascular malformation of Klippel-Trenaunay syndrome. *Am.J.Med.* 87:211-213, 1989.
74. **Poon, M-C.**, Russell, J., Low, S., Sinclair, G.D., Jones, A.R., Blahey, W., Ruether, B.A. and Hoar, D.I. Hemopoietic origin of factor XIII A-subunits in platelets, monocytes and plasma: evidence from bone marrow transplantation studies. *J.Clin.Invest.* 84:787-792, 1989.
75. Russell, J.A., Jones, A.R., Houwen, B., **Poon, M-C.** and Ruether, B.A. Double autologous bone marrow transplantation for acute myelogenous leukemia following therapy for Hodgkin's disease. *Med.Pediatr.Oncol.* 17:524-527, 1989.
76. Russell, J.A., \*Selby, P.J., Ruether, B.A., \*Mbidde, E.K., Ashley, S., Zulian, G., Berry, J., Houwen, B., Jones, A.R., **Poon, M-C.**, Blahey, W.B., Brada, M., Nandi, A., Geggie, P.H.S., Gore, M.E. and McElwain, T.J. Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation. *Bone Marrow Transpl.* 4:425-429, 1989.
77. Lafreniere, R., Borkenhagen, K., Bryant, L.D., Anton, A.R., Chung, A. and **Poon, M-C.** Analysis of liver cell subsets pre- and post- *in vivo* administration of human recombinant interleukin-2 in a C57BL/6 murine system. *Cancer Res.* 50:1658-1666, 1990.
78. Shiozawa, C., Kashiwagi, N., Gill, M.J., Ohnishi, M., Johnson, S., Church, D., **Poon, M-C.**, Adachi, M., Nantel, S., Parboosingh, J. and **Poon, M-C.** Treatment of an aggressive non-Hodgkin's lymphoma during pregnancy with MACOP-B chemotherapy. *Med.Pediatr.Oncol.* 8:143-145, 1990.
79. Hakomori, S. and Tamaoki, T. Progressive changes of carbohydrate antigen expression in HIV infection. *J.Immunol.Immunopharmacol.* 10:210, 1990.
80. Anton, A.R., Borkenhagen, K.B., Bryant, L.D., **Poon, M-C.** and Lafreniere, R. Morphologic, phenotypic and cytotoxic analysis of C57BL/6 murine non-parenchymal liver cells: new evidence associating murine

- liver large granular lymphocytes with monocyte precursors and implications for tumor immunotherapy. *Mol.Biother.* 3:108-116, 1991.
81. Ching, E., **Poon, M-C.**, Neurath, D. and Ruether, B.A. Red cell alloimmunization complicating plasma transfusion. *Am.J.Clin.Path.* 96:201-202, 1991.
  82. Junker, A.K., **Poon, M-C.**, Hoar, D.I. and Rogers, P.C.J. Severe combined immune deficiency presenting with cyclic haematopoiesis. *J.Clin.Immunol.* 11:369-377, 1991
  83. \*Krumdieck, R., Shaw, D.R., Huang, S.T., **Poon, M-C.** and Rustagi, P.K. Hemorrhagic disorder due to an isoniazid associated acquired factor XIII inhibitor in a patient with Waldenstrom's macroglobulinemia. *Am.J.Med.* 90:639-645, 1991.
  84. Walker, I. and the Canadian Hemophilia Clinic Directors' Group (including **Poon, M-C.**) Survey of the Canadian hemophilia population. *Canad.J.Pub.Health* 82:127-129, 1991.
  85. Wong, S.C., Tresanovic, M. and **Poon, M-C.** Detection of two abnormal hemoglobins, Hb Manitoba and Hb G-Coushatta, during analysis for glycated hemoglobin A1C by high-performance liquid chromatography. *Clin.Chem.* 37:1456-1459, 1991.
  86. Lemon, S.M., Becherer, P.R., Wang, J-G., White, G.C., Lesesne, H., Janco, R.L., Hanna, W.T., Davis, C., Johnson, C.A., **Poon, M-C.**, and Andes, A. Hepatitis delta infection among multiply-transfused hemophiliacs. *Prog.Clin.Biol.Res.* 364:351-360, 1991.
  87. \*Fraser, B.M., **Poon, M-C.** and Hoar, D.I. Identification of factor IX mutations in hemophilia B: application of polymerase chain reaction and single strand conformation analysis. *Hum.Genet.* 88:426-430, 1992
  88. **Poon, M-C.**, Hoar, D.I., Low, S., Pon, J.K., Anand, S. and Sinclair, G.D. Hemophilia A (classic hemophilia) carrier detection by restriction fragment length polymorphism (RFLP) analysis and enzyme linked immunosorbent assay (ELISA) based discriminant analysis of factor VIII and von Willebrand factor. *J.Lab.Clin.Med.* 119:751-762, 1992.
  89. Russell, J.A., **Poon, M-C.**, Jones, A.R., Woodman, R.C. and Ruether, B.A. Allogeneic bone marrow transplantation for adults with malignancy without protective isolation. *Lancet* 339:38-40, 1992.
  90. \*Ritchie, B., Woodman, R.C. and **Poon, M-C.** Deep venous thrombosis in hemophilia A. *Am.J.Med.* 93:699-700, 1992
  91. Growe, G.H., **Poon, M-C.** and Scarth, I. International Symposium on Recombinant Factor VIII: report of the proceedings. *Transfusion Medicine Review* 6:137-145, 1992.
  92. **Poon, M-C.** and Growe, G.H. International Symposium on Recombinant Factor VIII: Guest editorial. *Transfusion Medicine Review* 6:233-234, 1992.
  93. **Poon, M-C.** and Growe, G.H. International Symposium on Recombinant Factor VIII: Conclusions. *Transfusion Medicine Review* 6:294, 1992.
  94. **Poon, M-C.** Cryoprecipitate: uses and alternatives. *Transfusion Medicine Review* 7:180-92, 1993
  95. Giannelli, F., Green, P.M., High, K.A., Sommer, S., **Poon, M-C.**, Ludwig, M., Schwaab, R., Reitsma, P.H., Goossens, M., Yoshioka, A. and Brownlee, G.G. Haemophilia B: database of point mutations and short additions and deletions - fourth edition, 1993. *Nucl.Acids.Res.* 21:3075-3087, 1993.
  96. Canadian Hemophilia Clinic Directors Group (including **Poon, M-C.**). Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. *Br.Med.J.* 306:306-307, 1993



97. \*Tang, W., \*Cai, S.P., \*Eng, B., **Poon, M-C.**, Waye, J.S., Illum, N. and Chui, D.H.K. Expression of embryonic zeta- and epsilon-globin chains in a 10-year-old girl with congenital anemia. *Blood* 81:1636-1640, 1993
98. **Poon, M-C.**, Anand, S., \*Fraser, B.M., Hoar, D.I., and Sinclair, G.D. Hemophilia B carrier determination based on family specific mutation detection by DNA single strand conformation analysis. *J.Lab.Clin.Med.* 122:55-63, 1993
99. Grove, G.H., Chang, T.M.S., Slichter, S.J., Tartter, P. and **Poon, M-C.** New concepts in blood product usage. *Ann.Royal Coll.Phys.Surg.Canada* 26:106-108, 1993.
100. Kashiwagi, N., Gill, M.J., Adachi, M., Church, D., Wong, S.J., **Poon, M-C.**, Hakomori, S., Tamaoki, T. and Shiozawa, C. Lymphocyte membrane modifications induced by HIV infection. *Tohoku.J.Exp.Med.* 173:115-131, 1994.
101. \*Mah, M.W., Royce, R.A., Rathouz, P.J., Wang, J-G., White, G.C., Janco, R.L., Hanna, W.T., Davis, C., Johnson, C.A., **Poon, M-C.**, Andes, W.A. and Lemon, S.M. Prevalence of hepatitis A antibodies in hemophiliacs: preliminary results from the Southeastern delta hepatitis study. *Vox Sang* 67 (suppl 1): 21-23, 1994.
102. Russell, J.A., Woodman, R.C., **Poon, M-C.**, Jones, A.R., and Ruether, B.A. Addition of low dose folinic acid to a methotrexate/cyclosporine A regimen for prevention of acute graft-versus-host disease. *Bone Marrow Transplant* 14:397-401, 1994.
103. Grove, G.H., **Poon, M-C.**, Hoyer, L., Kessler, C.M., Rivard, G., Vick, S. and Kasper, C. Diagnosis and Treatment of Inhibitors of Coagulation. *Ann.Royal Coll.Phys.Surg.Canada* 27:296-300, 1994
104. Blanchette, V., Walker, I., Gill, P., Adams, M., Roberts, R., Inwood, M. and the Canadian Hemophilia Clinic Director's Group (including **Poon, M-C.**). Hepatitis C infection in patients with hemophilia: results of a national survey. *Transfusion Medicine Review* 8:210-217, 1994.
105. **Poon, M-C.** Recombinant factor VIII: Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients - impact on the immune and other systems. *Ann.Hematol* 68:S83-S86, 1994.
106. **Poon, M-C.**, Low, S., and Sinclair, G.D. Factor VIII gene rearrangement analysis and carrier determination in hemophilia A. *J.Lab.Clin.Med.* 125:402-406, 1995.
107. **Poon, M-C.**, Aledort, L.M., Anderle, K., Kunschak, M., Morfini, M. and the Factor IX Study Group. Clinical studies of recovery and half-life of a vapor heat-treated human factor IX concentrate. *Transfusion* 35:319-323, 1995.
108. **Poon, M-C.**, Ng, S.C. and Coppes, M.J. Acquired platelet dysfunction with eosinophilia in caucasian children. *J.Pediatr.* 126:959-961, 1995.
109. Association of Hemophilia Clinic Directors of Canada (Writers: **Poon, M-C.**, Lillicrap, D., Israels, S.). Clinical practice guidelines -- Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. *Canadian Med.Assoc.J.* 153:19-25, 1995.
110. Association of Hemophilia Clinic Directors of Canada (Writers: **Poon, M-C.**, Lillicrap, D., Israels, S.). Clinical practice guidelines -- Hemophilia and von Willebrand's disease: 2. Management. *Canadian Med.Assoc.J.* 153:147-157, 1995.
111. Berthiaume, Y., Boiteau, P., Fick, G., Kloiber, R., Sinclair, G.D., Fong, C., **Poon, M-C.** and Lafrenière, R. Pulmonary edema during IL-2 therapy: combined effect of increased permeability and hydrostatic pressure. *Am.J.Respir.Crit.Care Med.* 152:329-335, 1995

112. Walker, I., Pai, M., Akabutu, J., Ritchie, B., Growe, G., **Poon, M-C.**, Card, R., Ali, K., Israels, S., Teitel, J., Garvey, B., Blanchette, V., Giles, A., Lillicrap, D., Drouin, J., Luke, B., Gill, K., Herst, J., Lépine-Martin, M., Inwood, M., Rivard, G., Strawczynski, H., Jobin, F., Demers, C., Jardine, L., Whitman, L., Ingram, L., Robinson, S., Rubin, S., Scully, M-F., Dolan, S. and Ross, E. The Canadian hemophilia registry as the basis for national system to monitor the use of factor concentrates. *Transfusion* 35:548-551, 1995
113. \*Tay-Uyboco, J., **Poon, M-C.**, Ahmad, S. and Hollenberg, M.D. Contractile actions of thrombin receptor-derived polypeptides in human umbilical and placental vasculature: evidence for distinct receptor systems. *Brit.J.Pharmacol.* 119:569-578, 1995.
114. \*Aslam, S., **Poon, M-C.**, Yee, V.C., Bowen, D.J. and Standen, G.R. Factor XIII<sub>A</sub> Calgary: a candidate missense mutation (Leu667Pro) in the beta barrel 2 domain of the factor XIII<sub>A</sub> subunit. *Br.J.Haematol* 91:452-457, 1995.
115. \*Kanwar, S., Woodman, R.C., **Poon, M-C.**, Murohara, T., Lefer, A.M., Davenpeck, K.L. and Kubes, P. Desmopressin induces endothelial P-selectin expression and leukocyte rolling in post-capillary venules. *Blood* 86:2760-2766, 1995.
116. Giannelli, F., Green, P.M., Sommer, S., **Poon, M-C.**, Ludwig, M., Schwaab, R., Reitsma, P.H., Goossens, M., Yoshioka, A. and Brownlee, G.G. Haemophilia B: database of point mutations and short additions and deletions - sixth edition *Nucl.Acids.Res.* 24:103-118, 1996.
117. Russell, J.A., Bowen,T., Brown, C., Luider, J., Ruether, J.D., Stewart, D., Jorgenson, K., Coppes, M.J., Turner, A.R., Larratt, L., Chaudhry, A., Booth, K., **Poon, M-C.** and Klassen, J. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells. *Bone Marrow Transplant.* 18:501-505, 1996.
118. Russell, J., Brown, C., Bowen, T., Luider, J., Ruether, J.D., Stewart, D., Chaudhry, A., Jorgenson, K., Coppes, M.J., Turner, A.R., Larratt, L., Desai, S., **Poon, M-C.** and Klassen, J. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplanttion. *Bone Marrow Transplant* 17:703-708, 1996.
119. \*Ahmad, F., Solymoss, S., **Poon, M-C.**, Berube, C. and Sullivan, A.K. Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. *Brit.J.Haematol.* 93:700-703, 1996.
120. Giannelli, F., Green, P.M., Sommer, S., **Poon, M-C.**, Ludwig, M., Schwaab, R., Reitsma, P.H., Goossens, M., Yoshioka, A., Figueiredo, M.S. and Brownlee, G.G. Haemophilia B:- database of point mutations and short additions and deletions - seventh edition *Nucl.Acids.Res.* 25:133-135, 1997.
121. Russell, J.A., Desai, S., Herbut, B., Brown, C., Luider, J., Ruether, J.D. Stewart, D., Chaudhry, A., Booth, K., Jorgenson, K., Coopes, MJ., Turner, A.R., Larratt, L., **Poon, M-C.**, and Klassen, J. Partially mismatched blood cell transplants for high-risk hematologic malignancy. *Bone Marrow Transplant* 19:861-866, 1997
122. Sinclair, G.D., Low, S. and **Poon, M-C.** A heminested allele-specific whole blood PCR assay for the detection of factor V Leiden mutation associated with activated protein C resistance. *Thromb Haemost* 77:1154-1155, 1997
123. Stewart, D.A., Guo, D., Sutherland, J.A., Ruether, B.A., Jones, A.R., **Poon, M-C.**, deMetz, C., Klassen, J., Chaudhry, A., Brown C.B. and Russell, J.A. Single agent high dose melphalan salvage therapy for Hodgkin's disease: cost, safety, and long-term efficacy. *Ann Oncol* 8:1277-1279, 1997

124. Woodman, R.C., Ostrovsky, L., \*Teoh, D., Payne D., **Poon, M-C.**, Kubes, P. Antithrombin modulates neutrophil-endothelial interactions in certain forms of acute inflammation. *Blood Coagulation and Fibrinolysis* 9 (suppl 2):S7-S15, 1998.
125. \*Xu, J., **Poon, M-C.**, Ruether, B.A. and Roland, B. Two new cases of myelodysplastic syndrome with 45,X,-X. *Cancer Genet Cytogenet* 103:76-77, 1998.
126. Giannelli, F., Green, P.M., Sommer, S., **Poon, M-C.**, Ludwig, M., Schwaab, R., Reitsma, P.H., Goossens, M., Yoshioka, A., Figueiredo, M.S. and Brownlee, G.G. Haemophilia B:- database of point mutations and short additions and deletions - eighth edition *Nucl.Acids.Res.* 26:265-268, 1998.
127. Teitel, J.M., Card, R., Strawczynski, H. and the Association of Hemophilia Clinic Directors of Canada (including **Poon, M-C.**). Laboratory and clinical markers of HIV infection in a national hemophilia cohort treated with recombinant factor VIII concentrate. *Haemophilia* 4:731-738, 1998
128. Giles, A.R., Verbruggen, B, Rivard G.E., Teitel, J., Walker, I., and the Association of Hemophilia Centre Directors of Canada (include **Poon, M-C.**) A detailed comparison of the performance of the standard versus the Nijmegen Modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. *Thromb Haemost* 79:872-875, 1998
129. Walker, I.R., Julian, J.A. and Association of Hemophilia Clinic Directors of Canada (include **Poon, M-C.**) Causes of death in Canadians with haemophilia 1980-1995. *Haemophilia* 4:714-720, 1998
130. **Poon, M-C.** Hemophilia Care in Canada *Chinese Journal of Hematology* 19:501-503, 1998.
131. Stewart, D.A., Guo, D., Morris, D., **Poon, M-C.**, Ruether, B.A., Jones, A.R., Auer, I., Luider, J., Chaudhry, A., Brown, C. and Russell, J.A. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from intensive chemotherapy regimens. *Bone Marrow Transplant* 23:111-117, 1999
132. **Poon, M-C.**, Demers, C., Jobin, F. and Wu, J.W.Y. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. *Blood* 94:3951-3953, 1999
133. Russell, J.A., Larratt, L., Brown, C., Turner, A.R., Chaudhry, A., Booth, K., Woodman, R.C., Wolff, J., Valentine, K., Stewart, D., Ruether, J.D., Ruether, B.A., Klassen, J., Jones, A.R., Gyonyor, E., Egeler, M., Dunsmore, J., Desai, S., Coppes, M.J., Bowen, T., Anderson, R. and **Poon, M-C.** Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell course on outcome. *Bone Marrow Transplantation* 24:1177-1183, 1999.
134. \*Lee, D.H., Walker, I.R., Teitel, J., **Poon, M-C.**, Ritchie, B., Akabutu, J., Sinclair, G.D., Pai, M., Wu, J.W.Y., Reddy, S., Carter, C., Grove, G., Lillicrap, D., Lam, M. and Blajchman, M.A. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. *Thromb.Haemost* 83:387-391, 2000
135. Russell, J.A., Chaudhry, A., Booth, K., Brown, C., Woodman, R.C., Valentine, K., Stewart, D., Ruether, J.D., Ruether, B.A., Jones, A.R., Coopes, M.J., Bowen, T, Aderson, R., Boouchard, M., Rallison, L., Stotts, M., and **Poon, M-C.** Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: A ten-year experience. *Biology of Blood and Marrow Transplantation* 6:109-114, 2000
136. **Poon, M-C.**, d'Oiron R, and the International Registry on Recombinant factor VIIa and Congenital Platelet disorders Group. Recombinant factor VIIa (rFVIIa, NovoSeven) treatment of platelet related bleeding disorders *Blood Coagulation and Fibrinolysis* 11 (suppl):S55-S68, 2000
137. Kulkarni, R., Aledort, L. M., Berntorp, E., Brackman, H. H., Brown, D., Cohen, A. R., Ewing, N. P., Gringeri, A., Gruppo, R., Hoots, K., Leissenger, C., Peerlinck, K., **Poon, M-C.**, Wong, W-Y. Therapeutic

- choices for patients with hemophilia and high titer inhibitors. *American Journal of Hematology* 67: 240-246, 2001.
138. **Poon, M-C.** Use of recombinant factor VIIa in hereditary bleeding disorders. *Current Opinion in Hematology* 8:312-318, 2001
139. Roth, D. A., Kessler, C.M., Pasi, K.J., Rup, B., Courter, S.G., Tubridy, K.L. and Recombinant Factor IX Study Group (including **Poon, M-C.**) Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. *Blood*. 2001;98:3600-3606
140. **Poon, M-C.**, d'Oiron, R., Hann, I., Huth-Kuehne, A., Négrier, C., Fressinaud, E., Karafoulidou, A., Morfini, M., Petrini, P., de Lumley, L., Demers, C., von Depka, M., Musso, R., Street, A., Tengborn, L., Van Geet, C., Devecioglu, O., Houston, D.S., Lethagen, S., Thomas, A., Berger, C., Beurreier, P., Britton, H.A., Gerrits, W., Guthner, C., Ingerslev, J., Kuhle, S., Lorenzo, J. J. Makris, P. E., Nohe, N., Paugy, P., Pautard, B., Peters, M., Strauss, G., Torchet, M-F., Trillot, N., Vicariot, M., Wilde, J. and Winter, M. Use of recombinant factor VIIa (NovoSeven®) in patients with Glanzmann's thrombasthenia. *Seminar in Hematology* 38 (suppl 12): 21-25, 2001.
141. Lillicrap, D., **Poon, M-C.**, Walker, I., Xie, F., Schwartz, B. A., and members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P, administered in ristocetin cofactor unit doses to patients with von Willebrand disease. *Thrombosis and Haemostasis* 87:224-230, 2002
142. **Poon, M-C.**, Lillicrap, D., Hensman, C., Card, R., Scully, M-F., and Members of Association of Hemophilia Clinic Directors of Canada and Canadian Association of Nurses in Hemophilia Care. Recombinant factor IX recovery and inhibitor safety: A Canadian post-licensure surveillance study. *Thrombosis and Haemostasis* 87:431-435, 2002
143. O'Brien L A, \*James PD, Othman M, Berber E, Cameron C, Notley CRP, Hegadorn CA, Sutherland JJ, Hough C, Rivard GE, O'Shaunessey D, AHDCDC (including **Poon, M-C**), Lillicrap DP. A founder von Willebrand factor haplotype associated with Type 1 von Willebrand disease. *Blood*; 102:549-557, Jul 2003.
144. **Poon, M-C.** Management of thrombocytopenia bleeding: Is there a role for recombinant coagulation factor VIIa? *Current Hematology Reports* 2:139-147, 2003
145. \*Acharya SS, Coughlin A, DiMichele DM and the North American Rare Bleeding Disorder Study Group (including **Poon, M-C**). Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. *Journal of Thrombosis and Haemostasis* 2:248-256, 2004
146. Teitel, J., Barnard, D., Israels, S., Lillicrap, D., **Poon, M-C.**, Sek, J. Home management of hemophilia. *Haemophilia* 10(2):118-133, 2004
147. **Poon, M-C.**, d'Oiron, R., von Depka, M., Khair, K., Négrier, C., Karafoulidou, A., Huth-Kuehne, A., Morfini, M. and members of the International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: Results of an international survey. *Journal of Thrombosis and Haemostasis* 2:1096-1103, 2004
148. Courmoyer, D., Teffelmire, E.B., Wells, G.A., Barber, D.L., Barrett, B.J., Delage, R., Forrest, D.L., Gagnon, R.F., Harvey, E.A., Laneville, P., Patterson, B.J., **Poon, M-C.**, Posen, G.A., Messner, H.A., the members of the Canadian PRCA Focus Group. Anti-erythropoietin antibody-mediated pure red cells aplasia following treatment with recombinant erythropoietin products: recommendations for minimization of risk. *Journal of American Society of Nephrology* 15:2728-2734, 2004

149. \*James, P.D., O'Brien, L.A., Hegadorn, C.A., Notley, C.R.P., Sinclair, G.D., Hough, C., **Poon, M-C** and Lillicrap, D. A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of two non-adjacent exons. *Blood* 104: 2739 – 2745, 2004
150. d'Oiron, R., **Poon, M-C.**, Abshire, T., Berger, C., Beurrier, P., Blanchette, V., Britton, H.A., Chuansumrit, A., Demers, C., Devocioglu, O., Fressinaud, E., Gerrits, W.B.J., Guérin, V., Guethner, C., Heisel, M., Houston, D.S., Huth-Kuehne, A., Karafoulidou, A., Kenet, G., Khair, K., Kuhle, S., Kurnik, K., Lethagen, S., Lorenzo, J., Makris, P.E., Morfini, M., Musso, R., Négrier, C., Lambert, T., de Lumley, L., Marquès-Verdier, A., Paugy, P., Pautard, B., Petrini, P., Shapiro, A., Sié, P., Street, A., Tengborn, L., Thomas, A., Torchet, M-F., Trillot, N., Van Geet, C., von Depka, M., Vicariot, M., Warriar, I., Wilde, J., and Winter, M. Outcomes from the Glanzmann's thrombasthenia and recombinant factor VIIa data collection. *Haematologica* 98 (Suppl 5):38-40, 2004
151. Barrowcliffe, T., Berntorp, E., Blanchette, V., Bjorkman, S., Carcao, M., MiMichele, D., Lee, C., Morfini, M., Pencharz, P., **Poon, M-C.**, Saenko, E., Stass, H. State of the art international symposium on pharmacokinetics of factor concentrates in haemophilia: challenges and relevance to clinical practice. Summary Statement. *Haemophilia* 12 (Suppl 4):3-5, 2006
152. \*Chun, R., **Poon, M-C**, Haigh, J., Seal, D. Donahue, B., Royston, D. Cardiac surgery in congenital afibrinogenemia with thrombo-occlusive disease. *The Journal of Cardiothoracic and Vascular Anesthesia* 19(1):109-117, 2005
153. \*Jackson, S., Beck, P., Pineo, G. and **Poon, M-C**. Helicobacter pylori eradication: a novel therapy for immune thrombocytopenic purpura? A review of the Literature. *American Journal of Hematology* 78:142-150, 2005
154. Rivard, G., Lillicrap, D., **Poon, M-C.**, Demers, C., Lépine, M., St-Louis, J., and Warner, M. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after two years of age? *Haemophilia* 11(4):335-9, 2005
155. Shapiro, A., Korth-Bradley, J., **Poon, M-C**. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. *Haemophilia* 11(6):571-582, 2005
156. \*James, P.D., Raut, S., Rivard, G.E., **Poon, M-C**, Warner, M., McKenna, S., Leggo, J., Lillicrap, D. Aminoglycoside Suppression of Nonsense Mutations in Severe Hemophilia. *Blood* 106(9):3043-3048, 2005
157. \*Barnes, C., Rivard, G.E., **Poon, M-C.**, Teitel, J., Pai, M., Kern, M., Blanchette, V. and Carcao, M. on behalf of the Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada. Canadian multi-institutional survey of immune tolerance therapy (ITT) – experience with the use of recombinant factor VIII for ITT. *Haemophilia* 12(1):1-6, 2006.
158. Carcao, M., St. Louis, J., **Poon, M-C.**, Grunebaum, E., Lacroix, S., Stain, A.M., Blanchette, V.S., Rivard, G.E. on behalf of the Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada. Rituximab for congenital hemophiliacs with inhibitors: A Canadian experience. *Haemophilia* 12(1):7-18, 2006.
159. \*James PD, Patterson AD, Notely CRP, Hegadorn CA, Tinlin S, Brown C, Tuttle A, AHDCDC (including **Poon, M-C**), Lillicrap D. Genetic Linkage and Association Analysis in Type 1 von Willebrand Disease (VWD): Results from the Canadian Type 1 VWD Study. *Journal of Thrombosis and Hemostasis*, 4 (4): 783-92. Apr 2006
160. **Poon, M-C**. Pharmacokinetics of factor IX, recombinant human activated factor VII, and factor XIII. *Haemophilia* 12 (Suppl 4) 61-69, 2006.

161. \*Deyell, R., \*Jackson, S., Spier, S., Le, D. and **Poon, M-C.** Low oxygen saturation by pulse oximetry may be associated with a low oxygen affinity variant: case of Hemoglobin Titusville. *Journal of Pediatric Hematology Oncology* 28(2):100-102, 2006.
162. \* Zhou, B., \*Bi, Y.Y., Han, Z.B., Ren, H., **Poon, M-C.**, Han, Z.C. G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability. *Journal of Thrombosis and Haemostasis* 4:993-1002, 2006
163. Feldman, B.M., Pai, M., Rivard, G.M., Israels, S., **Poon, M-C.**, Demers, C., Robinson, S., Luke, K-H., Gill, K., Lillicrap, D., Babyn, P., McLimont, M., and Blanchette, V.S. Tailored prophylaxis in severe hemophilia A: data obtained during the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study (CHPS). *Journal of Thrombosis and Haemostasis* 4:1228-1236, 2006
164. Arnold, D.M., Julian, J.A., and Walker, I.R. for the Association of Hemophilia Clinic Directors of Canada (including **Poon, M-C.**) Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. *Blood* 108:460-464, 2006.
165. \*Zhou, B., \*Wu, K.H., **Poon, M-C.**, Han, Z.C. Endothelial progenitor cells transfected with PDGF: cellular and molecular targets for prevention of diabetic microangiopathy. *Medical Hypothesis* 67:1308-1312, 2006.
166. Hull, R.D., Pineo, G.F., Brant, R.F., Mah, A.F., Burke, N, Dear, R, Wong, T, Cook, R, Solymoss, S, **Poon, M-C.**, Raskob G, for the LITE Trial Investigators. Long-term low molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. *American Journal of Medicine* 119:1062-1072, 2006.
167. **Poon, M-C.**, Zotz, R., Di Minno, G., Abrams, Z.S., Knudsen, J.B., Laurian, Y. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII (rFVIIa) and other hemostatic agents. *Seminars in Hematology* 43 (suppl 1):S33-S35, 2006
168. Liu B, Zhao H, **Poon M-C.**, \*Han Z, \* Gu D, \*Xu M, \*Jia H. Yang R, Han ZC. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. *Eur J Haematol.* 2007;78(2):139-43.
169. \*Zhou, B., Liu, P.X., \*Lan, H.F., Fang, Z.H., Han, Z.B., Ren, H., **Poon, M.C.**, & Han, Z.C. Enhancement of neovascularization with mobilized blood cells transplantation: Supply of angioblasts and angiogenic cytokines. *Journal of Cell Biochemistry* 102: 183-195. 2007.
170. Hull, R.D., Pineo, G.F., Brant, R.F., Mah, A.F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., **Poon, M-C.**, Raskob, G., for the LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual-care anticoagulation for the treatment of patients with cancer and proximal venous thrombosis: the balance of benefits and harms. *American Journal of Medicine* 120:72-82, 2007.
171. \*Zhou, B., Cao, X-C., Fang, Z-H., Zheng, C-L., Han, Z-B., Ren, H., **Poon, M-C.**, Han, Z.C. Prevention of diabetic microangiopathy by prophylactic transplant of mobilized peripheral blood mononuclear cells. *Acta Pharmacologica Sinica* 28:89-97, 2007
172. **Poon, M-C.** Evidence for the Use of Recombinant Human Activated Factor VII (rFVIIa) in the Treatment of Bleeding Patients with Quantitative and Qualitative Platelet Disorders. *Transfusion Medicine Review* 21(3): 223-236, 2007
173. \*Zhou, B., **Poon, M.-C.**, Pu, W.T., and Han, Z.C. Therapeutic neovascularization for peripheral arterial diseases: advances and perspectives. *Histology and Histopathology*, 22: 677-686, 2007.
174. \*Zhou, B., Han, Z.C., **Poon, M.-C.**, and Pu, W. Mesenchymal stem/stromal cells (MSC) transfected with stromal derived factor 1 (SDF-1) for therapeutic neovascularization: enhancement of cell recruitment and entrapment. *Medical Hypotheses*, 68:1268-1271, 2007.

175. \*Zhou,B., Ma,F.X., Liu,P.X., Fang,Z.H., Wang,S.L., Han,Z.B., **Poon,M.-C.**, and Han,Z.C. Impaired therapeutic vasculogenesis by transplantation of OxLDL-treated endothelial progenitor cells. *Journal of Lipid Research* 48:518-527, 2007
176. Wells, P.S., Brown, A., Jaffey, J., McGahan, L., **Poon, M-C.**, Cimon, K. Safety and Effectiveness of Point-of-Care Monitoring Devices in Patients on Oral Anticoagulant Therapy: A meta-analysis. *Open Medicine* 1(3):e131-146, 2007
177. **Poon, M-C.** Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia *Vascular Health and Risk Management* 3(5): 655-664, 2007
178. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, AHCDC (including **Poon, M-C**), Lillicrap D. The Mutational Spectrum of Type 1 von Willebrand Disease: Results from a Canadian Cohort Study. *Blood*; 109(1):145-154. Jan 2007
179. James, P.D., Notley, C., Hegadorn, C., **Poon, M-C.**, Walker, I., Rapson, D., Association of Hemophilia Clinic Directors of Canada, and Lillicrap, D. Challenges in Defining Type 2M von Willebrand Disease: Results from a Canadian Cohort Study *Journal of Thrombosis and Haemostasis* 5:1914-22, 2007
180. Bowen, T., Cicardi, M., Bork,K., Zuraw, B., Frank, M., Ritchie, B., Farkas, H., Varga, L., Zingale, L.C., Binkley, K., Wagner, E., Adomaitis, P., Brosz, K., Burnham, J., Warrington, R., Kalicinsky, C., Mace, S., McCusker, C., Schellenberg, R., Celeste, L., Hebert, J., Valentine, K., ; **Poon, M-C**, Pineo, G., Serushago, B., Neurath, D., Yang, W., Lacuesta, G., Issekutz, A., Hamed, A., Kamra, P., Dean, J., Kanani, A., Stark, D., Rivard, G-E., Leith, E., Tsai, E., Waserman, S., Keith, P., Page, D., Marchesin, S. Canadian 2006 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema. *Annals of Allergy, Asthma and Immunology* 100 (Suppl 2): S30-S40, 2008
181. Moltzan, C.J., Anderson, D.A., Callum, J., Fremes, S., Hume, H., Mazer, D., **Poon, M-C.**, Rivard, G., Rizoli, S. and Robinson, S. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework. *Transfusion Medicine* 18: 112-120, 2008
182. Rubinger, M., Lillicrap, D., Rivard, G.E., Teitel, J., Carcao, M., Hensman, C., Walker, I. and the Association of Hemophilia Clinic Directors of Canada (AHCDC) (including **Poon, M-C.**) A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. *Haemophilia*. (2); 14: 281-286, 2008
183. **Poon, M-C.** and Luke, K-H. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia (WFH) Treatment Center Twinning activities. *Haemophilia* 14:879-888, 2008
184. \*Biss, T.T., Chan, A.K., Blanchette, V.S., Iwenofu,L.N., McLimont, M. and Carcao, M.D. for the Association of Hemophilia Clinic Directors of Canada (AHCDC) and the Canadian Association of Nurses in Hemophilia Care (CANHC) (including **Poon, M-C**). The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. *Haemophilia* 14:923-930, 2008
185. \*Jackson, S., Beck, P., Buret, A.G., O'Conner, P.M., Meddings, J., Pineo, G. and **Poon, M-C.** Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura. *International Journal of Hematology* 88:212-21, 2008
186. Owen, C.J., Toze, C.L., Koochin, A., Forrest, D.L., Smith, C.A., Eaves, C.J., \*Jackson, S., **Poon, M-C.**, Sinclair, G., Leber, B., Johnson, P.R.E., Macheta, A., Yin, J.A.L., Lister, T.A., Barnett, M.J., Fitzgibbon, J. New cases of familial platelet disorder with propensity to myeloid malignancy (FPD/AML) support the value of *RUNX1* screening in MDS/AML. *Blood* 2008;112: 4639-4645

187. \*Jackson, S.C., Sinclair, G.D., Cloutier, S., \*Duan, Z., Rand, M.L. and **Poon, M-C**. Montreal platelet syndrome kindred has type 2B von Willebrand disease with the *VWF* V1316M mutation *Blood* 2009;113:3348-3351 (DOI 10.1182/blood-2008-06-165233, with editorial and journal cover featuring)
188. Moradkani, K., Préhu, C., Old, J., Henderson S, Balamitsa, V., , Luo, H.-Y., **Poon, M-C.**, Chui, D.H., Wajcman, H. and Patrinos, G.P. Mutations in the paralogous human  $\alpha$ -globin genes yielding identical hemoglobin variants. *Ann Hematol.* 2009; 88:535–543 (DOI 10.1007/s00277-008-0624-3)
189. Hull, R.D., Pineo, G.F., Rant, R., Liang, J., Cook, R., Solymoss, S., **Poon, M-C.**, Raskob, G. for the LITE Trial Investigators. Home therapy of venous thrombosis with long-term low molecular weight heparin versus usual care: patient satisfaction and post-thrombotic syndrome. *American Journal of Medicine* 2009; 112:762-769
190. Di Minno, G., Coppola, A., Di Minno, MND, **Poon, M-C**. Glanzmann's thrombasthenia (defective platelet integrin  $\alpha$ IIb $\beta$ 3): proposals for management between evidence and open issues. *Thrombosis and Haemostasis* 2009; 102 (6):1157-1164.
191. \*Skeith L, \*Jackson SC, Brooks J, **Poon M-C**. Assessing baseline joint hypermobility as a risk factor for arthropathy in moderate and severe hemophilia. *Haemophilia* 2010; 16: 698-700 (DOI: 10.1111/j.1365-2516.2010.02214.x)
192. **Poon M-C**, Rand ML, Jackson SC. 2B or not to be – The 45 year saga of the Montreal Platelet Syndrome. *Thrombosis and Haemostasis* 2010; 104: 903-910 (doi:10.1160/TH10-01-0079)
193. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst H, Zuraw B, Aygoeren-Pürsün E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, **Poon M-C**, Rivard G-E, Schellenberg R, Rowan D, Rowe A, Stark D, Sur S, Tsai E, Warrington R, Wasserman S, Ameratunga R, Bernstein J, Björkander J, Brosz K, Brosz J, Bygum A, Caballero T, Frank M, Fust G, Harmat G, Kanani A, Kreuz W, Levi M, Li H, Martinez-Saguer I, Moldovan D, Nagy I, Nielsen EW, Nordenfelt P, Reshef A, Rusick E, Smith-Foltz S, Späth P, Varga L, Xiang ZY. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. *Allergy, Asthma & Clinical Immunology* 2010; 6:24-36. [<http://www.aacjjournal.com/content/6/1/24>]
194. Wu R, Luke K-H, **Poon M-C**, Wu X, \*Zhang N, Zhao L, Su Y, Zhang J. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate hemophilia children: a pilot study in China. *Haemophilia* 2011; 17(1): 70-74 (DOI: 10.1111/j.1365-2516.2010.02348.x)
195. \*Hang MX, Blanchette VS, Pullenayegum E, McLimont M, Feldman BM and the Canadian Hemophilia Primary Prophylaxis Study Group (including **Poon M-C**). Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. *J Thromb Haemost* 2011; 9(5): 1067-1069 (DOI: 10.1111/j.1538-7836.2011.04228.x)
196. **Poon M-C**, Card RT. Hemophilia management in transfusion medicine. *Transfusion and Apheresis Science* 2012; 46(3): 299-307
197. \*Goodyear MD, **Poon M-C**. Pain management issues in hemophilia. *Haemophilia* 2012; 18 (3): e81-e82
198. \*Schneider-MacRae N, \*Jackson SC, Valentine KA, Lockyer J, **Poon M-C**. A study of thrombophilia testing and Counseling practices of family physicians using the script concordance method in Calgary, Canada. *Clinical and Applied Thrombosis and Hemostasis* 2012; 18(4): 403-408 (DOI: 10.1177/1076029612445917)
199. \*Dowlatsahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A, Wasserman JK, **Poon M-C**, Coutts SB, on behalf of the CanPro Investigators. Poor prognosis in warfarin-associated intracranial



- hemorrhage despite anticoagulation reversal. *Stroke* 2012; 43(7): 1812-1817 (DOI: 10.1161/STROKEAHA.112.652065)
200. Wu RH, Zhang JS, Luke KH, Wu XY, Burke TA, \*Tang L, **Poon M-C**, Li XJ, Zhou M, Sun J, \*Hang M, Blanchette V, Young NL. Cross-Cultural Adaptation of the CHO-KLAT for Boys with Hemophilia in Rural and Urban China. Health and Quality of Life Outcomes. 2012; 10:112 (doi: 10.1186/1477-7525-10-112)
  201. Hay CRM, DiMichele DM on behalf of the International Immune tolerance Study (including **Poon M-C**). The principal results of the International Immune Tolerance Study: a randomized dose comparison. *Blood* 2012;119(6): 1335-44.
  202. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, **Poon MC**, Street A; Treatment Guidelines Working Group on behalf of the World Federation of Hemophilia. Guidelines for the Management of Hemophilia. *Haemophilia* 2013; 19(1): e1-e47 (DOI: 10.1111/j.1365-2516.2012.02909.x). Available at <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2012.02909.x/pdf> or [www.wfh.org](http://www.wfh.org)
  203. \*Tang L, Wu RH, Sun J, Zhang XS, Feng XQ, Zhang XQ, Luke K-H, **Poon M-C**. Short-term low-dose secondary prophylaxis for severe/moderate hemophilia A children with arthropathy is beneficial but there are obstacles in its execution: A multi-center pilot study in China. *Haemophilia* 2013; 19(1): 27-34 (DOI: 10.1111/j.1365-2516.2012.02926.x)
  204. Sinclair GD, **Poon M-C**. Interpreting results from Facotr V Leiden mutation analysis: a cautionary note. *Clinical and Applied Thrombosis/Hemostasis*. 2013; 19(1): 106-107 (doi: 10.1177/1076029612460427)
  205. Hilliard P, Zourikian N, Blanchette V, Chan A, Elliott B, Israels S, Laferriere N, Nilson J, **Poon M-C**, Van Neste C, Jarock C, Wu J, McLimont M, Feldman B. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. *Journal of Thrombosis and Haemostasis* 2013; 11:460-66 (DOI: 10.1111/jth.12113)
  206. \*Dowlatsahi D, Wasserman JK, Butcher KS, -Bernbaum ML, Cwinn AA, Giulivi A, Lang E, **Poon M-C**, Pope T, Sharma M, Coutts SB. Stroke pre-notification is associated with shorter treatment times for warfarin-associated intracerebral hemorrhage. *Cardiovascular Diseases* 2013; 36(5-6):383-387 (DOI:10.1159/000355500)
  207. \*Li G, Wu RH, Wu XY, Zhen YX, Zhang NN, Wang Y, He WW, Peng Y, Luke K-H, **Poon M-C**, Doria A. Efficacy and safety of recombinant coagulation factor IX in moderate and severe hemophilia B children in China: a single center observation study in China. *J Appl Clin Pediatr*. 2013;28 (15): 1128-1130 (in Chinese)
  208. \*Jackson SC, Odiaman L, Card RT, van der Born JG, **Poon M-C**. Suspected collagen disorders in the bleeding disorder clinic: a case control study *Haemophilia* 2013;19:246–250 (DOI: 10.1111/hae.12020)
  209. Chen L, Sun J, Hilliard P, Zourikian N, \*Hang M, Blanchette V, **Poon M-C**, Luke KH. Train-the-Trainer”: An effective and successful training model to accelerate training and improve physiotherapy services for persons with hemophilia in China. *Haemophilia* 2014; 20(3):441-445 (DOI: 10.1111/hae.12331)
  210. Sun J, Hilliard P, Feldman BM, Zourikian N, Chen L., Blanchette VS, Luke KH, **Poon M-C**. Chinese Hemophilia Joint Health Score 2.1 Reliability Study. *Haemophilia* 2014;20(3):435-440 (DOI: 10.1111/hae.12330)
  211. Arnold E, Lane S, Webert KE, Chan A, Walker I, Tufts J, Rubin S, **Poon M-C**, Heddle NM. What do Canadian men living with hemophilia need to know? Perspectives of individuals with Hemophilia. *Haemophilia* 2014; 20: 219–225 ( DOI: 10.1111/hae.12297)

212. Jackson SC, Yang M, Minuk L, St-Louis J, Sholzberg M, Card R, Iorio A, **Poon M-C**. Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe hemophilia B. *Haemophilia* 2014; 20: e199–e204 (DOI: 10.1111/hae.12391)
213. Wu R, Wu X, Zhang N, Zhao L, Zhang J, Luke, K-H, **Poon M-C**, Peng Y, Doria A. Joint disease status of severe and moderate hemophilia patients at the Beijing Children's Hospital: Early onset and rapid increasing severity of arthropathy in 90% of patients by 6 years of age. *Haemophilia* 2014; 20: e222--e242 (DOI: 10.1111/hae.12394)
214. Wu R, Zhang J, Sun J, Zhou M, Wu JS, Ni N, Li XJ, Luke KH, **Poon M-C**, Blanchette V, Young NL. Validation of the Chinese Version of the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (the CHO-KLAT). *Haemophilia* 2014; 20: 794–799 (DOI: 10.1111/hae.12489)
215. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF, A-LONG Investigators (including **Poon M-C**). Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. *Blood* 2014; 323 (3): 317-325
216. Abrahamyan L, Willan AR, Beyene J, Mclimont M, Blanchette V, Feldman BM, Canadian Hemophilia Primary Prophylaxis (CHPS) Study Group (including **Poon M-C**). Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A. *J Gen Intern Med*. 2014; 29 (Suppl 3): S767-73
217. Lalezari S, Coppola A, Lin J, Enriquez MM, Tseneclidou-Stoeter D, Powell J, Ingerslev J, LIPLONG Investigators (including **Poon M-C**). Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. *Haemophilia* 2014; 20 (3): 354-361
218. \*Binding A, Valentine K, **Poon M-C**, Sayani F. Adult sickle cell disease epidemiology and the potential role of a multidisciplinary comprehensive care centre in a city with low prevalence. *Hemoglobin*. 2014; 38(5): 312–315 (doi:10.3109/03630269.2014.954048)
219. \* Lee A, Sinclair GD, Valentine KA, James P, **Poon M-C**. Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status. *Blood* 2014; 124(5): e1-e3 (DOI:10.1182/blood-2014-02-557132)
220. Betschel S, Badiou J, Binkley K, Hébert J, Kanani A, Keith P, Lacuesta G, Yang B, Aygören-Pürsün E, Bernstein B, Bork K, Caballero T, Cicardi M, Craig T, Farkas H, Longhurst H, Zuraw B, Boysen H, Borici-Mazi R, Bowen T, Dallas K, Dean J, Lang-Robertson K, Laramée B, Leith E, Mace S, McCusker C, Moote B, **Poon M-C**, Ritchie B, Stark D, Sussman G, Wasserman S. Canadian hereditary angioedema guideline. *Allergy, Asthma & Clinical Immunology* 2014, 10:50 (18 pages, doi:10.1186/1710-1492-10-50)
221. Lane S, Walker I, Chan A, Heddle N, **Poon M-C**, Minuk L, Jardine L, Arnaold E, Sholapur N, Webert K. Treatment decision-making among Canadian youth with severe hemophilia: a qualitative approach. *Haemophilia* 2015; 21:180–189 (DOI: 10.1111/hae.12543)
222. \*Lee A, Boyd SK, Kline G, **Poon M-C**. Premature changes in trabecular and cortical microarchitecture results in decreased bone strength in hemophilia. *Blood* 2015; 125 (13): 2160-2163 (DOI: 10.1182/blood-2014-10-602060)
223. Jackson S, Yang M, Minuk L, Sholzberg M, St-Louis J, Iorio A, Card R, **Poon M-C**. Prophylaxis in older Canadian adults with hemophilia A: Lessons and more questions. *BMC Hematology* 2015, 15:4 (8 pages, DOI 10.1186/s12878-015-0022-8)
224. **Poon M-C**, d'Oiron R, Zotz RB, Bindslev N, Di Minno MND, Di Minno G, for the Glanzmann Thrombasthenia Registry Investigators. The international prospective Glanzmann Thrombasthenia

- Registry: treatment and outcomes in surgical intervention *Haematologica* 2015; 100(8):1038-1044 (doi:10.3324/haematol.2014.121384)
225. Di Minno G, Zotz RB, d'Oiron R, Bindslev N, Di Minno MND, **Poon M-C**, for the Glanzmann Thrombasthenia Registry Investigators. The international prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients. *Haematologica* 2015; 100(8):1031-1037 (doi:10.3324/haematol.2014.121475)
  226. Minuk L, Jackson S, Iorio A, **Poon M-C**, Dilworth E, Card R, Brose K, Chin-Yee B, Rizwaan I, Louzada M. Cardiovascular Disease in Canadians with Hemophilia: Age Related Cardiovascular Disease in Hemophilia Epidemiological Research (ARCHER Study). *Haemophilia* 2015;21:736-741 (DOI: 10.1111/hae.12768)
  227. Langley AR, Stain AM, Chan A, McLimont M, Chait S, Wu J, **Poon M-C**, Card R, Israels SJ, Laferriere N, Klaassen RJ, Rivard GE, Cloutier S, Hawes S, Feldman B, Blanchette V. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS). *Haemophilia* 2015; 21(4):469-76. (DOI:10.1111/hae.12713)
  228. Hua B, Li K, Lee A. **Poon M-C**, Zhao Y. Coexisting congenital dysfibrinogenemia with a novel mutation in fibrinogen  $\gamma$  chain ( $\gamma$ 322 Phe $\rightarrow$ Ile, Fibrinogen Beijing) and haemophilia B in a family. *Haemophilia* 2015; 21:846-851 (DOI: 10.1111/hae.12712)
  229. Hua B, \*Lian X, Li K, Lee A, **Poon M-C**, Zhao Y. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living (ADL) in adults with severe haemophilia A -- A single centre experience from Beijing. *Blood Coagulation and Fibrinolysis* 2016; 27:136-140 (DOI:10.1097/MBC.0000000000000389)
  230. \*Khanna P, Lee A, **Poon M-C**. Fracture risk in patients with hemophilia. *Haemophilia* 2016; 22:e99-e118 (DOI: 10.1111/hae.12892)
  231. **Poon M-C**, diMinno G, d'Oiron R, Zotz R. New Insights into the Treatment of Glanzmann's Thrombasthenia. *Transfusion Medicine Review* 2016; 30:92-99 (DOI: <http://dx.doi.org/10.1016/j.tmr.2016.01.001>)
  232. Li K-X, Xiao J, Zhao Y-Q, Shou W-L, Chen M, Li Z, **Poon M-C**, Han H-J. Moderate-intensity exercise improves the thromboelastography coagulation index in children with severe hemophilia A. *Blood Coagulation and Fibrinolysis* 2016; 27:797-803 (DOI:10.1097/MBC.0000000000000493)
  233. Hawke L, Bowman M, **Poon M-C**, Scully M-F, Rivard G-E, James PD. Characterization of aberrant splicing of von Willebrand factor (VWF) in von Willebrand disease (VWD): an under-recognized mechanism. *Blood* 2016;128(4):584-93 (doi:10.1182/blood-2015-10-678052)
  234. Urban D, Dehaeck R, Lorenzetti D, Guifoyle J, **Poon M-C**, Steele M, Lardner D, Ma IW, Brindle ME. Safety and efficacy of tranexamic acid in bleeding paediatric trauma patients: a systematic review protocol. *BMJ Open* 2016;6(9): e012947
  235. McEneny-King A, Foster G, Iorio A, Edginton AN, WAPPS-Hemo co-investigator network (including **Poon M-C**). Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). *JMIR Res Protoc.* 2016; 5(4):e232 (12 pages)
  236. Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L, WAPPS-Hemo co-investigator network (including **Poon M-C**). Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): study protocol. *JMIR Res Protoc.* 2016; 5(4):e239 (10 pages)

237. **Poon M-C**, Lee A. Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations? *Thrombosis Journal* 2016;14(Suppl 1):32. <http://rdcu.be/nh0j> (last accessed 2016 12 04)
238. **Poon M-C**, Lee A. Hemophilia. *BMJ Best Practice*, Nov 2016 (monograph 468). <http://bestpractice.bmj.com/best-practice/monograph/468.html> (last accessed 2016 12 01)
239. Hua BL, Lee A, \*Fan LK, Li KX, Zhang YH, **Poon M-C**, Zhao YQ. Low-dose Factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption. *Haemophilia* 2017;23(3) 417-421 (DOI: 10.1111/hae.13282)
240. \*Skeith L, Rydz N, O’Beirne M, Goodyear D, Li H, **Poon M-C**. Pregnancy loss in women with von Willebrand disease: a single-center pilot study. *Blood Coagulation and Fibrinolysis* 2017;28(5):393-7 (DOI: 10.1097/MBC.0000000000000620)
241. Wu R, Sun J, Xiao J, Liu Y, Xue F, Wang HF, \*Tang L, Zhao YQ, Li KX, Yang RC, Hu Y, Luke K-H, **Poon M-C**, Blanchette VS, Usuba K, Young NL. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment. *Haemophilia* 2017;23(3):430-436. (DOI: 10.2222/hae.13198)
242. Korte W, **Poon M-C**, Iorio A, Makris M. Thrombosis in inherited fibrinogen disorders. *Transfusion Medicine & Hemotherapy*. 2017;44(2):70–76 (DOI: 10.1159/000452864)
243. Recht M, Rajpurkar M, Chitlur M, d’Oiron R, Zotz R, Di Minno G, Cooper DL, **Poon M-C**. Independent Adjudicator Assessments of Platelet Refractoriness and rFVIIa Efficacy in Bleeding Episodes and Surgeries from the Multinational Glanzmann’s Thrombasthenia Registry. *American Journal of Hematology* 2017;92(7):646-652. (DOI: 10.1002/ajh.24741)
244. \*Sun HL, Yang M, Fung M, Chan S, Jawi M, Anderson T, **Poon M-C**, Jackson SC. Adult males with hemophilia have a different macrovascular and microvascular endothelial function profile compared with healthy controls *Haemophilia* 2017;23(5):777-783 (DOI: 10.1111/hae.13278)
245. **Poon M-C**, Di Minno G, Zotz R, d’Oiron R. Glanzmann’s thrombasthenia: Strategies for identification and management *Expert Opinion on Orphan Drugs*, 2017;5(8):641-653 (DOI: 10.1080/21678707.2017.1341306)
246. \*Tang L, Xu W, Li CG, Hou F, Feng XQ, Wang H, Li XJ, Li WL, Liu JP, Sun LR, Wang SH, Jin J, Fang Q, Luke KH, **Poon MC**, Blanchette V, Usuba K, Young NL, Wu R. Describing the Quality of Life of Boys with Haemophilia in China: Results of a Multi-Center Study using the CHO-KLAT. *Haemophilia* 2018;24(1):113-119 (DOI: 10.1111/hae.13349)
247. \*Li Z, Wu J, Zao Y, Liu R, Li K, Zhou Y, Wu R, Yang R, Zhang X, Lian S, Hu Q, Li X, Gu J, Zhou R, Sun J, Li C, Xu W, **Poon M-C**, Xiao J. Influence of Medical Insurance Schemes and Charity Assistance Projects on Regular Prophylaxis Treatment of the Boys with Severe Hemophilia A in China. *Haemophilia* 2018; 24(1):126-133 (DOI: 10.1111/hae.13372)
248. **Poon M-C**, d’Oiron R. Alloimmunization in congenital deficiencies of platelet surface glycoproteins: Focus on Glanzmann Thrombasthenia and Bernard-Soulier Syndrome. *Seminars in Thrombosis and Hemostasis* 2018;44(6):604-614 [DOI: 10.1055/s-0038-1648233]
249. \*Nahoo N, Rydz N. **Poon M-C**, Metz LM. Ischemic strokes in a man with congenital afibrinogenemia. *Canadian Journal of Neurological Sciences* 2018;45(5):590-592 [DOI: 10.1017/cjn.2018.57]
250. Feldman BM, Rivard GE, Babyn P, Wu JKM, Steele M, **Poon M-C**, Card RT, Israls SJ, Laferriere N, Gill K, Chan AK, Carcao M, Klaassen RJ, Cloutier S, Price VE, Dover S, Blanchette VS. Tailored frequency-

- escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. *Lancet Haematology* 2018 5(6):e252-e260. [doi: 10.1016/S2352-3026(18)30048-6]
251. Chen ZP, Li PJ, Li G, \*Tang L, Zhen YZ, Wu XY, Cheng XL, Luke KH, Blanchette VS, **Poon MC**, Ding QL, Wu RH. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. *Chin Med J (Engl)*. 2018;131(15):1780-1785. [doi: 10.4103/0366-6999.233604] Available from: <https://www.ncbi.nlm.nih.gov/pubmed/29848837>
  252. Hews-Girard J, Rydz N, Lee A, Goodyear D, **Poon M-C**. DDAVP in non-severe hemophilia A: Test-response and clinical outcomes in a single Canadian center review. *Haemophilia* 2018;24(5):720-725 [DOI: 10.1111/hae.13586]
  253. Lee A, **Poon M-C**. Inherited platelet functional disorders: General principles and practical aspects of management. *Transfusion and Apheresis Science* 2018;57(4):494-501. [doi: 10.1016/j.transci.2018.07.010]
  254. **Poon M-C**, Card RT. Samuel Armstrong Lane's first successful treatment of haemophilia with blood transfusion in 1840. Could this also be the first successful bypassing therapy? *Haemophilia* 2019;25(1):e46-e47 [DOI: 10.1111/hae.13645]
  255. Hews-Girard J, **Poon M-C**, Goodyear MD. Effect of an electronic treatment plan on acute management of hereditary angioedema. *Annals of Allergy, Asthma & Immunology* 2019;123(1): 98-100 (DOI: 10.1016/j.anai.2019.04.013)
  256. **Poon M-C**, \*Shedden N, Card RT. Healthcare professionals in the ‘tainted blood’ era in Canada: Their forgotten emotions. *Haemophilia* 2019;25(4):651–655 (DOI: 10.1111/hae.13805)
  257. \*Li Z, Chen ZP, Cheng XL, Wu XY, Li G, Zhen YZ, Cai SY, **Poon M-C**, Wu RH. Low-dose immune tolerance induction for hemophilia A children with poor-risk high-titer inhibitors: a pilot study in China. *Research and Practice in Thrombosis and Haemostasis* 2019; 3(4): 741-748 (DOI: 10.1002/rth2.12248)
  258. Zotz R, **Poon M-C**, Di Minno G, Bindslev N, d’Oiron , Glanzmann Thrombasthenia Registry Investigators. The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in pediatric patients. *Thrombosis and Haemostasis Open* 2019; 3(3):e286-e294
  259. Tang GH, Norris E, Petrci J, James P, Lee A, **Poon M-C**, Floros G, Boma-Fischer L, Teitel J, Nisenbaum R, Sholzberg M. Bone health in symptomatic carriers of hemophilia A: a multi-center prospective matched-cohort study. *BMJ Open* 2019; 9(12): e032891 (DOI: 0.1136/bmjopen-2019-032891)
  260. Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert, J, Kanani A, Keith P, Lacuesta G, Wasserman S, Yang B, Aygören-Pürsün E, Bernstein J, Bork K, Caballero T, Cicardi M, Craig T, Farkas H, Grumach A, Katelaris C, Longhurst H, Riedl M, Zuraw B, Berger M, Boursiquot J-N, Boysen H, Castaldo A, Chapdelaine H, Connors L, Fu L, Goodyear D, Haynes A, Kamra P, Kim H, Lang-Robertson K, Leith E, McCusker C, Moote B, O’Keefe A, Othman I, **Poon M-C**, Ritchie B, St-Pierre C, Stark D, Tsai E. The International/Canadian hereditary angioedema guideline. *Allergy Asthma Clin Immunol* 2019;15:72 (29 pages) (doi:10.1186/s13223-019-0376-8)
  261. Yang R, **Poon M-C**, Luke KH, Zhao Y, Sun J, Wang X, Wu R, Chen L, Zhang X, Wu J. Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China. *Blood Advances* 2019; 3(suppl 1): 34-37 (DOI: 10.1182/bloodadvances.2019GS121524)
  262. \*Li S, Fang Y, Li L, Lee A, **Poon M-C**, Zhao Y, Zhang X, Wang S, Cheng Y, Li K. Bleeding assessment in haemophilia carriers – high rates of bleeding after surgical abortion and intrauterine device placement: a multi-centre study in China. *Haemophilia* 2020; 26(1):122-128 (DOI: 10.1111/hae.13889)

263. \*Li Z, Chen Z, Cheng X, Wu X, Li G, Zhen Y, **Poon M-C**, Wu R. A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations. *International Journal of Immunopathology and Pharmacology* 2020; 34: 1–4 (DOI: 10.1177/2058738420934618)
264. Liu Y, Chen L, Li K, Shi M, **Poon M-C**. Severe hemophilia A children on low-dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on-demand treatment: A six-year follow-up study. *Haemophilia* 2020;26(5):779–785. <https://doi.org/10.1111/hae.14016>
265. \*Dou X, **Poon M-C**, Yang R. Hemophilia care in China: achievements in the past decade *Haemophilia* 2020; 26(5):759–767. (DOI: 10.1111/hae.14101)
266. \*Zhang A, \*Liu W, **Poon M-C**, Hu Q, Yang R. Management of hemophilia patients in the COVID-19 pandemic: experience in Wuhan and Tianjin, two differently affected cities in China. *Haemophilia* 2020(6); 26:1031–1037 (DOI: 10.1111/hae.14108)
267. Sims M, \*Mayer L, Collins J, Bariana T, Megy K, Lavenu-Bombled C, Seyres D, Kollipara L, Burden F, Greene D, Lee D, Rodriguez-Romera A, Alessi M-C, Astle W, Bahou W, Bury L, Chalmers E, Da Silva R, De Candia E, Deevi S, Farrow S, Gomez K, Grassi L, Greinacher A, Gresele P, Hart D, Hurtaud M-F, Kelly A Kerr R, Le Quellec S, Leblanc T, Leinøe E, Mapeta R, McKinney H, Michelson A, Morais S, Nugent D, Papadia S, Park S, Pasi J, Podda GM, **Poon M-C**, Reed R, Sekhar M, Shalev H, Sivapalaratnam S, Steinberg-Shemer O, Stephens J, Tait R, Turro E, Wu J, Zieger B, NIHR BioResource, Kuijpers T, Whetton A, Sickmann A, Freson K, Downes K, Erber W, Frontini M, Nurden P, Ouwehand W, Favier R, Guerrero J. Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. *Blood* 2020;136(17):1956-1967 (DOI: 10.1182/blood.2019004776)
268. **Poon M-C**. The use of recombinant activated factor VII (rFVIIa) in patients with Glanzmann’s thrombasthenia. *Thrombosis and Haemostasis* 2021;121:332–340 (DOI: 10.1055/s-0040-1718373)
269. \*Li Z, Chen Z, Cheng X, Wu X, Li G, Zhen Y, Cai S, **Poon M-C**, Wu R. A low-dose immune tolerance induction strategy incorporating immunosuppression agents in hemophilia A children with high-titer factor VIII inhibitor. *Haemophilia* 2021;27:469–472. (DOI: 10.1111/hae.14157)
270. \*Dou X, \*Liu W, **Poon M-C**, Zhang X, Wu J, Zeng X, Wu R, Hu Q, Li C, Wang X, Song X, Chen L, Zhang L, Xue F, Yang R. Haemophilia A patients with inhibitors in China: A national real-world analysis and follow-up. *British Journal of Haematology* 2021;192(5):900–908 (DOI: 10.1111/bjh.17322)
271. \*Wu Y, Lu J, Zhou Y, Li K, Liu Y, Liu S, Li A, Zhai Y, **Poon M-C**, Xiao J. Long-term joint outcomes of regular low-dose prophylaxis in Chinese children with severe hemophilia A. *Haemophilia* 2021(2);27:237–244. (DOI: 10.1111/hae.14256)
272. Mann D, Stafford K, **Poon M-C**, Matino D, Stafford D. The Function of extravascular coagulation factor IX in haemostasis. *Haemophilia* 2021;27(3):332–339 (DOI:10.1111/hae.14300)
273. \*Li Z, Chen Z, Cheng X, Wu X, Li G, Zhen Y, Cai S, **Poon M-C**, Wu R. Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors *Research and Practice in Thrombosis and Haemostasis* 2021;5 (5): e12562 (DOI: 10.1002/rth2.12562) [*RPTH Editors’ award to Dr. Z Li at the XXXth ISTH Congress in July 2022 for being one of 3 best RPTH papers published in 2021 by an early career professional*]
274. Casini A, von Mackensen S, Santoro C, Khayat CD, Behani M, Ross C, Dorgalaleh A, Naz A, Unal E, Abdelwahab M, Lozeron ED, Trillot N, Susen S, Peyvandi F, de Moerloose P, on behalf of the QalyAbib Study Group (including **Poon, M-C**). Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. *Blood* 2021;137(22):3127-3136



275. \*Liu W, Xue F, **Poon M-C**, Chen L, Jin Z, Zhang L, Yang R. Current status of hemophilia inhibitor management in mainland China: A hemophilia treatment centers survey on treatment preferences and real-world clinical practices. *British Journal of Haematology*, 2021;194(4):750–758 (doi.org/10.1111/bjh.17677)
276. Sun H, Yang M, **Poon M-C**, Lee A, Robinson KS, Sholzberg M, Wu J, Iorio A, Blanchette V, Carcao M, Klaassen R, Jackson S. Factor product utilization and health outcomes in patients with hemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes. *Haemophilia* 2021;27(5):751–759 (DOI: 10.1111/hae.14369)
277. \*Lee H, **Poon M-C**, Allan GM. Iron dosing frequency (Tools for Practice). *Canadian Family Physician | Le Médecin de famille canadien* 2021;67(6):436; DOI: <https://doi.org/10.46747/cfp.6706436>
- \*Lee H, **Poon M-C**, Allan GM. Posologie du fer (Outils pour la pratique). *Canadian Family Physician | Le Médecin de famille canadien* 2021, 67 (6) e142-e143; DOI: <https://doi.org/10.46747/cfp.6706e142>
278. **Poon M-C**, Goodyear DM, Rydz N, Lee A. Surgery in mild haemophilia A patients with a history of inhibitor antibodies against factor VIII: Individualized management. *Haemophilia* 2021;27:e768–e771 DOI: <https://doi.org/10.1111/hae.14415>
279. Sun H, Yang M, **Poon M-C**, Lee A, Robinson KS, Sholzberg M, Wu J, Iorio A, Blanchette V, Carcao M, Klaassen J, Jackson S. Impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. *Research and Practice in Thrombosis and Haemostasis* 2021;5:e12601 DOI: <https://doi.org/10.1002/rth2.12601>
280. \*Li Z, Liu G, Yao W, Chen Z, Li G, Cheng Z, Zhen Y, Ai D, Huang K, **Poon M-C**, Wu R. Nephrotic syndrome in two haemophilia B children with inhibitor under low-dose immune tolerance induction combined with rituximab-based immunosuppressant protocol. *Haemophilia* 2022;28:e42–e45. (DOI: 10.1111/hae.14471)
281. Matino D, Iorio A, Keepanasseril A, Germini F, Caillaud A, Carcao M, Hews-Girard J, Iserman E, James P, Lee A, Phua CW, Sun HL, Teitel J, **Poon M-C**. Switching to nonacog beta pegol in hemophilia B: Outcomes in a Canadian multicenter, retrospective study. *Research and Practice in Thrombosis and Haemostasis*. 2022;6:e12661 (DOI: 10.1002/rth2.12661)
282. \*Zhang W, Song X, Dou X, **Poon M-C**, \*Liu W, Chen L, Zhang L, Xue F, Yang R. Demographics, clinical profile and treatment landscape of patients with hemophilia B in China. *Haemophilia* 2022; 28:e56–e60. DOI: <https://doi.org/10.1111/hae.14484>
283. Agbani EO, Schneider P, McDonald B, Skeith L, **Poon M-C**, Lee A. Activated platelets harbor SARS-CoV-2 during severe COVID-19. *Thromb Haemost* 2022; 122:308–309 (DOI: 10.1055/a-1683-8455)
284. de Almeida, LGN, \*Young D, Chow L, Nicholas J, Lee A, **Poon M-C**, Dufour A, and Agbani EO. Proteomics and metabolomics profiling of platelets and plasma mediators of thrombo-inflammation in gestational hypertension and preeclampsia. *Cells* 2022; 11:1256. (DOI 10.3390/cells11081256)
285. \*Li Z, Liu G, Yao W, Chen Z, Li G, Cheng X, Zhen Y, Ai D, Huang K, Sun J, **Poon M-C**, Wu R. Eradication of FIX inhibitor in haemophilia B children using low-dose immune tolerance induction with rituximab-based immunosuppressive agent(s) in China. *Haemophilia* 2022; 28(4):625-632 (DOI <https://doi.org/10.1111/hae.14577>)
286. Hua B, \*Yan X, \*He B, Shen L, **Poon M-C**. Protein S gene mutation c.946C>T (p.R316C) contributed to ischemic stroke in a man with von Willebrand disease type 3 caused by two novel VWF gene mutations, c.2328delT (p.A778Lfs\*23) and c.6521G>T (p.C2174F). *Clin Case Rep*. 2022;10:e06269 (DOI: <https://doi.org/10.1002/ccr3.6269>)

287. \*Dou X, \*Zhang W, **Poon M-C**, Zhang X, Wu R, Feng X, Yang L, Cheng P, Chen S, Wang Y, Zhou H, Huang M, Song Y, Jin C, Zhang D, Chen L, Liu W, Zhang L, Xue F, Yang R. Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China. *Haemophilia* 2023; 29:123–134 (<https://doi.org/10.1111/hae.14665>)
288. \*Zhang W, Li K, **Poon M-C**, Zhang X, Wu J, Zhao X, Zhou M, Wang X, Zhang M, Xu W, Yang L, Huang M, Jin C, Wang X, Zhang D, Chen L, Liu Wei, Zhang L, Xue F, Yang R. Women and girls with haemophilia: a retrospective cohort study in China. *Haemophilia*, 2023;29:578–590 (DOI: <http://doi.org/10.1111/hae.14740>)
289. Iorio A, MacDonald V, Caillaud A, Luckevich M, Christoffersen C, Matino D, Keepanasseril A, Iserman E, Germini F, Bentley A, **Poon M-C**. Treatment switch to nonacog beta pegol in hemophilia B: a cost-consequence analysis based on real-world factor IX consumption and clinical outcomes from Canada. *Research and Practice in Thrombosis and Haemostasis* 2023;7:e100106 (<https://doi.org/10.1016/j.rpth.2023.100106>)
290. \*Li Z, Li Z, \*Sun J, Cheng Z, Liu G, Yao W, Huang K, Chen Z, Li G, Zhen Y, **Poon M-C**, Wu R. The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China. *Thrombosis Research* 2023;223:123-126 (<https://doi.org/10.1016/j.thromres.2023.01.025>)
291. \*Li ZP, Li ZK, \*Sun J, Cheng X, Liu G, Yao W, Huang K, Chen Z, Li G, Zhen Y, **Poon M-C**, Wu R. The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China *Thrombosis Research* 2023;224:60-64 (<https://doi.org/10.1016/j.thromres.2023.02.011>)
292. **Poon M-C**, d’Oiron R, Baby S, Zotz RB, Di Minno G. The Glanzmann Thrombasthenia Registry: safety of platelet therapy in patients with Glanzmann thrombasthenia and changes in alloimmunization status. *Haematologica* 2023;108(10):2855-2868 (DOI: 10.3324/haematol.2022.281973)
293. \* Li Z, \*Sun J, Li Z, Chen Z, Liu G, Yao W, Li G, Zhen Y, Cheng X, Huang K, **Poon, M-C**, Wu R. Low-dose immune tolerance induction therapy in severe hemophilia A children in China: starting earlier resulted in better inhibitor eradication outcomes. *Thrombosis Research* 2023;225:33-38 (<https://doi.org/10.1016/j.thromres.2023.02.016>)
294. Agbani EO, Chow L, Nicholas J, Skeith L, Schneider P, Gregory A, Dobson G, Poole AW, Mahe E, \*Yamaura L, Young D, Dufour A, Paul PP, Walker AM, Mukherjee PG, Poole AW, **Poon M-C**, Lee A. Overexpression of Facultative Glucose Transporter-3 and Membrane Procoagulation in Platelets of Preeclampsia. *Journal of Thrombosis and Haemostasis*, 2023;21:1903-1919 (<https://doi.org/10.1016/j.jtha.2023.03.014>)
295. \*Chandrakumaran P, Hews-Girard J, **Poon M-C**. Desmopressin (DDAVP) use in patients with von Willebrand Disease: A single-centre retrospective review of test response and clinical outcomes. *Haemophilia* 2023;29:1095-1103 (<https://doi.org/10.1111/hae.14801>)
296. Agbani EO, Young D, \*Chen SA, Smith S, Lee A, Poole AW, Dufour A, **Poon M-C**. Membrane Procoagulation and N-Terminomics/TAILS Profiling in Montreal Platelet Syndrome Kindred with VWF p.V1316M mutation. *Communications Medicine* 2023;3:125 (DOI: 10.1038/s43856-023-00354-1)
297. \*Xu Y, Wang Y, Wu R, Zheng C, Zhang L, Xu W, Feng X, Wang H, Cao X, He L, Xue T, Jin M, Xie B, Ling J, Sun L, Su R, Chang H, Fang Y, **Poon M-C**, Liu W, Zhang L, Xue F, Yang R. Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicenter real-world study in China. *Haemophilia* 2024;30:959–969. (<http://doi.org/10.1111/hae.15062>)
298. \*Li Z, Sun J, Li Z, Chen Z, Liu G, Yao W, Cheng X, Li G, Zhen Y, Zhou Y, \*Mao Q, **Poon M-C**, Wu R. Low-dose immune tolerance induction therapy for severe hemophilia A inhibitor patients:



immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL. *Pediatric Investigation*. 2024;8(2):91-100 (<https://doi.org/10.1002/ped4.12429>)

299. \*Mao Q, Chen Z, Liu G, Liu G, Li G, Zhen Y, Cheng X, Li Z, Yao W, Ai D, Wang N, **Poon M-C**, Wu R. Real-world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a Comprehensive care center. *Pediatric Investigation*. epub ahead of print (<https://doi.org/10.1002/ped4.12439>)
300. Skeith L, James P, Kouides P, Uminski K, Duffett L, JacksoS, Sholzberg M, Ragni MV, Cuker A, O'Beirne M, Hews-Girard J, Rydz N, Goodyear DM, Baxter J, James A, Garcia D, Vesely SK, **Poon M-C**, for the VWD Pregnancy Loss Study Group. Pregnancy loss in individuals with von Willebrand disease and unspecified mucocutaneous bleeding disorders: A multicentre cohort study. *Journal of Thrombosis and Haemostasis* 2024; epub ahead of print (<https://doi.org/10.1016/j.jtha.2024.09.037>)
- 301.

(B) **Peer-Reviewed** Manuscripts Submitted

1. Hews-Girard J, **Poon M-C**. Examining the need for DDAVP-response testing among individuals with non-severe hemophilia A: A retrospective review. (Submitted to *Haemophilia*)
2. Lee A, Burt L, Boyd S, Macdonald H, Jackson S, Kline G, **Poon M-C**. Low bone strength is associated with poor bone microarchitecture and disease severity in hemophilia patients (submitted to *Haemophilia*)
- 3.

(C) **peer-reviewed** Electronic web-based Publications

1. Association of Hemophilia Clinic Directors of Canada (Writers: **Poon, M-C.**, Lillicrap, D., Israels, S.). Clinical Practice Guidelines: Hemophilia and von Willebrand's disease. 1. Diagnosis, comprehensive care and assessment – edition 2, update 2. [http://www.ahcdc.ca/Care\\_Assessment.htm](http://www.ahcdc.ca/Care_Assessment.htm), 1999
2. Association of Hemophilia Clinic Directors of Canada (Writers: **Poon, M-C.**, Lillicrap, D., Israels, S.). Clinical Practice Guidelines: Hemophilia and von Willebrand's disease. 2. Management – edition 2, update 2. <http://www.ahcdc.ca/Management.htm>, 1999.
3. Green, P.M., Giannelli, F., Sommer, S.S., **Poon, M-C.**, Ludwig, M., Schwaab, R., P.H. Reitsma, P.H., Goossens, M., Yoshioka, A., Figueiredo, M.S., Tagariello, G. and Brownlee, G.G. The Haemophilia B Mutation Database – version 12. <http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html>, 2003.
4. Green, P.M., Giannelli, F., Sommer, S.S., **Poon, M-C.**, Ludwig, M., Schwaab, R., P.H. Reitsma, P.H., Goossens, M., Yoshioka, A., Figueiredo, M.S., Tagariello, G. and Brownlee, G.G. The Haemophilia B Mutation Database – version 13. <http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html>, 2004

5. World Federation of Hemophilia (writers: Srivastava, A., Giangrande, P., **Poon, M-C.**, Chua, M., McCraw, A. and Wiedel, J.). World Federation of Hemophilia Guidelines for the Management of Hemophilia. <[http://www.wfh.org/Content\\_Documents/Other\\_Publications/Gudelines\\_Mng\\_Hemophilia.pdf](http://www.wfh.org/Content_Documents/Other_Publications/Gudelines_Mng_Hemophilia.pdf)> 2005
6. National Advisory Committee (NAC) on Blood and Blood Products. Policy Framework for Recombinant Activate Factor VII Utilization Management. Edited by Moltzen CJ. available on-line at <[www.nacblood.ca](http://www.nacblood.ca)> (**Poon M-C** as a member of Recombinant Factor VIIa Medical Task Force that developed the Policy Framework) 2006
7. National Advisory Committee (NAC) on Blood and Blood Products. Recommendations for Use of octaplex® in Canada. Edited by Nahirniak, S. <no longer available on-line - superceded by "NAC Recommendations for Use of Prothrombin Complex Concentrates" (see updated versions below). (**Poon M-C** as a member of the NAC octaplex® subcommittee that developed the Recommendations) 2008
8. National Advisory Committee (NAC) on Blood and Blood Products. Recommendations for Use of Prothrombin Complex Cocnetrates (PCC) in Canada. Edited by Nahirniak S, available on-line at <[www.nacblood.ca/resources/guidelines/PCC.html](http://www.nacblood.ca/resources/guidelines/PCC.html)> (**Poon M-C** as a member of the NAC PCC Working Group that developed the Recommendations), 2011 06 29
9. \*Lin K, Yu Y, **Poon M-C.** Hemolytic Anemia: Pathophysiology behind the normocytic anemia. “*The Calgary Guide to Understanding Disease*”, ed Yu Y, University of Calgary Publications in Medical Education. < [www.thecalgaryguide.com](http://www.thecalgaryguide.com) > 2012
10. **Poon, M-C, Goodyear, M.D.** Coagulation Factor Concentrate (Chapter 5). “*Canadian Blood Services Clinical Guide to Transfusion*”. Online Edition, ed: Clark G and Chargé S, Canadian Blood Services 9ISBN 978-1-926581-18-7), available at <[http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%205\\_March2013\\_FINAL.pdf](http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%205_March2013_FINAL.pdf) or <http://transfusionmedicine.ca/resources/clinical-guide-transfusion>> 2013
11. **Poon, M-C, Goodyear, M.D.** Hemostatic Disorders (Chapter 17). “*Canadian Blood Services Clinical Guide to Transfusion*”. Online Edition, ed: Clark G and Chargé S. Canadian Blood Services 9ISBN 978-1-926581-18-7), available at <[http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%2017\\_March2013\\_FINAL2.pdf](http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%2017_March2013_FINAL2.pdf) or <http://transfusionmedicine.ca/resources/clinical-guide-transfusion> > 2013
12. National Advisory Committee (NAC) on Blood and Blood Products. Recommendations for Use of Prothrombin Complex Cocnetrates (PCC) in Canada. Edited by Nahirniak S, available on-line at <[www.nacblood.ca/resources/guidelines/PCC.html](http://www.nacblood.ca/resources/guidelines/PCC.html)> (**Poon M-C** as a member of the NAC PCC Working Group that developed the Recommendations), 2014 04 02
13. **Poon M-C, Goodyear MD, Lee A.** Coagulation Factor Concentrate (Chapter 5). “*Canadian Blood Services Clinical Guide to Transfusion*”. Online Edition, ed: Clark G and Chargé S, Canadian Blood Services (ISBN 978-1-926581-18-7), available at <[http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%205\\_March2013\\_FINAL.pdf](http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%205_March2013_FINAL.pdf) or <http://transfusionmedicine.ca/resources/clinical-guide-transfusion>> June 2015 update
14. **Poon M-C, Goodyear MD, Lee A.** Hemostatic Disorders (Chapter 17). “*Canadian Blood Services Clinical Guide to Transfusion*”. Online Edition, ed: Clark G and Chargé S. Canadian Blood Services (ISBN 978-1-926581-18-7), available at <[http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%2017\\_March2013\\_FINAL2.pdf](http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%2017_March2013_FINAL2.pdf) or <http://transfusionmedicine.ca/resources/clinical-guide-transfusion> > June 2015 update
15. Lee A, Boyd SK, Kline G, **Poon M-C.** Supplement commentary on: “Premature changes in trabecular and cortical microarchitecture results in decreased bone strength in hemophilia. *Blood* 2015; 125 (13):

2160-2163 (DOI: 10.1182/blood-2014-10-602060)" World Biomedical Frontiers 2015 October (<http://biomedfrontiers.org/osteoporosis-2015-5-8/>)

16. **Poon M-C**, Goodyear MD, Rydz N, Lee A. Coagulation Factor Concentrate (Chapter 5). "*Canadian Blood Services Clinical Guide to Transfusion*". Online Edition, ed: Clark G and Chargé S, Canadian Blood Services (ISBN 978-1-926581-18-7), available at <[http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%205\\_March2013\\_FINAL.pdf](http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%205_March2013_FINAL.pdf) or <http://transfusionmedicine.ca/resources/clinical-guide-transfusion>> August 2018 update
17. **Poon M-C**, Goodyear MD, Rydz N, Lee A. Hemostatic Disorders (Chapter 17). "*Canadian Blood Services Clinical Guide to Transfusion*". Online Edition, ed: Clark G and Chargé S. Canadian Blood Services (ISBN 978-1-926581-18-7), available at <[http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%2017\\_March2013\\_FINAL2.pdf](http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/articles/CGTTChapter%2017_March2013_FINAL2.pdf) or <http://transfusionmedicine.ca/resources/clinical-guide-transfusion>> August 2018 update
18. \*Lee H, **Poon M-C**, Allan M. Iron dosing frequency: Is less more or just less? Alberta College of Family Medicine/the College of Family Physicians of Canada. [https://gomainpro.ca/wp-content/uploads/tools-for-practice/1613773166\\_tfp284irondosingfv.pdf](https://gomainpro.ca/wp-content/uploads/tools-for-practice/1613773166_tfp284irondosingfv.pdf). February 22, 2021 (distributed to just under 40,000 clinicians in Canada and elsewhere)
19. National Advisory Committee (NAC) on Blood and Blood Products. Recommendations for Use of Prothrombin Complex Concentrates (PCC) in Canada. Edited by Shi A, available on-line at <[Recommendations for Use of Prothrombin Complex Concentrates in Canada | National Advisory Committee on Blood and Blood Products \(NAC\) \(nacblood.ca\)](https://nacblood.ca/recommendations-for-use-of-prothrombin-complex-concentrates-in-canada)> (**Poon M-C** as an External Expert member of the NAC PCC Working Group that developed the Recommendations), 2022 updated [2022 April 07]
20. **Poon M**, Goodyear D, Rydz N, Lee A. Concentrates for hemostatic disorders and hereditary angioedema. In: Clarke G, Abe T, editors. *Clinical Guide to Transfusion* [Internet]. Ottawa: Canadian Blood Services, 2022 update [2022 May 06]. Chapter 5. Available on-line at <[Concentrates for hemostatic disorders and hereditary angioedema | Professional Education \(blood.ca\)](https://professionaleducation.blood.ca/concentrates-for-hemostatic-disorders-and-hereditary-angioedema)> from: <https://professionaleducation.blood.ca>
21. **Poon M**, Goodyear MD, Rydz N and Lee A. Hemostatic disorders and hereditary angioedema. In: Clarke G, Abe T, editors. *Clinical Guide to Transfusion* [Internet]. Ottawa: Canadian Blood Services, 2022 update [2022 June 28]. Chapter 17. Available on-line at <[Hemostatic disorders and hereditary angioedema | Professional Education \(blood.ca\)](https://professionaleducation.blood.ca/hemostatic-disorders-and-hereditary-angioedema)> from: <https://professionaleducation.blood.ca>
22. **Poon M-C**, Lee A. Hemophilia. BMJ Best Practice, August 4, 2022 (monograph 468). <http://bestpractice.bmj.com/best-practice/monograph/468.html> (last accessed 2022 08 13)

(D) Electronic Web-based Continuing Medical Education Program

1. **Poon, M-C.** A 69-Year-Old Man with Prostate Cancer and Extensive Spontaneous Ecchymoses [a case of Acquired Hemophilia – for discussion of appropriate laboratory investigation, diagnosis and management]. eMedicine ([http://cmestaging.emedicine.com/acqhem\\_cme/caseindex.html](http://cmestaging.emedicine.com/acqhem_cme/caseindex.html)) 2007
2. **Poon, M-C.** Glanzmann's thrombasthenia in surgery and pregnancy . Novo Nordisk Online Hemophilia Education: available at <http://novonordisk.cme-academy.eu> 2013
3. **Poon, M-C.** Glanzmann's thrombasthenia in children. Novo Nordisk Online Hemophilia Education: available at <http://novonordisk.cme-academy.eu> 2013

(E) Technology Reports

1. Brown, A., Wells, P., Jaffey, J., McGrahan, L., **Poon, M-C.**, Cimon, K., Campbell, K. Devices for point-of-care monitoring of long-term oral anticoagulation therapy: clinical and cost effectiveness [Technology overview number 24]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); (<http://www.cadth.ca/index.php/en/publication/679>) 2007

(F) Books, Chapters

1. The Southern Alberta Hemophilia Program (including **Poon, M-C.**). *Partnerships in Hemophilia Care*, Calgary: Alberta Children's Hospital Southern Alberta Hemophilia Program (ISBN 0-88953-138-2) pp 33, 1990
2. Lam, A.K.S, McDonald, J.R. and **Poon, M-C.** *The Chinese Elderly in Calgary. A Needs Assessment.* Calgary: Faculty of Social Work, University of Calgary. pp 81, 1992
3. McDonald JR, Devins GM, Poon M-C. Canadians HIV Positive secondary to Blood Transfusion. Final Report, Health and Welfare Canada National Health Research and Development Program.
4. **Poon, M-C.**, Growe, G.H. (Guest editors). Proceeding of the International Symposium on Recombinant Factor VIII. *Transfusion Medicine Review* 6:233-294, 1992
5. **Poon, M-C.** and Klein, P. Clotting Factor Therapy, In “*All About Hemophilia: A Guide for Families*” Edited by Blanchette, V., Creighton, K., Stain, A.M., Wilton, P. Canadian Hemophilia Society. 4-1 – 4-24, 2001
6. **Poon, M-C.** Factor VIIa (Chapter 57). In “*Platelets*”. Edition 1, Edited by Michelson, AD. New York: Academic Press. 867-873, 2002
7. Israels, S., **Poon, M-C.**, and Rand, M.L. on behalf of the Canadian Children's Platelet Study Group. Disorders of Platelet Function: An Information Booklet for Patients, Families and Health Care Providers. 2002.
8. **Poon, M-C.** Coagulation Factor Concentrate (Chapter 5). “*Canadian Blood Services Clinical Guide to Transfusion*”, edited by Blajchman, M and Clark, G. Toronto; Canadian Blood Services, pp 46-57, 2006.
9. **Poon, M-C.** Hemostatic Disorders (Chapter 17). “*Canadian Blood Services Clinical Guide to Transfusion*”, edited by Blajchman, M and Clark, G. Toronto; Canadian Blood Services, pp 158-169, 2006.

10. **Poon, M-C.** Factor VIIa (Chapter 68). In *“Platelets”*. Edition 2, Edited by Michelson, AD. New York: Academic Press, pp 1251-1261. 2006
11. **Poon, M-C.** and Luke K.H. Hemophilia Care in Canada (Section 5-Chapter 3). In *“Hemophilia”* Edited by Yang, R.C., Wang, H.L., Zhou, Y.Q. and Wang X.F. Shanghai Science & Technology Press, pp 178-193, 2007 (in Chinese)
12. **Poon, M-C.** Glanzmann’s thrombasthenia and gastrointestinal angiodysplasia, In *“Haemophilia and Haemostasis: A Case-based Approach to Management”* Edited by Roberts, H.R., Carrizosa, D., and Ma, A. Oxford: Blackwell Publishing, pp 153-155, 2007
13. **Poon, M-C.** Glanzmann’s thrombasthenia and pregnancy, In *“Haemophilia and Haemostasis: A Case-based Approach to Management”* Edited by Roberts, H.R., Carrizosa, D., and Ma, A. Oxford: Blackwell Publishing, pp 157-158, 2007
14. **Poon, M-C.** Unknown thrombophilia and surgery, In *“Haemophilia and Haemostasis: A Case-based Approach to Management”* Edited by Roberts, H.R., Carrizosa, D., and Ma, A. Oxford: Blackwell Publishing, pp 221-222, 2007
15. **Poon, M-C.** \*Jackson SC, Brown M, and McClure W. Clotting factor therapy (Chapter 5). In *“All About Hemophilia: A Guide for Families, edition 2”*, Canadian Hemophilia Society ([www.hemophilia.ca](http://www.hemophilia.ca)), pp5-1 – 5-31, 2010
16. Breakey VR, Carcao M, **Poon M-C** and Blanchette V. The Role of prophylaxis in the management of hemophilia (Chapter 6). In *“All About Hemophilia: A Guide for Families, edition 2”*, Canadian Hemophilia Society([www.hemophilia.ca](http://www.hemophilia.ca)), pp6-1 – 6-10, 2010
17. **Poon, M-C.** Factor VIIa (Chapter 61). In *“Platelets”*. Edition 3, Edited by Michelson, AD. New York: Academic Press, pp 1257-1273., 2013
18. Israels, S., **Poon, M-C**, and Rand, M.L. on behalf of the Canadian Pediatric Thrombosis and Haemostasis Network. Disorders of Platelet Function: An Information Booklet for Patients, Families and Health Care Providers. Edition 3. 2013
19. Dorgalaleh, A., **Poon, M-C.**, \*Shiravand, Y. Glanzmann thrombasthenia (Chapter 14). In *“Congenital Bleeding Disorders”*. Edited by Dorgalaleh A. Springer, Cham, Switzerland, pp 327-355, 2018
20. **Poon, M-C.** Factor VIIa (Chapter 63). In *“Platelets”*. Edition 4, Edited by Michelson AD, Cattaneo M, Frelinger ALI and Newman PJ. New York: Elsevier/Academic Press, pp 1121-1135, 2019
21. **Poon M-C**, \*Safdari SM. Glanzmann Thrombasthenia: Diagnosis and Management (Chapter 15). In *“Congenital Bleeding Disorders: Diagnosis and Management”* Edition 2, Edited by Dorgalaleh A. Springer, Cham, Switzerland (ISBN: 978-3-031-43158-6, DOI:10.1007/978-3-031-43156-2\_4) 2024

(G) Books and Chapters in press

1. **Poon, M-C.** Glanzmann’s thrombasthenia. In *“Syndromology”*. Edited by Conrad R and Mücke M. Elsevier Publisher, München, Germany (to be published 2024)

(H) Non- peer-reviewed Reviews/Invited Manuscripts

1. **Poon, M-C.** Medical conditions in Haiti. *Canad.Assoc.Med.Stud.Interns J.* 26:14, 1967.
2. **Poon, M-C.** The laboratory diagnosis of coagulation disorders. *Continuing Education for the Family Physicians* 7:27-34, 1978.
3. **Poon, M-C.** The evaluation of clotting disorders. *J.Med.Assoc.State Alabama* 48:35-49, 1979.
4. **Poon, M-C.,** Landay, A., Alexander, J., Birch, W., Eyster, M.E., Al-Mondhiry, R., Ballard, J.O., White, E., Hayes, C., Pass, L.O., Meyers, J.P., Politis, C., Goldberg, R., Bhatti, M., Arnold, M., York, J., Halpin, T., Herwaldt, L., Spivack, A., Donnell, H., Powars, D., Fannin, S.L. and Chin, J. Update on acquired immune deficiency syndrome (AIDS) among patients with hemophilia A. *Mort.Morbid.Weekly Rep.* 31(48):644-652, 1982
5. **Poon, M-C.** Symptomatology, diagnosis, laboratory examination and treatment of acquired immune deficiency syndrome (AIDS). *Proceedings of the Fourth International Symposium on Hemophilia Treatment* 4:31-43, 1985.
6. **Poon, M-C.** Present status of acquired immune deficiency syndrome (AIDS) in Canada. *Proceedings of the Fourth International Symposium on Hemophilia Treatment* 4:65-68, 1985.
7. **Poon, M-C.** Assessment of self-infusion therapy of hemophiliacs in Canada. *Proceedings of the Fourth International Symposium on Hemophilia Treatment* 4:225-232, 1985.
8. **Poon, M-C.** Hemophilia care in evolution. *Psychosocial Issues in Hemophilia: A Canadian Bulletin* 3:1-2, 1988.
9. **Poon, M-C.** Disorders of hemostasis and thrombosis: hemophilia and thrombophilia. *Medicine North America* 30:5531-5539, 1989.
10. **Poon, M-C.** Coagulation factor concentrates in Canada: what are available, how are they available, and what are their uses. *Hemophilia Today* 28 (2):1, 11-12. 1993.
11. Growe GH, Chang TMS, Slichter SJ, Tartter P, Poon M-C. New concepts in blood product usage. *Annals of the Royal College of Physicians and Surgeons Canada* 1993;26(2):106-108
12. **Poon, M-C.** How much has hemophilia care advanced? *Hemophilia Today* 29 (1):5-6. 1993.
13. **Poon, M-C.** Easy bruising and bleeding. How to evaluate it. *Medicine North America* 17:189-194, 1994.
14. **Poon, M-C.** Factor VIII inhibitors: a second outbreak. *International Monitor on Hemophilia* 5(2):16-17, 1997.
15. **Poon, M-C.** Mild hemophilia in children. *International Monitor on Hemophilia* 6(2):16, 1998.
16. **Poon, M-C.** Can we test for neoantigens that induce antibodies to factor VIII? *International Monitor on Hemophilia* 7(1):24-25, 1999.
17. **Poon, M-C.** Tackling a giant: fighting hemophilia in China. *Haemophilia World.* 6(1):1-3, 1999. [with Isaac, B. Reprinted with modifications in *Hemophilia Today* 34(3): 14-17, 1999]

18. **Poon, M-C.**, Robinson, S. Observations and comments on the recent Kogenate “quarantine”. *Hemophilia Today*. 34(1): 23-25, 1999.
19. **Poon, M-C.** Modified factor IX peptides neutralizes factor IX inhibitors. *International Monitor on Hemophilia* 7(2): 26-27, 1999.
20. **Poon, M-C.** Recovery and disappearance of infused factor IX activity: underlying mechanisms *International Monitor on Hemophilia* 8(1): 20-21, 2000
21. **Poon, M-C.** Novel treatment of congenital platelet bleeding disorder. Hong Kong Association of Transfusion Medicine and Hematology Newsletter 7(1): 1-5, 2000
22. **Poon, M-C.** Factor VIII inhibitors: new approach to treatment and prevention. *International Monitor on Hemophilia* 8(2):24-25, 2000
23. **Poon, M-C.** Recombinant factor IX for prophylaxis and continuous infusion. *International Monitor on Hemophilia* 9(2):27-28, 2001
24. **Poon, M-C.** rFIX absorption into the circulation after subcutaneous injections. *International Monitor on Hemophilia* 2:22-23, 2002.
25. **Poon, M-C.** In vitro test for responsiveness to FVIIa in hemophilia. *International Monitor on Hemophilia* 11(1):27-28, 2003
26. **Poon, M-C.** Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates *International Monitor on Hemophilia* 11(2):26-27, 2003
27. **Poon, M-C.** Prophylaxis is under used for severe Hemophilia A boys. *International Monitor on Hemophilia* 12(1): 15-16, 2004
28. **Poon, M-C.** Different assay-systems have different accuracy and sensitivity at low and high FVIII levels. *International Monitor on Hemophilia* 1(1): 27-28, 2004
29. **Poon, M-C.** Targeting megakaryotes for delivery of FVIII gene therapy. *International Monitor on Hemophilia* 12(2): 8-9, 2004
30. **Poon M-C,** Luke KH. Hemophilia care in China: new strategies and opportunities in 2005 and beyond. *Hemophilia Today*: 40 (2):23, 2005 (available at [8449\\_SCH\\_ANG\\_C1\(hemophilia.ca\)](http://8449_SCH_ANG_C1(hemophilia.ca)))
31. **Poon, M-C.** FVIII inhibitor development among users of rFVIII (Recombinate rAFH/Bioclote®) is low. *International Monitor on Hemophilia* 13(1):27-28, 2005.
32. **Poon, M-C.** rFVIIa is more effective at higher doses for inhibitor patients. *International Monitor on Hemophilia* 13 (2):31-2, 2005.
33. **Poon, M-C.**, Preferences for hemophilia treatment products among patients, physicians and pharmacists. *International Monitor on Hemophilia* 14 (1):18-19, 2006.
34. **Poon, M-C.** Thromboelastographic pattern in severe hemophilia and effects of ex vivo antifibrinolytics. *International Monitor on Hemophilia* 16 (1):15-16, 2008
35. **Poon, M-C.** Generation and characterization of potentially long-acting glycoPEGylated factor VIIa derivatives. *International Monitor on Hemophilia* 17 (1):27-28, 2009
36. **Poon, M-C.** Home treatment with bypassing agents in inhibitor patients is safe. *International Monitor on Hemophilia* 17 (2):35-36, 2009

37. **Poon, M-C.** Factor VIII-pulsed dendritic cells reduces inhibitor formation in haemophilia A mouse . *International Monitor on Hemophilia* 18;31-32, 2010
38. **Poon, M-C.** Acquired hemophilia A: Data from the European Acquired Haemophilia Registry (EACH2). *International Monitor on Hemophilia* 20;40-41, 2012
39. **Poon, M-C.** Novel stem cell based hemophilia A gene therapy. *The International Monitor on Hemophilia.* 22: 22-23, 2014
40. **Poon, M-C.** Hemophilia A with current inhibitors has a higher mortality rate. *The International Monitor on Hemophilia* 2015;23:35-36
41. **Poon, M-C.** Inhibitors in previously treated hemophilia A: natural history and characteristics. *The International Monitor on Hemophilia* 2017; 25:42-44

(I) Theses

1. **Poon, M-C.** Characterization of *Artemia* Hemoproteins. M.D. Thesis, Faculty of Medicine, University of British Columbia, 1968. (Supervisor: Drs. Gordon Dixon and Sarane Bowen)
2. **Poon, M-C.** The Human Plasma Kinin System. M.Sc. Thesis, Department of Pathology, University of Toronto, 1970. (Supervisor: Dr. Henry Z. Movat)

(J) Letters to the Editor (non-peer reviewed)

1. Walker, I. and **Poon, M-C.** Recombinant factor VIII concentrate. *Lancet* 339:61-62, 1992.
2. Haase, M., Marder, H., Ewenstein, B.M., Roth, D.A., Kessler, C.M., Pasi, K.J., Ragni, M.V., White, G.C.II., Giangrande, P.L., Blanchette, V.S., Brackmann, H-H., Heisel, M.A., Hoots, W.K., Lee, C., Ludlam, C.A., Lusher, J.M., Negrier, C., Philipp, C., **Poon, M-C.**, Rivard, G.E., Rosenfield, C.G., Shapiro, A., Thomas, A., Thompson, A.R., and Vermynen, J. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. *Blood*, 100:4242, 2002
3. Rand M, Jackson S, Cloutier S, **Poon M-C.** Platelet dysfunction in von Willebrand disease type 2B with the Montreal Platelet Syndrome mutation, VWF V1316M.(E-letter for Casari C, Berrou E, Lebret M et al, von Willebrand factor mutation promotes thrombocytopenia by inhibiting integrin  $\alpha$ IIb $\beta$ . *Journal of Clinical Investigation* 2013; 123(12):5071–5081 Published Dec 13, 2013



## (K) Abstracts

1. **Poon, M-C.** and Movat, H.Z. Small molecular weight activator of the human plasma kinin-system. *Fed.Proc.* 29:289, 1970.
2. **Poon, M-C.** and Ratnoff, O.D. Non-covalent linkage of functional sub-units of antihemophilic factor (factor VIII). *Clin.Res.* 24:313A, 1976.
3. Saito, H. and **Poon, M-C.** Radioimmunoassay for a human plasma prekallikrein (Fletcher factor). *Fed.Proc.* 36:313, 1977.
4. **Poon, M-C.** and Ratnoff, O.D. Identification of a nonfunctional low molecular weight (MW) subcomponent in the antihemophilic factor (AHF, factor VIII)-like protein in classic hemophilia. *Ann.Royal Coll.Phys.Surg.Canada* 11:55, 1978.
5. **Poon, M-C.**, Prchal, J.T., Okos, J.J. and Prchal, J.F. Combined myelo- and lymphoproliferative disorders in the same patient. *Blood* 50 (Suppl 1):204, 1978.
6. Prchal, J.T., Prchal, J.F., Wu, A.W., Fuson, E.W., Carroll, A.J.III and **Poon, M-C.** The clonal nature of acquired sideroblastic anemia for myeloid and lymphoid lines. *Am.J.Hum.Genet.* 30:121A, 1978.
7. **Poon, M-C.**, Moore, M.R., Prchal, J.T. and Weir, A.B. Prothrombin Birmingham: a new structurally abnormal prothrombin. *Blood* 54 (Suppl 1):297A, 1979.
8. **Poon, M-C.**, Moore, M.R. and Carpenter, J.T. Lupus inhibitors with hypo-prothrombinemia: the immunoglobulin nature of the inhibitors and the characteristics of prothrombin. *Blood* 54 (Suppl 1):296A, 1979.
9. \*Floyd, D.M., Huang, S.T. and **Poon, M-C.** Detection of mixed cell population by peroxidase-anti-peroxidase immunoenzyme technique. *Transfusion* 20:635, 1980.
10. Huang, S.T., \*Floyd, D.M. and **Poon, M-C.** Detection of mixed red cell populations by two enzyme-linked immunochemical methods. *Transfusion* 21:627, 1981.
11. Huang, S.T., **Poon, M-C.**, Lin, J., \*Barnes, H.M., Conrad, M.E. and McGowan, E.I. Severe febrile transfusion reaction caused by granulocyte autoantibodies. *Transfusion* 21:617, 1981.
12. Maddox, W.T., McDaniel, H.G., **Poon, M-C.** and Rackley, C.E. Serial platelet responsiveness to arachidonic acid in acute myocardial infarction. *Clin.Res.* 29:855A, 1981.
13. \*Moore, M.R., **Poon, M-C.**, Parmley, R.T. and Conrad, M.E. Experimental bone marrow necrosis and fibrosis: genesis and evolution. *Clin.Res.* 29:341A, 1981.
14. **Poon, M-C.** and Hurst, R.E. Thrombin and factor Xa inhibition by hog mucosal heparins fractionated according to charge density. *Thrombos.Haemostas.* 46:234, 1981.
15. **Poon, M-C.**, Parmley, R.T. and Chang-Poon, V.Y-H. Non-immune interaction of leukocytes with platelets and megakaryocytes. *Clin.Res.* 29:344A, 1981.
16. **Poon, M-C.** and Hurst, R.E. Platelet factor 4 (PF4) and protamine sulfate (PS) neutralization of heparin fractionated according to charge density. *Thrombos.Haemostas.* 46:377, 1981.
17. **Poon, M-C.** Congenital prothrombin defects: study of a patient with double heterozygosity for dysprothrombinemia and hypoprothrombinemia. *Blood* 58 (Suppl 1):223A, 1981.
18. **Poon, M-C.**, Saito, H. and Koopman, W.J. Characterization of an unique and potent factor XI (PTA) inhibitor. *Blood* 58 (Suppl 1):224A, 1981.

19. Maddox, W.T., McDaniel, H.G., **Poon, M-C.** and Rackley, C.E. Serial platelet responsiveness to arachidonic acid in acute myocardial infarction. *Am.J.Cardiol.* 49:901, 1982.
20. \*Osborn, R.C., McDaniel, H.G., **Poon, M-C.** and Rackley, C.E. Platelet activation by acute cigarette smoking in chronic smokers. *Clin.Res.* 30:833A, 1982.
21. **Poon, M-C.** and Hurst, R.E. Heparin activity with antithrombin II/III and heparin cofactor II: role of heparin charge density and antithrombin affinity. *Blood* 60 (Suppl 1):219A, 1982.
22. **Poon, M-C.**, Saito, H. and Koopman, W.J. Characterization of a unique autoantibody directed against factor XI (PTA) in SLE. *Clin.Res.* 30:622A, 1982.
23. **Poon, M-C.** and \*Landay, A. Longitudinal immunologic studies on asymptomatic hemophiliacs. *Ann.Royal Coll.Phys.Surg.Canada* 16:345, 1983.
24. **Poon, M-C.**, \*Landay, A. and Huang, S.T. Cellular and humoral immune alterations in asymptomatic hemophilia patients, a longitudinal study. *Blood* 62 (Suppl 1):115A, 1983.
25. Ramsey, R., Palmer, E., Feorino, P., Cabradilla, C., **Poon, M-C.** and Evatt, B. Isolation of human T-cell leukemia virus from circulating lymphocytes of two hemophiliacs with AIDS. *Blood* 62 (Suppl 1):116A, 1983.
26. Chui, D.H.K., Wong, S.C., \*Chung, S-W. and **Poon, M-C.** Expression of human embryonic  $\xi$ -globin genes in adult individuals. *Blood* 64 (Suppl 1):55A, 1984.
27. Field, S.F. and **Poon, M-C.** Sarcoidosis presenting as chronic thrombocytopenia. *Ann.Royal Coll.Phys.Surg.Canada* 17:353, 1984.
28. Green, B.J., **Poon, M-C.**, Fritzler, M.J., Bowen, T.J. and Matheson, D.S. Differential response of natural killer cells from hemophiliacs to interferon- $\beta$  and  $\gamma$ . *Clin.Invest.Med.* 7 (Suppl 2):61, 1984.
29. Matheson, D.S., Green, B.J., **Poon, M-C.** and Bowen, T.J. Defective response of natural killer cells from hemophiliacs to interferon- $\alpha$  and  $\beta$ . *Alberta Heritage Foundation for Medical Research Heritage Days Abstracts* 1984.
30. Palmer, E.L., Ramsey, R.B., **Poon, M-C.** and Evatt, B. Detection of HTLV-1 and LAV in lymphocytes of a hemophiliac with AIDS. *Blood* 64 (Suppl 1):99A, 1984.
31. Pontisso, P., Dejean, P., **Poon, M-C.**, Tiollais, P. and Brechot, C. Detection of hepatitis B virus DNA in human blood mononuclear cells. In: *Viral Hepatitis and Liver Disease*, edited by Vyas, G.N., Dienstag, J.L. and Hoofnagle, J.H. Orlando: Grune and Stratton, 1984, p. 630.
32. **Poon, M-C.** Assessment and self-infusion therapy of hemophiliacs in Canada. *The Fourth International Symposium on Hemophilia Treatment Abstracts* 4:49-50, 1984.
33. **Poon, M-C.** Present status of acquired immune deficiency syndrome (AIDS) in Canada. *The Fourth International Symposium on Hemophilia Treatment Abstracts* 4:15-16, 1984.
34. **Poon, M-C.**, Bowen, T., Matheson, D.S. and Hoar, D.I. Hepatitis B virus (HBV) DNA is enriched in polymorphonuclear leukocytes (PMN). *Blood* 64 (Suppl 1):229A, 1984.
35. **Poon, M-C.**, Bonner, J., Huang, S.T. and Prchal, J.T. Positive Coombs test in patients with acquired immune deficiency syndrome (AIDS) may not indicate hemolysis. *Clin.Res.* 32:320A, 1984.

36. **Poon, M-C.** Symptomatology, diagnosis, laboratory examination and treatment of acquired immune deficiency syndrome (AIDS). *The Fourth International Symposium on Hemophilia Treatment Abstracts* 4:6-10, 1984.
37. Bowen, T., Matheson, D.S., Green, B.J., Bennett, C., Hoar, D.I. and **Poon, M-C.** Hemophilia *in vitro* lymphocyte proliferation to factor VIII concentrates. *U.S.National Hemophilia Foundation-Canadian Hemophilia Society Joint Annual Meeting abstracts* 1985.
38. **Poon, M-C.** Status of comprehensive hemophilia care in Canada. *U.S.National Hemophilia Foundation-Canadian Hemophilia Society Joint Annual Meeting abstracts* 1985.
39. **Poon, M-C.**, Landay, A., \*Paul, D. and Falk, L. HTLV-III antigen in hemophiliacs: a longitudinal study. *Blood* 66 (Suppl 1):115A, 1985.
40. **Poon, M-C.** and Landay, A. Serial HTLV-III serology in hemophiliacs with and without AIDS related complex (ARC). *Clin.Res.* 33:351A, 1985.
41. **Poon, M-C.**, Low, S., Pan, T., Dawes, R., Bowen, T. and Sinclair, G.D. Sensitive enzyme immunosorbent assay (ELISA) for factor VIII:C antigen: development and application. *The Third Canadian Red Cross Blood Transfusion Service Scientific Meeting Abstracts* 1985.
42. The Alberta Children's Hospital Comprehensive Hemophilia Home Care Program (including **Poon, M-C.**) An I.D.E.A.L.S. approach to comprehensive program planning for management of hemophilia . *U.S.National Hemophilia Foundation-Canadian Hemophilia Society Joint Annual Meeting abstracts* 1985.
43. Cassol, S., Hoar, D.I., Snider, C., Beckett, T., Smith, L., England, B., Boswell, A., **Poon, M-C.** and Bowen, T. A longitudinal study of cytomegalovirus (CMV) antibody activity in blood donors. *The Fourth Canadian Red Cross Blood Transfusion Service Scientific Meeting Abstracts* 1986.
44. \*Chow, K.S., Low, S., Sinclair, G.D. and **Poon, M-C.** Detection and analysis of different molecular forms of factor VIII:C from cryoprecipitates. *Alberta Heritage Foundation for Medical Research Heritage Days Abstracts* 1986.
45. **Poon, M-C.**, Landay, A., \*Paul, D. and Falk, L. Human immunodeficiency viral (HIV) infection markers in hemophiliacs. *Blood* 68 (Suppl 1):132A, 1986.
46. **Poon, M-C.**, Hoar, D.I. and Chui, D.H.K. Hemophilia B carriers and factor IX variant detection using DNA probes. *Clin.Invest.Med.* 9:A76, 1986.
47. **Poon, M-C.**, Hoar, D.I. and Chui, D.H.K. DNA probing assay for the identification of factor IX (FIX) variants and hemophilia B carriers . *La Ricerca In Clinica E In Laboratorio* 16:163, 1986.
48. **Poon, M-C.**, Hoar, D.I. and Chui, D.H.K. Identification of factor IX (FIX) variants and hemophilia B carriers using cloned DA probes. *Clin.Res.* 34:662A, 1986.
49. **Poon, M-C.**, Landay, A., \*Paul, D. and Falk, L. Human immunodeficiency viral (HIV) infection markers in hemophiliacs. *The Fourth Canadian Red Cross Blood Transfusion Service Scientific Meeting Abstracts* 1986.
50. **Poon, M-C.**, Chow, K.S., Low, S. and Sinclair, G.D. Detection and analysis of different molecular forms of factor VIII:C from cryoprecipitates. *The Fourth Canadian Red Cross Blood Transfusion Service Scientific Meeting Abstracts* 1986.
51. Berman-Wong, E., Pal, R., Bowen, T. and **Poon, M-C.** Immunodetection on mini-gels. *The Second Workshop and Conference on Platelet Serology Abstracts* 1987.

52. Kashiwagi, N., Ohnishi, M., Shiozawa, C., Tamaoki, T., Gill, M.J., Bowen, T., **Poon, M-C.**, Matheson, D.S., Johnson, S., Church, D., Adachi, M., Mizuta, T., Kosedo, T., Nakajima, K., Akuzawa, K., Williamson, J.A., Hayami, M., Ohta, Y., Handa, K. and Hakomori, S. Expression of carbohydrate antigen on HIV infected cells. II. A change in expression of carbohydrate antigen in peripheral blood lymphocytes from HIV infected patients. *The First Japanese AIDS Research Meeting Abstracts* 1987.
53. Kosedo, T., Adachi, M., Mizuta, T., Nakajima, K., Akuzawa, K., Williamson, J.A., Hayami, M., Ohta, Y., Kashiwagi, N., Ohnishi, M., Shiozawa, C., Tamaoki, T., Gill, M.J., Bowen, T., **Poon, M-C.**, Matheson, D.S., Johnson, S., Church, D., Handa, K. and Hakomori, S. Expression of carbohydrate antigen on HIV infected cells. I. HIV infection and expression of LeY antigen in T-cell line. *The First Japanese AIDS Research Meeting Abstracts* 1987.
54. Mizuta, T., Adachi, M., Kosedo, T., Nakajima, K., Akuzawa, K., Williamson, J.A., Kashiwagi, N., Ohnishi, M., Shiozawa, C., Tamaoki, T., Gill, M.J., Bowen, T., **Poon, M-C.**, Matheson, D.S., Johnson, S., Church, D., Handa, K., Hakomori, S., Ohta, Y. and Hayami, M. Expression antigen and the change of host cells. *The First Japanese AIDS Research Meeting Abstracts* 1987.
55. **Poon, M-C.**, Card, R.T. and Bowen, T. Human immunodeficiency virus antibody in hemophiliacs and von Willebrand disease patients in Southern Alberta and Saskatchewan: evidence for seroconversion in 1980-95. *Clin.Invest.Med.* 10:B81, 1987.
56. **Poon, M-C.**, Russell, J., Low, S., Blahey, W. and Sinclair, G.D. Evidence that factor XIII-A subunit in platelets and monocytes are synthesized de novo and/or by their progenitor cells. *Clin.Res.* 35:892A, 1987.
57. **Poon, M-C.**, \*Chow, K.S., Low, S. and Sinclair, G.D. Differential responses of different factor VIII molecular forms to thrombin and EDTA. *Thrombos.Haemostas.* 58:343, 1987.
58. Russell, J.A., Berry, J., Houwen, B., Jones, A.R., **Poon, M-C.**, Blahey, W.B., Geggie, P.H.S. and Ruether, B.A. Melphalan and autotransplantation for Hodgkin's disease. *The Third International Conference on Malignant Lymphomas Abstracts* 1987.
59. \*Calvin, B.M., **Poon, M-C.** and Hoar, D.I. The molecular characterization of two hemophilia mutations by PCR amplification and dideoxy sequencing of patient DNA. *The Fifth Canadian Red Cross Blood Transfusion Service Scientific Meeting Abstracts* 1988.
60. Cassol, S., Bowen, T., **Poon, M-C.**, Pal, R., Naylor, M., Culver-James, J. and Hoar, D.I. DNA amplification for the early diagnosis of CMV infection in bone marrow transplant recipient. *Blood* 72 (Suppl 1):382A, 1988.
61. Church, D., Gill, M.J. and **Poon, M-C.** The prevalence of enteric pathogens in human immunodeficiency virus (HIV) infection. *The Fourth International Conference on AIDS Abstracts* 1:406, 1988.
62. Gill, M.J., Kashiwagi, N., Ohnishi, M., Shiozawa, C., **Poon, M-C.**, Matheson, D.S., Johnson, S. and Church, D. Expression of carbohydrate antigen on HIV infected cells II. A change in expression of carbohydrate antigen in peripheral blood lymphocytes from HIV infected patients. *The Fourth International Conference on AIDS Abstracts* 2:151, 1988.
63. Gill, M.J., Kashiwagi, N., Johnson, S., **Poon, M-C.**, Church, D., Adachi, M., Ohnishi, M., Tamaoki, T., Shiozawa, C. and Hakomori, S. Progressive changes with time in expression of carbohydrate antigen in peripheral blood lymphocytes (PBL) of HIV infected patients. *The Second Japanese AIDS Research Meeting Abstracts* 2:58, 1988.
64. **Poon, M-C.**, Russell, J.A., Low, S., Sinclair, G.D., Jones, A.R., Blahey, W., Ruether, B.A. and Hoar, D.I. Contribution of hemopoiesis to factor XIII-A subunits (XIII-A) in the circulation. *Blood* 72 (Suppl 1):306A, 1988.

65. **Poon, M-C.**, Russell, J., Low, S. and Sinclair, G.D. Hemopoietic cell origin of factor XIII-A subunits (XIII-A) in plasma, platelets and monocytes. *XVIII International Congress of the World Federation of Hemophilia Abstracts* 18:112, 1988.
66. Shiozawa, C., Kosedo, T., Adachi, M., Mizuta, T., Williamson, J.A., Hayami, M., Kashiwagi, N., Ohnishi, M., Gill, M.J., Bowen, T., **Poon, M-C.**, Matheson, D.S., Johnson, S., Church, D., Hakomori, S. and Tamaoki, T. Expression of carbohydrate antigen on HIV infected cells. I. HIV infection and expression of LeY antigen in T-cell line. *The Fourth International Conference on AIDS Abstracts* 2:151, 1988.
67. Tsoukas, C.M., Ali, S.K., Card, R.T., Garvey, M.B., Growe, G.H., Kobrinsky, N., **Poon, M-C.**, Rivard, G., Ross, E., Rubin, S. and Strawczynski, H. Immune changes associated with HIV infection among blood product recipients. *XVIII International Congress of the World Federation of Hemophilia Abstracts* 18:104, 1988.
68. Ali, S.K., Tsoukas, C., Card, R.T., Garvey, M.B., Growe, G.H., Kobrinsky, N., **Poon, M-C.**, Rivard, G., Ross, E., Rubin, S. and Strawczynski, H. A prospective study of HIV infection in children with hemophilia. *The Fifth International Conference on AIDS Abstracts* p.419, 1989.
69. Gill, M.J., Shiozawa, C., Kashiwagi, N., Church, D., Ohnishi, M., **Poon, M-C.**, Johnson, S. and Adachi, M. Progressive changes with time in expression of carbohydrate antigen in PBL of HIV infected patients. *The Fifth International Conference on AIDS Abstracts* p.249, 1989.
70. Jazem, P., Tsoukas, C., Burke, D., Strawczynski, H., Growe, G.H. and **Poon, M-C.** Hemophilia septic arthritis and human immunodeficiency virus. *The Fifth International Conference on AIDS Abstracts* p.417, 1989.
71. **Poon, M-C.**, Tsoukas, C., Gold, P., Ali, S.K., Card, R.T., Garvey, M.B., Growe, G.H., Kobrinsky, N., Rivard, G., Ross, E., Rubin, S., Strawczynski, H. and O'Shaughnessy, M. Canadian National Hemophilia Study: HIV infection in hemophilia and other bleeding disorders (1985-1989). *Clin.Invest.Med.* 12 (Suppl):B45, 1989.
72. **Poon, M-C.**, Hoar, D.I. and Sinclair, G.D. Hemophilia A carrier detection by combined DNA probing techniques and ELISA for factor VIII (FVIII) and von Willebrand factor (vWF). *Clin.Invest.Med.* 12 (Suppl):B65, 1989.
73. **Poon, M-C.**, Ali, S.K., Card, R.T., Garvey, M.B., Growe, G.H., Kobrinsky, N., Rivard, G., Ross, E., Rubin, S., Strawczynski, H. and Tsoukas, C. Canadian National Hemophilia Study: HIV infection in hemophilia and other bleeding disorders (1985-1989). *The Fifth International Conference on AIDS Abstracts* p.207, 1989.
74. Russell, J., Jones, A.R., **Poon, M-C.** and Ruether, B.A. Nephrotoxicity of high dose melphalan (HDM). *The fifth European Conference on Clinical Oncology Abstracts* 1989.
75. Russell, J., Wierzbicki, R., MacCormick, R., Jones, A.R., **Poon, M-C.**, Arthur, K., Temple, W. and Ruether, B.A. Adult Ewing's sarcoma treated with high dose melphalan (HDM) +/- total body irradiation (TBI) and bone marrow transplant. *The fifth European Conference on Clinical Oncology Abstracts* 1989.
76. Tsoukas, C., Ali, S.K., Card, R.T., Garvey, M.B., Growe, G.H., Kobrinsky, N., **Poon, M-C.**, Rivard, G., Ross, E., Rubin, S., Shuster, J., Strawczynski, H. and O'Shaughnessy, M. Immune status of HIV seronegative hemophiliacs. *Clin.Invest.Med.* 12 (Suppl):B6, 1989.
77. Dimnik, L.S., \*Fraser, B.M., **Poon, M-C.** and Hoar, D.I. Molecular diagnosis of single strand DNA conformational variation. *Am.Soc.Hum.Genet.* 1990.
78. Jarolim, P., Ruff, P., Coetzer, T.L., Prchal, J.T., Ballas, S.K., **Poon, M-C.**, Brabec, V. and Palek, J. A subset of patients with dominantly inherited hereditary spherocytosis has a marked deficiency of the band 3 protein. *Blood* 79 (Suppl 1):37A, 1990.

79. **Poon, M-C.**, Akabutu, J., Card, R.T., Gill, M.J., Growe, G.H., Martin, S., Mathias, R., Ramsum, D. and Tsoukas, C. Canadian multicenter study of heterosexual HIV transmission in hemophiliacs. *The Sixth international Conference on AIDS Abstracts* 2:268, 1990.
80. Russell, J., **Poon, M-C.**, Jones, A.R. and Ruether, B.A. Allogeneic bone marrow transplantation (BMT) without protective isolation - is it safe? *Blood* 76 (Suppl 1):562A, 1990.
81. \*Dichmann, R., **Poon, M-C.**, Jones, A.R., Culver-James, J., Bowen, T., Allaire, S., Ruether, B.A., and Russell, J.A. The prognostic significance of clinically silent cytomegalovirus (CMV) infection and the role of CMV negative blood products in bone marrow transplant (BMT) patients. *Alberta Cancer Board Scientific Meeting, Kananaskis, Alberta* 1991.
82. **Poon, M-C.**, Sinclair, G.D., \*Fraser, B.M., Anand, S. and Hoar, D.I. Screening of factor IX mutations by single strand conformation variation (SSCV) analysis. *The Seventh Canadian Red Cross Blood Transfusion Service Scientific Meeting Abstracts* 1991. *Transfusion Medicine* 2:85, 1992
83. Russell, J.A., Jones, A.R., **Poon, M-C.** and Ruether, B.A. Concurrent chronic myelogenous leukemia and hairy cell leukemia treated by three bone marrow transplants from two donors. *17th Annual Meeting of EBMT, Cortina d'Ampezzo, Italy* 1991.
84. Russell, J.A., Jones, A.R., **Poon, M-C.**, Snodgrass, T. and Ruether, B.A. Influence of isolation and conditioning protocols on early infection in allogeneic bone marrow transplant (BMT) patients. *17th Annual Meeting of EBMT, Cortina d'Ampezzo, Italy* 1991.
85. Russell, J.A., Jones, A.R., **Poon, M-C.**, Woodman, R.C. and Ruether, B.A. Addition of folinic acid to a methotrexate/cyclosporine regimen for prevention of acute graft-versus-host disease. *Alberta Cancer Board Scientific Meeting, Kananaskis, Alberta* 1991.
86. Russell, J.A., **Poon, M-C.**, Jones, A.R., Woodman, R.C. and Ruether, B.A. Allogeneic bone marrow transplantation for adults with malignancy without protective isolation. *Alberta Cancer Board Scientific Meeting, Kananaskis, Alberta* 1991.
87. Russell, J.A., Jones, A.R., **Poon, M-C.**, Woodman, R.C. and Ruether, B.A. Addition of folinic acid to a methotrexate/cyclosporine regimen for prevention of acute graft-versus-host disease. *J.Cell.Biochem. Suppl* 16A:187, 1992
88. **Poon, M-C.**, Anand, S., Low, S. and Sinclair, G.D. Hemophilia B mutation and carrier detection by single strand conformation variation (SSCV) analysis. *Joint Meeting of The Canadian Society for Transfusion Medicine and The Canadian Red Cross Society Scientific Meeting, Winnipeg, Manitoba* May 28-31, 1992.
89. **Poon, M-C.** DNA recombinant technology in future transfusion medicine. Canadian Society of Laboratory Technologist Congress Abstract, 1992
90. Sinclair, G.D. and **Poon, M-C.** Molecular diagnosis of coagulation disorders: theory and critical appraisal of current technology. Canadian Society of Laboratory Technologist Congress Abstract, 1992
91. **Poon, M-C.** and Sinclair, G.D. Molecular diagnosis of coagulation disorders: Calgary experience. Canadian Society of Laboratory Technologist Congress Abstract, 1992
92. **Poon, M-C.**, Akabutu, A., Anand, C., Card, R., Fonseca, K., Gill, J., Growe, G., Marion, S., Mathias, R. and Tsoukas, C. Sexual transmission of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in hemophilia: A Canadian Multicenter Study. *World Federation of Hemophilia Meeting Abstract*, 1992

93. **Poon, M-C.**, Aledort, L.M., Anderle, K., Kunschak, M., Morfini, M. and the International Investigator Group. Clinical study of recovery and half-life of factor IX concentrate (human) vapor heated, IMMUNO. *World Federation of Hemophilia Meeting Abstract*, 1992
94. Walker, I.R., and the Canadian Hemophilia Clinic Directors Group (including **Poon, M-C**). HIV in Canadians with hemophilia: prevalence, mortality and the impact of safer factor concentrates. *World Federation of Hemophilia Meeting Abstract*, 1992
95. Blanchette, V.S., Walker, I., Inwood, M., Adams, M., Gill, P., and the Canadian Hemophilia Centre Directors Group (including **Poon, M-C**). Prevalence of hepatitis C infection in individuals with hemophilia: results of a national study. *World Federation of Hemophilia Meeting Abstract*, 1992
96. Boiteau, P., Berthiaume, Y., Sinclair, G.D., Kloiber, R., Fong, C., Fick, G., Lafreniere, R., and **Poon, M-C**. von Willebrand factor antigen and interleukin-2 induced pulmonary edema. *Amer Rev Resp Dis* 145:A453, 1992
97. **Poon, M-C.**, Russell, J., Sinclair, G.D., Bowen, T. and the Canadian International Matched Unrelated Search and Transplant Investigators. Chimerism in bone marrow transplantation: a preliminary report. *Alberta Cancer Board Scientific Meeting Abstract*, 1992
98. Russell, J.A., Ruether, B.A., **Poon, M-C.**, Jones, A.R., Snodgrass, T., and Woodman, R.C. Failure of intravenous immunoglobulin to reduce early morbidity after allogeneic BMT. *18th Annual Meeting of the European Group for Bone Marrow Transplantation*. Stockholm, May 31-June 3, 1992
99. Russell, J.A., **Poon, M-C.**, Jones, A.R., Ruether, B.A., Gyonyor, E., Brown, C., and Woodman, R. Bone marrow transplantation - towards cost-effectiveness. *Alberta Cancer Board Scientific Meeting , Banff, Alberta*, Nov 20-22, 1992
100. Tsoukas, C.M., Ali, S.K., Card, R.T., Garvey, M.B., Growe, G.H., Kobrinski, N., **Poon, M-C**, Rivard, G., Ross, E., Rubin, S., Sampalis, J., and Strawczynski, H. Immune changes associated with HIV seroconversion among blood product recipients. *Third Annual Canadian Conference on HIV/AIDS Research, Montreal, Quebec*, May 13-15, 1993
101. Russell, J.A., Brown, C., Ruether, B.A., Woodman, R.C., Jones, A.R., and **Poon, M-C**. Low morbidity of allogeneic bone marrow transplantation (BMT) for adult acute myelogenous leukaemia (AML) in first complete remission (CR). *International Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem Cell Transplantation in Malignancies*, Lyon, France, June 4-6, 1993
102. Russell, J.A., Brown, C., Jones, A.R., Ruether, B.A., Woodman, R.C., and **Poon, M-C.**, Factors influencing graft failure after allogeneic BMT. *J Cell Biochem Suppl* 18B:71, 1994
103. Inwood, M.J., Clegg, E., Carter, S. and the Canadian Hemophilia Centre Directors and Nurse Coordinators Group (including **Poon, M-C**). A survey of central venous access devices (CVAD) in a Canadian hemophilia population. *XXI International Congress of the World Federation of Hemophilia*. Abstract 68, Mexico City, April 24-29, 1994
104. Walker, I. and the Canadian Hemophilia Clinic Directors Group (including **Poon, M-C**). Canadian hemophilia registry - update and assessment of completeness. *XXI International Congress of the World Federation of Hemophilia*. Abstract 165, Mexico City, April 24-29, 1994
105. Inwood, M.J., Clegg, E., Carter, S. and the Canadian Hemophilia Centre Directors and Nurse Coordinators Group (including **Poon, M-C**). A survey of pyoarthrosis in a Canadian hemophilia population. *XXI International Congress of the World Federation of Hemophilia*. Abstract 321, Mexico City, April 24-29, 1994

106. \*Tay-Uyboco, J., **Poon, M-C.**, and Hollenberg, M.D. Contractile actions of thrombin receptor-derived peptides in human umbilical and placental artery: evidence for receptor subtypes. *Clin. Res.* 42:334A, 1994.
107. Russell, J., Bowen, T., Ruether, B., Woodman, R. and **Poon, M-C.** Allogeneic transplants for high-risk acute leukaemia using blood instead of bone marrow as a source of haemopoietic cells. *Exp. Hematol.* 22:692, 1994.
108. Russell, J., Luider, J., Klassen, J., Bowen, T., Brown, C., Weaver, M., Karlsson, L., Railton, C., Neurath, D., Ching, E., Selinger, S. and **Poon, M-C.** Mobilization and collection of hemopoietic progenitor cells from donors for allogeneic transplants. *Exp. Hematol.* 22:696, 1994.
109. Russell, T., Bowen, T., Brown, C., Klassen, J., Luider, J., Weaver, M. and **Poon, M-C.** Allogeneic blood cell transplants for high-risk hematologic malignancy - a comparison of engraftment and acute GVHD with BMT. *Blood* 84 (suppl 1):337a, 1994.
110. \*Aslam, S., **Poon, M-C.**, Yee, V., Bowen, D. and Standen, G.R. Factor XIII<sup>A</sup><sub>Calgary</sub>: a candidate missense mutation (leu667pro) in the beta barrel 2 domain of the XIII<sup>A</sup> subunit. *Br. J. Haematol.* 89 (suppl 1):33, 1995.
111. **Poon, M-C.**, Fritsch, S., Kunschak, M., Morfini, M. and the Factor IX Study Group. Comparison of pharmacokinetics of factor IX concentrate and factor IX complex preparations. *Thromb.Haemost.* 73:1020, 1995.
112. **Poon, M-C.**, Teitel, J., Blanchette, V., Walker, I., Anand, C., Petric, M., Garvey, B., Pai, M., Wu, J. and the Association of Clinic Directors of Canada. Seroprevalence of anti-hepatitis A (HAV) IgG in Canadian patients with hemophilia. *Thromb.Haemost.* 73:1031, 1995.
113. **Poon, M-C.**, \*Kaur, J., Low, S., Morrison, J., Valentine, K. and Sinclair, G.D. Activated protein C (APC) resistance in patients with thrombosis: family studies. *Thromb.Haemost.* 73:1123, 1995.
114. Giles, A.R., Rivard, G.E., Teitel, J., Walker, I., Lillicrap, D., Dwyre, L. and the Association of Hemophilia Clinic Directors of Canada (including **Poon, M-C.**). The prevalence of factor VIII inhibitors detected in a national study to assess the effect of widespread introduction of high purity factor VIII for the treatment of hemophilia A. *Thromb.Haemost.* 73:1029, 1995.
115. \*Jain, B. and **Poon, M-C.** Antithrombin III (ATIII), protein C (PC) and protein S (PS) deficiency: a retrospective review of Foothills Hospital experience. *Clin.Invest.Med.* 18 (suppl):B65, 1995. (Abstract 444)
116. \*Gordon, J., Ferland, A. and **Poon, M-C.** Immune hemolysis - that wasn't. *Clin.Invest.Med.* 18 (suppl):B795, 1995. (Abstract 534)
117. **Poon, M-C.**, Williams, C.K.O. and Sinclair, G.D. Host origin of recurrent hepatocellular carcinoma in a transplanted liver: evidence for the role of circulating hepatocellular progenitor cells. *Alberta Cancer Board Annual Scientific Meeting*, Edmonton, Alberta Nov 2-4, 1995
118. Association of Hemophilia Clinic Directors of Canada (including **Poon, M-C.**) Causes of death in Canadians with hemophilia. *National Hemophilia Foundation Symposium on Liver Disease in Hemophilia.* Atlanta, GA, March 1995
119. Russell, J.A., Brown, C.B., Ruether, D., Bowen, T., Coppes, M., Jorgenson, K. and **Poon, M-C.** Second allogeneic transplants using blood instead of bone marrow. 1<sup>st</sup> International Symposium on Allogeneic BPPCT. Geneva, October 26-28, 1995



120. Russell, J.A., Ruether, D., Bowen, T., Brown, C.B., Coppes, M., Jorgenson, K. and **Poon, M-C.** Unmanipulated allogeneic blood cell transplants from mismatched related donors. 1<sup>st</sup> International Symposium on Allogeneic PBPCT. Geneva, October 26-28, 1995.
121. Russell, J.A., Bowen, T., Brown, C.B., Ruether, D., Coppes, M., Jorgenson, K. and **Poon, M-C.** Analysis of engraftment, acute and chronic GVHD in 32 recipients of blood cell transplants from family donors. 1<sup>st</sup> International Symposium on Allogeneic BPPCT. Geneva, October 26-28, 1995.
122. \*Lee, D.H., Walker, I.R., **Poon, M-C.**, Rivard, G., Teitel, J., Ritchie, B., Akabutu, J., Sinclair, G.D., Pai, M., Wu, J., Reddy, S., Crowther, M.A., Blajchman, M.A. Factor V Leiden is not protective in severe hemophilia. *Haemophilia 2* (suppl. 1): 47, 1996 (abstract 178), XXII International Congress of the World Federation of Hemophilia, Dublin, Ireland, June 23-27, 1996.
123. Teitel, J.M., Card, R., Strawczynski, H. and the Association of Hemophilia Clinic Directors of Canada (including **Poon, M-C.**). Immune function in Canadian HIV antibody positive hemophiliacs switched to high purity factor VIII concentrates. *Haemophilia 2* (suppl. 1): 54, 1996 (abstract 207), XXII International Congress of the World Federation of Hemophilia, Dublin, Ireland, June 23-27, 1996.
124. Walker, I. and Association of Hemophilia Clinic Directors of Canada (including **Poon, M-C.**). Causes of death in Canadians with hemophilia 1980-1995. *Haemophilia 2* (suppl. 1): 66, 1996 (abstract 253), XXII International Congress of the World Federation of Hemophilia, Dublin, Ireland, June 23-27, 1996.
125. Giles, A.R., Rivard, G.E., Teitel, J., Walker, I. and the Association of hemophilia Clinic Directors of Canada (including **Poon, M-C.**). The prevalence of factor VIII inhibitor development in the Canadian hemophili A population following the wide-scale introduction of high purity factor VIII replacement therapy. *Haemophilia 2* (suppl. 1): 89, 1996 (abstract 341), XXII International Congress of the World Federation of Hemophilia, Dublin, Ireland, June 23-27, 1996.
126. **Poon, M-C.**, \*Jain, B., Morrison, J. and Sinclair, G.D. Antithrombin III (ATIII), protein C (PC), protein S (PS) deficiency and activated protein C resistance (APCR): a retrospective review of experience in a Canadian tertiary care hospital. *International Journal of Hematology 64* (Suppl. 1) S52 (abstract 195), 1996 [26th Congress of the International Society of Haematology, Singapore, August 25-29, 1996]
127. **Poon, M-C.**, \*Yee, D., Low, S. and Sinclair, G.D. Coinheritance of type 1 and 2N von Willebrand disease (vWD). *International Journal of Hematology 64* (Suppl. 1) S104 (abstract 395), 1996 [26th Congress of the International Society of Haematology, Singapore, August 25-29, 1996]
128. Ching, E.P., Neurath, D., Neil, P.E., Ruether, B.A., Russell, J.A., and **Poon, M-C.** Absence of bag breakage in freezing and thawing bone marrow and peripheral stem cells. *Transfusion 36* (suppl):13S, 1996 (abstract S52).
129. Stewart, D.A., McLaughlin, J., Klassen, J., Luider, J.M., Blahey, W.B., Thael, J.F., Jones, A.R., Ruether, B.A., **Poon, M-C.**, Woodman, R.C., deMetz, C., Arthur, K., Railton, C., Brown, C.B. and Russell, J.A. Autologous blood stem cell mobilization and "in-vivo purging" with dose intensive cyclophosphamide, etoposide, and cisplatin prior to autologous blood stem cell transplantation. *5th International Meeting of the Canadian Bone Marrow Transplantation Group*, Calgary, Alberta, November 14-17, 1996.
130. Russell, J.A., Brown, C.B., Ruether, J.D., Stewart, D., Coppes, M.J., Jorgenson, K., Turner, A.R., Larratt, L., Desai, S., Klassen, J. and **Poon, M-C.** Allogeneic blood cell transplantation: the Alberta experience. *5th International Meeting of the Canadian Bone Marrow Transplantation Group*, Calgary, Alberta, November 14-17, 1996.
131. White, G., Lusher, J., Shapiro, A., Tubridy, K., Courter, S. and the Recombinant Factor IX Study Group (including **Poon, M-C.**). Recombinant factor IX in the treatment of previously-treated patients with hemophilia B. *Blood 88* (Suppl. 1): 327a (abstract 1296), 38th Annual Meeting of the American Society of Hematology, Orlando, Florida, December 6-10, 1996.

132. Gill, J.C., Leissing, C., Kasper, C., Sexauer, C., Inwood, M., Cohen, A. and Hemophilia Research Society Inhibitor Registry Investigators (including **Poon, M-C.**). Hemophilia inhibitors in the 80's and 90's: a first look at the Hemophilia Research Society (HRS) inhibitor registry. *Blood* 88 (Suppl. 1): 330a (abstract 1307), 38th Annual Meeting of the American Society of Hematology, Orlando, Florida, December 6-10, 1996.
133. Ching, E.P., Neurath, D., Neil, P.E., Ruether, B.A., Russell, J.A. and **Poon, M-C.** Absence of bag breakage in freezing and thawing bone marrow and peripheral stem cells. *Transfusion* 36 (suppl):13S, 1996 (abstract S52).
134. Russell, J.A., Brown, C.B., Ruether, J.D., Stewart, D., Coopes, M.J., Jorgenson, K., Klassen, J. and **Poon, M-C.** Evaluation of allogeneic blood cell transplants (BCT) in a single centre. *4th International Symposium on Recent Advances in Haematopoietic Stem Cell Transplantation - Clinical Progress, New Technology in Gene Therapy.* San Diego, April 11-13, 1996.
135. Russell, J.A., Bowen, T., Brown, C., Luider, J., Jorgenson K., Coopes, M.J., Turner, A.R., Larratt, L., Desai, S., **Poon, M-C.** and Klassen, J. Allogeneic blood cell transplants (BCT) for haematological malignancy: comparison of engraftment, GVHD and support with BMT. *Bone Marrow Transplant.* 17 (Suppl 1) S117, 1996 (abstract 511). 22nd Annual Meeting of the European Bone Marrow Transplant Group. Vienna, March 1996.
136. Russell, J.A., Bowen, T., Brown, C., Ruether, D., Coppes, M., Jorgenson, K. and **Poon, M-C.** Analysis of engraftment, acute and chronic GVHD in 32 recipients of blood cell transplants from family donors. *Bone Marrow Transplant.* 17 (Suppl 2):S69, 1996 (abstract 15).
137. Russell, J.A., Brown, C., Ruether, D., Bowen, T., Coppes, M., Jorgenson, K. and **Poon, M-C.** Second allogeneic transplant using blood instead of bone marrow. *Bone Marrow Transplant.* 17 (Suppl 2):S75, 1996 (abstract 37).
138. Russell, J.A., Brown, C., Ruether, J.D., Buether, B.A., Jones, A.R., Woodman, R.C. and **Poon, M-C.** Allogeneic bone marrow and blood cell transplantation for malignancy without protective isolation. *Bone Marrow Transplant.* 17 (Suppl 1) S43, 1996 (abstract 216).
139. Russell, J.A., Brown, C., Ruether, J.D., Buether, B.A., Jones, A.R., Woodman, R.C. and **Poon, M-C.** Bone marrow transplantation for "standard risk" leukaemia: different causes of failure for AML and CML. *Bone Marrow Transplant.* 17 (Suppl 1) S68, 1996 (abstract 318).
140. Russell, J.A., Ruether, D., Bowen, T., Brown, C., Coppes, M., Jorgenson, K. and **Poon, M-C.** Unmanipulated allogeneic blood cell transplants from mismatched related donors. *Bone Marrow Transplant* (in press)
141. **Poon, M-C.** and the Canadian Factor IX Study Group. Results from an international efficacy study of factor IX concentrate. IMMUNINE. *Thromb. Haemost.* Supplement: 54, 1997 (26th Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, June 6-12, 1997) (Abstract PS-219).
142. **Poon, M-C.** and the Canadian Factor IX Study Group. No inhibitors after administration of factor IX concentrate, IMMUNINE. *Thromb. Haemost.* Supplement: 54, 1997 (26th Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, June 6-12, 1997) (Abstract PS-220).
143. **Poon, M-C.**, Williams, Z. and Sinclair, G.D. Molecular analysis of factor IX (FIX) variants: association of hemophilia B phenotype with specific factor IX gene point mutations. *Thromb. Haemost.* Supplement: 231, 1997 (26th Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, June 6-12, 1997) (Abstract PS-941).
144. White, G., Pasi, K.J., Lusher, J., Brackmann, H.H., Magill, M., Courter, S. and the Recombinant Factor IX Study Group (including **Poon, M-C.**). Recombinant factor IX in the treatment of previously-treated

- patients with hemophilia B. *Thromb. Haemost.* Supplement: 52, 1997 (26th Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, June 6-12, 1997) (Abstract PS-211)
145. Stewart, D.A., Gui, D., Brown, C., **Poon, M-C.**, Ruether, B., Jones, A., Klassen, J., Luidier, J., Morris, D., Chaudhry, A. and Russell, J.A. Superior autologous blood stem cell mobilization with dose-intensive cyclophosphamide, etoposide, cisplatin, DICEP) + G-CSF than with less intensive chemotherapy +G-CSF. *Blood* 90 (suppl): 99a, 1997 (American Society of Hematology 39th Annual Meeting Dec 5-9, 1997) (Abstract 433)
  146. Shapiro, A., Pasi, K.J., Abshire, T., Kisker, C.T., Cohen, A., Goddard, J., Courter, S. and the Recombinant Factor IX Study Group (including **Poon, M-C.**). Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUPS) with severe or moderately severe hemophilia B. *Blood* 90 (suppl): 156a, 1997 (American Society of Hematology 39th Annual Meeting Dec 5-9, 1997) (Abstract 684)
  147. Kessler, C.M., Philipp, C., Thompson, A., Negrier, C., Keutzer T., Courter, S. and the Recombinant Factor IX Study Group (including **Poon, M-C.**). Recombinant factor IX is an effective and safe replacement therapy for previously treated patients with hemophilia B. *Blood* 90 (suppl): 157a, 1997 (American Society of Hematology 39th Annual Meeting Dec 5-9, 1997) (Abstract 688)
  148. Thompson A, Negrier C, Brackmann H, **Poon, M-C**, Gencarella N, and the Recombinant Factor IX Study Group. Recombinant factor IX is an effective and safe replacement therapy for previously treated patients with hemophilia B. *Hemophilia* 4:196, 1998 (World Federation of Hemophilia XXIIIth Congress May 17-21, 1998) (Abstract 164)
  149. Sandham, J.D., Abbott, K., Brant, R., **Poon, M-C**, Campbell, N., Todd, K. A prospective randomized trial of CBC utilization in a tertiary care teaching hospital. *Clin.Invest.Med.* 1998 (Suppl) S47 Royal College of Physicians and Surgeons of Canada Annual Meeting, Sept 24-27, 1998) (Abstract 196)
  150. **Poon, M-C.**, Williams, Z., Wong, K., Hollenberg, M. and Sinclair G.D. von Willebrand factor (vWF) release from endothelial cells mediated by protease activated receptor (PAR): evidence for crosstalk between Ca<sup>++</sup> and cAMP intracellular signaling pathways. *Blood* 92 (Suppl 1): 79B, 1998 (abstract 3321)
  151. Kessler, C., **Poon, M-C.**, Negrier, C., Fernands, A., Gencarella, N. and the Recombinant Factor IX Study Group. Recombinant factor IX is an effective and safe replacement therapy for previously treated patients with hemophilia B. *Thromb.Haemost* 82 (suppl): 331, 1999 (abstract 1046)
  152. Sinclair, G.D., Williams, Z. and **Poon, M-C**. Cholera toxin enhances PAR-1 peptide stimulation of acute von Willebrand factor release from cultured umbilical vein endothelial cells through a protein kinase A dependent pathway. *Thromb.Haemost.* 82 (suppl): 349, 1999 (abstract 1108)
  153. Israel, S.J., Drouin, J., **Poon, M-C.**, Akabutu, J.J., He, L., Blanchette, V.S. and Rand, M.L. Congenital platelet function disorders in Canada: analysis of the first year of a national registry. *Thromb.Haemost.* 82 (suppl): 616, 1999 (abstract 1939)
  154. **Poon, M-C.**, Demers, F., Jobin, F. and Wu, J.W.Y. Use of recombinant factor VIIa (rFVIIa) for bleeding and surgery in patients with Glanzmann thrombasthenia. *Thromb.Haemost.* 82 (suppl): 744, 1999 (abstract 2353).
  155. \*Shulman, L., Russell, J. and **Poon, M-C**. HLA antibody after bone marrow transplantation (BMT). *Clin.Invest.Med.* 22 (Suppl):S21, 1999 (Abstract 181)
  156. **Poon, M-C**, Demers, F., Jobin, F. and Wu, J.W.Y. Recombinant factor VIIa (rFVIIa) is an attractive alternative to platelet transfusions for Glanzmann thrombasthenia (GT) bleeding. *Clin.Invest.Med.* 22 (Suppl):S23, 1999 [Abstract 193]
  157. **Poon, M-C.**, Huth-Khuen, A., Karafoulido, A., Demers, C., Fressinaud, E., Hann, Y., Nohe, N., Negrier, C., Makris, P.E., Molho, P., Pautard, B., Berger, C., Wilde, J. and d'Oiron, R. New aspect in the

- treatment of platelet-related bleeding disorders. *Annals of Hematology* 79 (suppl 1):A15, 2000 (44<sup>th</sup> Annual Meeting of the German Society of Thrombosis and Hemostasis Research [GTH], Freiburg, Germany, Feb 16-19, 2000) [Abstract 108]
158. Lillicrap, D., **Poon, M-C.**, Walker, I., Xie, F., Schwartz, B.A., the Haemate-P® Canadian Study Investigators and the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of Haemate-P® in Canadian von Willebrand disease patients. *Hemophilia Nurses. Haemophilia* 6:227, 2000. 23<sup>rd</sup> World Federation of Hemophilia Congress, Montreal, July 16-21, 2000 (Abstract 34)
  159. Walker, I., \*Julian, J. and members of the Association of Hemophilia Clinic Directors of Canada and Canadian Association of Hemophilia Nurses (including **Poon, M-C.**). Canadian Hemophilia Registry: HIV, HCV and mortality. *Haemophilia* 6:341, 2000. 23<sup>rd</sup> World Federation of Hemophilia Congress, Montreal, July 16-21, 2000 (Abstract 22)
  160. **Poon, M-C.**, Lillicrap, D., Card, R., Scully, M.F., Blanchette, V., Bond, M., Davis, J., Delorme, M., Dolan, S., Garvey, B., Growe, G., Herst, J., Israels, S.J., Ledpine-Martin, J., McCusker, P.J., Pai, M., Rubinger, M., Silva, M., Stobart, K., Teitel, J., Vickars, L., Walker, I., Wu, J.K.M., Wu, J.W.Y. and members of the Association of Hemophilia Clinic Directors of Canada and Canadian Association of Hemophilia Nurses. Recovery of recombinant factor IX concentrate: A Canadian post-licensure surveillance study. *Haemophilia* 6:238, 2000. 23<sup>rd</sup> World Federation of Hemophilia Congress, Montreal, July 16-21, 2000 (Abstract 49)
  161. Lillicrap, D., the Association of Hemophilia Clinic Directors of Canada (AHCDC) and the Canadian Association of Nurses in Hemophilia Care (including **Poon, M-C.**). The Canadian Hemophilia Assesment and Resource Management Information System: CHARMS. *Hemophilia Nurses. Haemophilia* 6:435, 2000. 23<sup>rd</sup> World Federation of Hemophilia Congress, Montreal, July 16-21, 2000 (Abstract 12)
  162. \*Jarand, J.M. and **Poon, M-C.** Lupus-type inhibitor: relationship with clinical indications and aPTT. *International Journal of Hematology* 72 (Suppl 1):12-13, 2000. International Society of Hematology Congress, Toronto, August 26-30, 2000 (abstract 15987)
  163. **Poon, M-C.**, Katsarou, O., Huth-Kuehne, A., Petrini, P., Hann, I., Demers, C., Fressinaud, E., Tengborn, L., Thomas, A., Nohe, N., Strauss, G., Négrier, C., Makris, P.E., Molho, P., Pautard, B., Berger, C., Beurrier, P., Wild, J., Devecioglu, O., Peters, M., d'Oiron, R. and members of the International Registry on rFVIIa and Congenital Platelet Disorders. Recombinant factor VIIa in congenital platelet bleeding disorders. *Blood* 96 (Suppl 1):256a, 2000. American Society of Hematology 42<sup>nd</sup> Annual Meeting, San Francisco, Dec 1-5, 2000 (abstract 1102)
  164. Feldman, B.M., Rivard, G., Israels, S., Robinson, S., Hedden, D., Babyn, P., Oh, P., Einerson, T., McLimont, M., Stain, A., Hilliard, P., Blanchette, V. and the Association of Hemophilia Clinic Directors of Canada, (including: **Poon, M-C.**) Preliminary results from the Canadian hemophilia prophylaxis trial [abstract P1830]. *Thromb Haemost* 2001; (Suppl).
  165. Luke, K.H., Sun, J., Yang, R. and **Poon, M-C.** Haemophilia twinning centers China: 4-year progress, new opportunities and strategies. *Haemophilia* 8:518, 2002. XXV International Congress of the World Federation of Hemophilia, Seville, Spain, May 19-24, 2002 [Abstract 08 PO 26]
  166. Yang, R., **Poon, M-C.**, Ji, L. and Han, Z.C. Haemophilia twinning centers: Tianjin, China and Calgary, Canada. Four years experience. *Haemophilia* 8:521, 2002. XXV International Congress of the World Federation of Hemophilia, Seville, Spain, May 19-24, 2002 [Abstract 08 PO 43]
  167. Yang, R. and **Poon, M-C.** Haemophilia care in China: current status and challenges. *Haemophilia* 8:521, 2002. XXV International Congress of the World Federation of Hemophilia, Seville, Spain, May 19-24, 2002 [Abstract 08 PO 44]
  168. Courmoyer, D., Toffelmire, E., Barber, D., Barrett, B., Delage, R., Forrest D., Gagnon, R., Harvey, E., Laneville, P., Patterson, B., **Poon, M-C.**, Posen, G., Wells, G. and Messner, H. Anti-EPO mediated pure

- red cell aplasia related to erythropoietin products: Guidelines from the PRCA Focus Group. Canadian Society of Nephrology Meeting, St. John's, Newfoundland, May 22-26, 2003.
169. Toffelmire, E., Cournoyer, D., Wells, G., Barber, D., Barrett, B., Delage, R., Forrest D., Gagnon, R., Harvey, E., Laneville, P., Patterson, B., **Poon, M-C.**, Posen, G. and Messner, H. Anti-EPO mediated pure red cell aplasia related to erythropoietin products: Guidelines from the Canadian PRCA Focus Group. American Society of Nephrology Meeting, 2003
  170. James, P.D., Rivard. G., **Poon M-C.**, Warner, M., Raut, S., McKenna, S., Leggo, J. and Lillicrap, D. Aminoglycoside suppression of nonsense mutations in severe hemophilia. American Society of Hematology 45<sup>th</sup> Annual Meeting, San Diego, December 5-9, 2003 [Abstract 176]
  171. O'Brien L, James PD, Notley CRP, Hegadorn CA, Sinclair G, **Poon M-C**, Hough C, Lillicrap DP. A novel splice site mutation (IVS26+2g>a) resulting in exon skipping of two non-adjacent exons in Type 2A von Willebrand disease. American Society of Hematology 45<sup>th</sup> Annual Meeting, San Diego, December 5-9, 2003 [Abstract 1115]
  172. James, P.D., Notley, C.R.P., Cameron, C., O'Brien, L.A., Hegadorn, C.A., Berber, E., Hough, C., Rivard, G.E., AHDCDC, Lillicrap, D.P. (including **Poon M-C**) The Spectrum of Phenotype/Genotype Associations in Type 1 von Willebrand Disease: Results from the Canadian Type 1 VWD Study. American Society of Hematology 45<sup>th</sup> Annual Meeting, San Diego, December 5-9, 2003 [Abstract 303]
  173. \*McArthur, H., \*Chou, S., **Poon, M-C.**, Southern, D., Mackay, E. Assessment of indications cited for thrombophilia screening in an urban Health Region. American Society of Hematology 45<sup>th</sup> Annual Meeting, San Diego, December 5-9, 2003 [Abstract 4137]
  174. Russell, J.A. **Poon, M-C**, Turner, A.R., Chaudhry, A.M. Parameswaran, R., Quinlan, D., Jeje, O., Brown, C.B., Glück, S., Morris, D., Stewart, D. and Larratt, L.M. GVHD, Mortality and Control of Leukemia in Adult Allogeneic BMT Recipients with CML in CP1 Given Daily IV Busulfan, Fludarabine, and Low-Dose Antithymocyte Globulin (ATG): Comparison with Historical Experience Using BuCy2 without ATG. American Society of Hematology 45<sup>th</sup> Annual Meeting, San Diego, December 5-9, 2003 [Abstract 5583]
  175. \*McArthur, H., \*Chou, S., **Poon, M-C.**, Southern, D., Mackay, E. Assessment of indications cited for thrombophilia screening in an urban Health Region. Canadian Society of Internal Medicine 27th Annual Meeting, Quebec City, PQ, June 2-6, 2004.
  176. Fitzsimons A, Geddes M, **Poon M-C**. Traumatic and surgical bleeds: non-protocol use of recombinant factor VIIa (rFVIIa). Joint Canadian Society of Transfusion Medicine Scientific Conference 2004.
  177. Klein, P., Wu, J.W.Y., Brown, M., Pritchard, A., **Poon, M-C**. Combined type 1 von Willebrand disease (vWD) and severe hemophilia B: nine years experience with one case. *Haemophilia* 10 (suppl 3):129, 2004. XXVI International Congress of the World Federation of Hemophilia, Bangkok, Thailand, October 17-22, 2004 [Abstract 24 PO 11]
  178. Yang, R., **Poon M-C.**, Luke, K-H., and Chinese Hemophilia Centers Collaborative Network. Progress in national hemophilia registry in China. *Haemophilia* 10 (suppl 3):25, 2004. XXVI International Congress of the World Federation of Hemophilia, Bangkok, Thailand, October 17-22, 2004 [Abstract 04 PO 27]
  179. Luke, K-H. and **Poon, M-C**. Hemophilia care in China: a decade of achievements under WFH. *Haemophilia* 10 (suppl 3):41, 2004. XXVI International Congress of the World Federation of Hemophilia, Bangkok, Thailand, October 17-22, 2004 [Abstract 09 OC 24]
  180. Sun, J., Luke, K-H., and **Poon, M-C**. Hemophilia nursing: a priority project for developing hemophilia care in China. *Haemophilia* 10 (suppl 3):91, 2004. XXVI International Congress of the World Federation of Hemophilia, Bangkok, Thailand, October 17-22, 2004 [Abstract 17 PO 21]

181. \*Barnes, C., Rivard, G., **Poon, M-C.**, Teitel, J., Pai, M., Kern, M., Blanchette, V. and Carcao, M. on behalf of the Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada. Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT. *Haemophilia* 10 (suppl 3):55, 2004. XXVI International Congress of the World Federation of Hemophilia, Bangkok, Thailand, October 17-22, 2004 [Abstract 12 PO 19]
182. Rivard, G.E., Demers, C., **Poon, M-C.**, Warner, M., Lillicrap, D., Lepine, M., Amesse, C. and St-Louis, J. Can rFVIIa be used to postpone the use of FVIII in hemophiliac infants? *Haemophilia* 10 (suppl 3):5, 2004. XXVI International Congress of the World Federation of Hemophilia, Bangkok, Thailand, October 17-22, 2004 [Abstract 02 OC 06]
183. Fitzsimons, A., Geddes, M. and **Poon, M-C.** Traumatic and surgical bleeds: non-protocol use of recombinant factor VIIa (rFVIIa). Joint Conference of the Canadian Society of Transfusion Medicine (CSTM), Canadian Blood Services (CBS), and Héma-Québec, Banff, AB, Canada, April 21-24, 2005 [Abstract O16]
184. **Poon M-C**, Zotz R, Di Minno G, Abrams Z, Knudsen JB, Laurian Y. Treatment of Glanzmann's Thrombasthenia: A prospective observational registry on the use of recombinant human activated factor VII (rFVIIa) and other hemostatic agents. XXth Congress of the International Society on Thrombosis and Haemostasis. Sydney, Australia, August 6-12, 2005
185. Fitzsimons, A., Geddes, M. and **Poon, M-C.** Traumatic and surgical bleeds: non-protocol use of recombinant factor VIIa (rFVIIa). *Transfusion* 45 (Supplement 3):139A, 2005. American Association of Blood Banks Annual meeting, Seattle, WA, October 15-18, 2005, Abstract SP384
186. Sun, J., Zhao, J., Lin J., Luke, K., and **Poon, M-C.** Hemophilia nursing manual development in China – planning and process. *Haemophilia* 12 (Supplement 2):92, 2006. International Congress of the World Federation of Hemophilia. Vancouver, Canada, May 21-25, Abstract 19 FP 613
187. Chen, L., Luke, K., and **Poon, M-C.** Promotion for physiotherapy care in China. *Haemophilia* 12 (Supplement 2):105, 2006. International Congress of the World Federation of Hemophilia. Vancouver, Canada, May 21-25, Abstract 22 PO 693.
188. Notley, C., Walker, I., **Poon, M.**, Rapson, D., Lillicrap, D. and James, P.D. Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study. XXIst Congress of the International Society on Thrombosis and Haemostasis. Geneva, Switzerland, July 6-12, 2007 [Abstract O-T-064]
189. Wells, P.S., Brown, A., Jaffey, J. and **Poon, M.** Do point of care devices improve outcomes in patients on oral anticoagulant therapy. XXIst Congress of the International Society on Thrombosis and Haemostasis. Geneva, Switzerland, July 6-12, 2007 [Abstract P-T-697]
190. Wells, P.S., McGahan, L., Cimon, K., Faffey, J., **Poon, M.** and Brown, A. Economic evaluation of point-of-care monitoring devices for long-term oral anticoagulation therapy. XXIst Congress of the International Society on Thrombosis and Haemostasis. Geneva, Switzerland, July 6-12, 2007 [Abstract P-W-498]
191. Kraft, J., Feldman, B., Pai, M., Ricard, G., Nicholson, A., Babyn, P., Israels, S., **Poon, M-C.**, Price, V., Klaassen R., Demers, C., Gomer, S., McLimont, M. MRI Results from the Canadian Hemophilia Dose-Escalation Prophylaxis Trial. Radiological Society of North American Annual Meeting, 2007 (November 25-30, 2007, Chicago, Illinois, USA)
192. Brown, A.G., Wells, P., Jaffey, ., McGahan, ., **Poon, M-C.**, Cimon, K. and Campbell, K. Economic Evaluation of Point-of-Care Monitoring Devices for Long-Term Oral Anticoagulation Therapy (February 2007). iHEA 2007 6th World Congress: Explorations in Health Economics Paper
193. \*Jackson, S., Cloutier, S, Rand, M. and **Poon, M.-C.**, Montreal Platelet Syndrome: Revisited. Association of Hemophilia Clinic Directors of Canada Annual Meeting, Saskatoon, SK, Canada, May 03-04. 2008

194. **Poon, M-C.**, Luke, K-H. Hemophilia Care in China: A decade of World Federation of Hemophilia (WFH) Treatment center Twinning Activities. *Haemophilia* 14 (Supplement 2):136  
XXVIII International Congress of the World Federation of Hemophilia, Istanbul, Turkey, June 1-5, 2008  
[Abstract 25 FP 01]
195. Luke, K.-H., **Poon, M-C.**, Sun, J., Chen, L.X., Wu, R.H., Yang, R.C. and the Prophylaxis Working Group of the Hemophilia Treatment Center Collaborative Network of China (HTCCNC). Prophylaxis in China: An Urgent Crisis and Challenge. *Haemophilia* 14 (Supplement 2):100  
XXVIII International Congress of the World Federation of Hemophilia, Istanbul, Turkey, June 1-5, 2008  
[Abstract 16 PO 09]
196. Sun, J., Zhong, X.-H., Luke, K.-H., **Poon, M-C.** and the Prophylaxis Working Group, HTCCN, China. A survey on the Current Health and Care Status of Hemophilia Children In China: A Retrospective Survey on 215 Hemophilia Children of the Hemophilia Treatment Centre Collaborative Network, China (HTCCNC). *Haemophilia* 14 (Supplement 2):123  
XXVIII International Congress of the World Federation of Hemophilia, Istanbul, Turkey, June 1-5, 2008  
[Abstract 20 PO 09]
197. \*Jackson, S., Sinclair, G., Duan, Z.-X., Cloutier, S. and **Poon, M.-C.**, Montreal Platelet Syndrome: Revisited. *Haemophilia* 14 (Supplement 2):112  
XXVIII International Congress of the World Federation of Hemophilia, Istanbul, Turkey, June 1-5, 2008  
[Abstract 18 PO 12]
198. \*Hang, M., Hilliard, P., Chen, L., Sun, J., Wakefield, C.D., Abad, A., Young, N.L., Feldman, B.M., Blanchette, V.S., Luke, K.-H., and **Poon, M.-C.** Development of the Chinese translated version of the Hemophilia Joint Health Score (HJHS) and the Canadian Hemophilia Outcome - Kids' Life Assessment Tool (CHO-KLAT). *Haemophilia* 14 (Supplement 2):87  
XXVIII International Congress of the World Federation of Hemophilia, Istanbul, Turkey, June 1-5, 2008  
[Abstract 13 PO 13]
199. Chen, L., Luke, K.-H., **Poon, M-C.**, for Hemophilia Treatment Center Collaborative Network, China (HTCCNC). Physiotherapy Promotion in China: Development of Home Care Hemophilia Physiotherapy and Exercise Education Materials. *Haemophilia* 14 (Supplement 2):75  
XXVIII International Congress of the World Federation of Hemophilia, Istanbul, Turkey, June 1-5, 2008  
[Abstract 12 FP 29]
200. Chen, L., Sun, J., Wu, R.H., Luke, K.H., **Poon, M.-C.**, Hang, M., Hillard, .P, Feldman, B., and Blanchette, V. Joint Health Status of Chinese Hemophilia Children: A pilot study using the Hemophilia Joint Health Assessment Scale (HJHS). *Haemophilia* 14 (Supplement 2):79  
XXVIII International Congress of the World Federation of Hemophilia, Istanbul, Turkey, June 1-5, 2008  
[Abstract 12 PO 51]
201. Vincent, A-M., Chan, A., Israels, S.J., **Poon, M-C.**, Wu, J.K. and Rivard, G.E. Use of factor VIII/von Willebrand factor complex for inducing immune tolerance in hemophiia A patients who have failed with recombinant FVIII: recent Canadian experience. *Blood (American Society of Hematology Annual Meeting Abstracts)* 112:4520, 2008
202. Owen, C.J., Toze, C.L., Koochin, A., Forrext, D.L., Smith, C.A., \*Jackson, S., **Poon, M-C.**, Sinclair, G.D., Leber, B., Johson, P., Macheta, A., Yin, J.A.L., Barnett, M.J., Lister, T.A. and Fitzgibbon, J. Five new pedigrees with inherited *RUNXI* mutations causing familial platelet disorders with propensity to myeloid malignancy (FPD/AML). *Blood (American Society of Hematology Annual Meeting Abstracts)* 112:5067, 2008
203. \*Jackson, S.C., Card, R.T., Brown, M., Spitzer, C., **Poon, M-C.** Prevalence of suspected collagen disorders in the adult bleeding disorder clinic. Association of Hemophilia Clinic Directors of Canada Annual Meeting, Ottawa, ON, May 9, 2009

204. **Poon, M-C.**, Blanchette, V., Card, R.T., Chan, A.K.C., Israels, S., Lillicrap, D., Rivard, G., Robinson, S., Vickars, L., Williams, Z., Wu, J.K.M. and Sinclair, G.D. Does heterogeneity in measured calibrated thrombin generation assay or FVIII activity (<1%) explain clinical heterogeneity in severe hemophilia A? Association of Hemophilia Clinic Directors of Canada Annual Meeting, Ottawa, ON, May 9, 2009
205. \*Jackson, S.C., Card, R.T., Brown, M., Spitzer, C., **Poon, M-C.** Prevalence of suspected collagen disorders in the adult bleeding disorder clinic. XXIIInd Congress of the International Society on Thrombosis and Haemostasis. Boston, USA, July 11-16, 2009. [Abstract PP-WE-695]
206. \*Skeith, L.A., Jackson, S.C., Brooks, J. and **Poon, M.-C.** Hypermobility and arthropathy in hemophilia: a retrospective evaluation of joint hypermobility as a risk factor for arthropathy in severe and moderate hemophilia. XXIIInd Congress of the International Society on Thrombosis and Haemostasis. Boston, USA, July 11-16, 2009. [Abstract PP-WE-549]
207. Sinclair, G.D., Blanchette, V., Card, R.T., Chan, A.K.C., Israels, S., Lillicrap, D., Rivard, G., Robinson, S., Vickars, L., Williams, Z., Wu, J.K.M. and **Poon, M-C.** Does heterogeneity in measured calibrated thrombin generation assay or FVIII activity (<1%) explain clinical heterogeneity in severe hemophilia A? XXIIInd Congress of the International Society on Thrombosis and Haemostasis. Boston, USA, July 11-16, 2009. (oral presentation) [Abstract OC-TU-068]
208. Blanchette, V.S., Babyn, P., Card, R., Chan, A., Demers, C., Gill, K., Israels, S., Klaassen, R., Laferriere, N., Lillicrap, D., Luke, K.H., McLimont, M., Pai, M., **Poon, M.-C.**, Price, V., Rivard, G.E., Robinson, S., Steele, M., Wu, J.K.M. and Feldman, B.M. Long term (10 year) results from the Canadian Hemophilia Primary Prophylaxis Study. XXIIInd Congress of the International Society on Thrombosis and Haemostasis. Boston, USA, July 11-16, 2009.(Abstract Symposium) Abstract: [AS-WE-003]
209. \*Hang, M.X., Blanchette, V.S., Pullenayegum, E., Babyn, P., Card, R., Chan, A., Demers, C., Gill, K., Israels, S., Klaassen, R., Laferriere, N., Lillicrap, D., Luke, K.H., McLimont, M., Pai, M., **Poon, M.-C.**, Price, V., Rivard, G.E., Robinson, S., Steele, M., Wu, J.K.M. and Feldman, B.M. Risk factors of bleeding severity in young boys with severe hemophilia A on tailored prophylaxis: long-term (10-year) results from the Canadian Hemophilia Primary Prophylaxis Study. XXIIInd Congress of the International Society on Thrombosis and Haemostasis. Boston, USA, July 11-16, 2009 [Abstract: PP-WE-553]
210. **Poon, M-C.**, diMinno, G., d'Oiron, R., Zotz, R. Therapeutic tools for the clinical management of Glanzmann's Thrombasthenia. *Haemophilia* 2010; 16: 398  
European Association for Haemophilia and Allied Disorders 3<sup>rd</sup> Annual Congress, Edinburgh, Scotland, UK, February 3-5, 2010. [Abstract 13]
211. **Poon, M-C**, d'Oiron R, Zotz R, di Minno G. Glanzmann's thrombasthenia Registry (GTR): a tool for the development of consensus guidelines for the management of Glanzmann's thrombasthenia (GT). *Haemophilia* 2010;16 (Suppl. 4): 123 [Abstract 28P07]
212. Wu R, Young NL, Zhang J, Luke KH, Hang M, Blanchette V, Sun J, Li X, **Poon M-C.** Content validity of the paediatric Haemophilia Quality of Life assessment tool in China. *Haemophilia* 2010;16 (Suppl. 4): 139  
World Federation of Hemophilia Congress, Buenos Aires, Argentina, July 10-14, 2010. [Abstract 31P29]
213. Sun J, Hilliard P, Zourikian N, Chen L, Luke K-H, Feldman BM, Blanchette V. **Poon M-C.** Hemophilia joint health score (HJHS) reliability study in China. *Haemophilia* 2010;16 (Suppl. 4): 99  
World Federation of Hemophilia Congress, Buenos Aires, Argentina, July 10-14, 2010. [Abstract 22FP15]
214. Wu R, Sun J, Zhang X, Feng X, Zhang X, Zhao L, Zhang N, Zhang J, Luke K-H, **Poon M-C.** Low dose secondary prophylaxis reduces joint and severe bleeding in severe and moderate hemophilia children: a multicenter pilot study in China. *Haemophilia* 2010;16 (Suppl. 4): 115-116  
World Federation of Hemophilia Congress, Buenos Aires, Argentina, July 10-14, 2010. [Abstract 26P16]



215. Chen L, Sun J, Hilliard P, Zourikian N, Hang M, Blanchette V, **Poon M-C**, Luke K-H. "Train the Trainer": the key to successfully accelerating training and improving physiotherapy services for persons with hemophilia in China. *Haemophilia* 2010;16 (Suppl. 4): 117  
World Federation of Hemophilia Congress, Buenos Aires, Argentina, July 10-14, 2010. [Abstract 27S01]
216. DiMichele DM, Goldberg I, Foulkes M, Hay CRM on behalf of the International Immune Tolerance Study Group. (including **Poon M-C**). International prospective randomized immune tolerance (ITI) study: preliminary results of therapeutic efficacy and safety. *Haemophilia* 2010; 16 (Suppl 4): 29  
World Federation of Hemophilia Congress, Buenos Aires, Argentina, July 10-14, 2010. [Abstract 07S03]
217. De Asis K, Vickars L, Sinclair G, Williams Z, **Poon M-C**, Jackson S. Thrombin activatable fibrinolysis inhibitor in adult hemophilia. Earl Davies Symposium, Vancouver, BC, Nov 4, 2010
218. \*Jackson SC, Odiaman L, Brown M, Spitzer C, Card RT, **Poon M-C**. Prevalence of suspected collagen disorders in the adult bleeding disorder clinic. 52nd American Society of Hematology Annual Meeting, Orlando, FL, USA (December 4-7, 2010). Abstract 1399
219. \*Jackson SC, Brown M, Spitzer C, Odiaman L, Fung M, Anderson TJ, **Poon M-C**. Impaired microvascular endothelial function in adult males with hemophilia. Association of Hemophilia Clinic Directors of Canada Annual Scientific Meeting, Calgary, AB, May 28, 2011
220. \*Lee A, Sinclair GD, Valentine K, **Poon M-C**. A rare case of acquired von Willebrand syndrome in the setting of new diagnosis polymyositis. Association of Hemophilia Clinic Directors of Canada Annual Scientific Meeting, Calgary, AB, May 28, 2011
221. \*Jackson SC, Brown M, Spitzer C, Odiaman L, Anderson TJ, **Poon M-C**. Impaired microvascular endothelial function in adult males with hemophilia. *J Thromb Haemost* 2011;9 (Suppl 2):463  
[ XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23-29, 2011 Abstr P-TU-495]
222. Jackson S, **Poon M-C**, Grabell J, Lillicrap D, James P. Diagnostic Utility of the Condensed MCMDM-1 VWD Bleeding Questionnaire in Hematology Clinics. *J Thromb Haemost* 2011;9 (Suppl 2):452  
[ XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23-29, 2011 Abstr P-TU-459]
223. \*Goodyear MD, Wu JK, **Poon M-C**. Long-term intermittent use of Rituximab to control inhibitors in congenital severe Hemophilia A. *J Thromb Haemost* 2011;9 (Suppl 2):563  
[ XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23-29, 2011 Abstr P-WE-137]
224. \*Lee A, Sinclair GD, Valentine K, **Poon M-C**. A rare case of acquired von Willebrand syndrome in the setting of new diagnosis polymyositis. *J Thromb Haemost* 2011;9 (Suppl 2):205  
[ XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23-29, 2011 Abstr P-MO-470]
225. **Poon M-C** C, di Minno G, Zotz R, d'Oiron R. rFVIIa is as effective as platelets in Glanzmann thrombasthenia (GT) with or without platelet antibodies and/or refractoriness (PA/PR): Data from GT Registry (GTR). *J Thromb Haemost* 2011;9 (Suppl 2):89-90  
[ XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23-29, 2011 Abstr P-MO-100]
226. Nahirniak S, **Poon M-C**, Whitman L, Doncaster C, Lin Y, Callum J. Multi-institutional audit of octaplex® & comparison with national recommendations. 2011 AABB Annual Meeting, San Diego, CA, USA, October 22-25, 2011 (Abstract SP381). *Transfusion* 2011; 51:186A

- 227 \*Lee LJ, Wu JK, **Poon M-C**, Jackson S. An increase in factor VIII levels with increasing age in a subgroup of individuals with mild hemophilia A. American Society of Hematology Annual Meeting, Dec 2011. *Blood* 2011; 118:2278.
- 228 \*Goodyear MD, Wu J, Webert K, Chan A, **Poon M-C**. Canadian Experience: Severe factor V deficiency. Association of Hemophilia Clinic Directors of Canada Scientific Meeting. May 26, 2012
- 229 \*Lee A, Boyd S, Kline G, Card R, **Poon M-C**. In vivo assessment of bone microarchitecture using high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemophilia patients: Insight into etiology of decreased BMD in this patient population. Association of Hemophilia Clinic Directors of Canada Scientific Meeting. May 26, 2012
- 230 Wu RH, Zhang JS, Luke KH, Wu XY, Burke T, Tang L, **Poon M-C**, Li XJ, Zhou M, Sun J, Blanchette V, Young NL. Cross-cultural adaptation of the Canadian Haemophilia outcomes-Kids Life Assessment Tool (CHO-KLAT35) for use in boys with haemophilia in China. World Federation of Hemophilia (WFH) 2012 World Congress, Paris, France. July 8-12, 2012
- 231 Wu RH, Wu XY, Zhang NN, Zhao L, Zhang JS, Luke KH, **Poon M-C**. Long-term low-dose secondary prophylaxis for severe and moderate hemophilia children with arthropathy: a single-center prospective study in China. World Federation of Hemophilia (WFH) 2012 World Congress, Paris, France. July 8-12, 2012 (Abstract PO-TU-201)
- 232 Wu R, Wu X, Zhang NN, Zhao L, Zhang J, Luke KH, **Poon M-C**. Modified long-term low-dose secondary prophylaxis for severe and moderate hemophilia A children with arthropathy: A single-center prospective study in China. The XXX International Congress of the World Federation of Hemophilia (July 2012 – Paris, France)
- 233 Au WY, Kho B, Lee V, Lam H, **Poon M-C**. Disarray to distinction: fast track restructuring of hemophilia care in Hong Kong. World Federation of Hemophilia (WFH) 2012 World Congress, Paris, France. July 8-12, 2012 (Abstract PO-MO-059)
- 234 Jackson SC, Yang M, Bucevska M, Brose K, Webert K, Minuk L, Card R, **Poon M-C**. What are the predictors for use of prophylaxis in older adults with severe hemophilia?: a multicentre Canadian study. World Federation of Hemophilia (WFH) 2012 World Congress, Paris, France. July 8-12, 2012
- 235 \*Goodyear MD, Wu JKM, Webert K, Chan A, **Poon M-C**. The Canadian experience: severe Factor V deficiency. World Federation of Hemophilia (WFH) 2012 World Congress, Paris, France. July 8-12, 2012 (Abstract PO-TU-250)
- 236 \*Goodyear MD, Lauf AM, Jenkins D, McDonald J, **Poon M-C**. Caring for mild hemophilia: a challenge to comprehensive hemophilia treatment centers. World Federation of Hemophilia (WFH) 2012 World Congress, Paris, France. July 8-12, 2012 (Abstract PO-TU-120)
- 237 Lane S, Walker I, Chan A, Heddle N, Arnold E, **Poon M-C**, Minuk L, Jardine L, Chin-Yee I, Webert K. Understanding health and treatment decision making among youth with hemophilia: a qualitative approach. World Federation of Hemophilia (WFH) 2012 World Congress, Paris, France. July 8-12, 2012 (Abstract PO-WE-274)
- 238 Arnold E, Walker I, Chan A, Webert K, Lane S, **Poon M-C**, Rubin S, Heddle N. What do Canadian men living with Hemophilia need to know to facilitate optimal disease management? A mixed methods approach. World Federation of Hemophilia (WFH) 2012 World Congress, Paris, France. July 8-12, 2012 (Abstract PO-TU-206)
- 239 Rand M, Jackson S, Sinclair GD, Cloutier S, **Poon M-C**. Evaluation of the Defect in Platelet Calpain in Montreal Platelet Syndrome Patients with Type 2B von Willebrand Disease. World Federation of Hemophilia (WFH) 2012 World Congress, Paris, France. July 8-12, 2012 (Abstract PO-WE-259)

- 240 d'Oiron R, **Poon M-C**, Zotz R, di Minno G. The international prospective Glanzmann's Thrombasthenia Registry (GTR). Special Issues in Women. American Society of Hematology Annual Meeting, Atlanta USA, Dec 2012 (Abstract 3341)
- 241 Zotz R, di Minno G, d'Oiron R, **Poon M-C**. The international prospective Glanzmann's Thrombasthenia Registry (GTR). Special Issues in Children. American Society of Hematology Annual Meeting, Atlanta USA, Dec 2012 (Abstract 2202)
- 242 \*Lee A, Goodyear D, Valentine K, **Poon M-C**. Challenging management of a hemophilia patient with inhibitor undergoing bilateral laser lithotripsy and ureteric stenting, Association of Hemophilia Clinic Directors Annual Scientific Meeting, Winnipeg, Canada, May 25, 2013
- 243 Goodyear MD, **Poon M-C**. Atorvastatin ameliorates angiodysplasia-associated bleeding in von Willebrand Disease. [ XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, June 29-Jul 04, 2013] (Abstract PB4.43-3)
- 244 Hawke LG, **Poon M-C**, Scully M-F, James PD. Alterations in aberrant and alternative endothelial splicing of von Willebrand factor under high laminar shear stress . [ XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, June 29-Jul 04, 2013] (*Abstract PBI.44-1*)
- 245 \*Suryanarayan D, Goodyear MD, **Poon M-C**. DDAVP use and cardiovascular outcomes in patients with bleeding disorders undergoing invasive procedures [ XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, June 29-Jul 04, 2013] (*Abstract PB4.44-6*)
- 246 \*Lee A, Boyd S, Kline G, **Poon M-C**. High-resolution peripheral quantitative computed tomography (HR-pQCT): a novel imaging technology detects microarchitectural skeletal pathology in hemophilia patients [ XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, June 29-Jul 04, 2013] (*Abstract PA2.06-4*)
- 247 **Poon M-C**, d'Oiron R, Zotz R, Di Minno G for the Glanzman's Thromasthenia Registry investigators. Treatment modalities and outcomes in 204 surgical procedures in 96 Glanzmann thrombasthenia (GT) patients: The International Prospective Glanzmann's Thrombasthenia Registry. [ XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, June 29-Jul 04, 2013] (*Abstract OC34.4*)
- 248 Di Minno, d'Oiron R, Zotz R, **Poon M-C** for the Glanzman's Thromasthenia Registry investigators. Treatment modalities and outcomes in 870 non-surgical bleedings in 184 Glanzmann thrombasthenia (GT) patients. The International Prospective Glanzmann's Thrombasthenia Registry (GTR). [XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, June 29-Jul 04, 2013] (*Abstract PO 498*)
- 249 Wu RH, Wu XY, Li G, Zhen YZ, Zhang NN, Wang Y, He WW, Luke K-H, **Poon M-C**, The efficacy and safety of BeneFIX in severe and moderate haemophilia children in China: A single centre observation study. [XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, June 29-Jul 04, 2013] (*Abstract PO 182*)
- 250 Minuk L, Irum R, Dilworth E, Jackson S, Iorio A, **Poon M-C**, Card R, Louzada M Cardiac Risk Factors in Older Patients with Hemophilia. Report of the Age Related Cardiovascular Disease in Hemophilia Epidemiologic Research (ARCHER) Study. World Federation of Hemophilia (WFH) 2012 World Congress, Melbourne Australia, May 11-15 Haemophilia 2014; 20 (Suppl. 3): 5
- 251 Xu WQ, Yang JY, Tang YM, Luke K-H, Young NL, **Poon M-C**, Wu RH. A survey on treatment and quality of life (QoL) of hemophilia A (HA) and hemophilia B (HB) children in Zhejiang Province in Southern China. World Federation of Hemophilia (WFH) 2014 World Congress, Melbourne Australia, May 11-15. *Haemophilia* 2014; 20 (Suppl. 3): 11

- 252 Jackson SC, Yang M, Minuk L, St-Louis J, Sholzberg M, Card R, Iorio A, **Poon M-C**. Is chronic hemophilic arthropathy of the ankles in young adults with severe hemophilia continue to be a problem? World Federation of Hemophilia (WFH) 2014 World Congress, Melbourne Australia, May 11-15 *Haemophilia* 2014; 20 (Suppl. 3): 73
- 253 Jackson S, **Poon M-C**, Yang M, Kalmar L, Currie L, Oliffe J. Changing views on the use of prophylaxis in men with severe hemophilia across the age spectrum. World Federation of Hemophilia (WFH) 2014 World Congress, Melbourne Australia, May 11-15. *Haemophilia* 2014; 20 (Suppl. 3): 97
- 254 Wu RH, Sun J, Xiao J, Liu Y, Xue F, Wang HF, Tang L, Zhao YQ, Li KX, Yang RC, Hu Y, Luke KH, **Poon M-C**, Blanchette V, Young NL. **A Quality of Life Study (CHO-KLAT) of Boys with Severe Hemophilia A (HA) in China: A comparison of on-demand to short-term full-dose prophylaxis.** World Federation of Hemophilia (WFH) 2014 World Congress, Melbourne Australia, May 11-15. *Haemophilia* 2014; 20 (Suppl. 3): 97
- 255 \*Lee A, Sinclair GD, **Poon M-C**. VWF propeptide (VWFpp) demonstrates the relationship between antibody-mediated VWF clearance and VWF production in the phenotypic expression in a case of acquired von Willebrand Syndrome (aVWS). World Federation of Hemophilia (WFH) 2014 World Congress, Melbourne Australia, May 11-15 *Haemophilia* 2014; 20 (Suppl. 3): 113-114
- 256 Card RC, **Poon M-C**. An Oral History of the Development of the Hemophilia Clinic Directors Group in Canada. World Federation of Hemophilia (WFH) 2014 World Congress, Melbourne Australia, May 11-15 *Haemophilia* 2014; 20 (Suppl. 3): 141
- 257 \*Vijay A, Lee A, Poon M-C, Vijayakumar N. Challenges of hemophilia care in a developing country. University of Calgary Department of Medicine Residents Research Day, Calgary, Canada, April 27, 2016
- 258 Chitlur M, Rajpurkar M, Recht M, Cooper D, d'Oiron R, Zotz R, Di Minno G, **Poon M-C**. Independent Adjudicator assessment of efficacy of recombinant factor VIIa in bleeding/surgery in the Glanzmann's Thrombasthenia Registry (GTR). The Hemostasis and Thrombosis Research Society (HTRS) 2015 Scientific Symposium, New Orleans, LA, USA Apr 16-18. *Haemophilia* 2015; 21: e261
- 259 Recht M, Rajpurkar M, Chitlur M, Cooper D, d'Oiron R, Zotz R, Di Minno G, **Poon M-C**. Results of assessment of refractoriness of the observational multinational Glanzmann's Thrombasthenia Registry (GTR). The Hemostasis and Thrombosis Research Society (HTRS) 2015 Scientific Symposium, New Orleans, LA, USA Apr 16-18. *Haemophilia* 2015; 21: e273
- 260 \*Lee A, \*Khanna P, **Poon M-C**. Patient-reported fractures in Hemophilia. 14<sup>th</sup> International Musculoskeletal Congress, May 7-10 (*Haemophilia* 2015)
- 261 Steele M, VanGunst S, Odiaman L, **Poon M-C**, Jackson S. Benign joint hypermobility syndrome is prevalent in children with undefined bleeding disorders. [XXV Congress of the International Society on Thrombosis and Haemostasis, Toronto, Canada, June 20-25, 2015; Abstract #PO440-Tue). *J Thromb Haemost* 2015;13 (Suppl S2): 666
- 262 \*Serebrin A, vanGunst S, Poon M-C, Steele M. Subcutaneous DDAVP use in pediatric von Willebrand disease and hemophilia A. American Society of Pediatric Hematology/Oncology 29<sup>th</sup> Annual meeting (May 11-14, 2016, Abstract 565)
- 263 Luke KH, **Poon M-C**, Sun J, Wu RH, Chen LX, Hilliard P, Feldman B, Young N, Doria A, Abad A, Blanchette. A successful nine-year journey by a China-Canada professional collaboration to transfer current hemophilia assessment tools to advance pediatric hemophilia care in China. World Federation of Hemophilia (WFH) 2016 World Congress, Orlando, USA, July 24-28 (oral poster presentation); *Hemophilia* 2016; 22 (suppl S4):8
- 264 \*Sun HWL, Yang M, Fung M, Chan S, Anderson T, **Poon M-C**, Jackson S. Macrovascular and microvascular endothelial function in adult males with hemophilia. World Federation of Hemophilia

- (WFH) 2016 World Congress, Orlando, USA, July 24,-28 (oral presentation); *Hemophilia* 2016; 22 (suppl S4):40
- 265 \*Vijay A, Pillai VN, Viswam D, SD Susmita, Sidharthan N, Lee A, **Poon M-C**. Challenges of Hemophilia care in a developing country. World Federation of Hemophilia (WFH) 2016 World Congress, Orlando, USA, July 24,-28, 2016 (poster presentation)
- 266 \*Davies GA, **Poon M-C**, Rydz N, Goodyear MD. Attitudes Toward Prenatal Diagnosis and Pregnancy Management in Carriers of Hemophilia: A Qualitative Analysis Exploring the Views of Carriers in Southern Alberta. American Society of Hematology Annual Scientific Meeting, San Diego, CA December 3-6, 2016 (abstract 4742)
- 267 Sidharthan N, Pillai VN, Mathew S, Sudevan R, Viswam D, Joseph C, Soman S, Vijay A, Lee A, **Poon M-C**. Low Dose Secondary/Tertiary Prophylaxis Is Feasible and Effective in Resource Limited Setting in South India for Children with Hemophilia. American Society of Hematology Annual Scientific Meeting San Diego, CA December 3-6, 2016 (abstract 2336)
- 268 Zotz R, **Poon M-C**, Di Minno G, Bindslev N, d'Oiron R. Effectiveness and safety of rFVIIa in paediatric Glanzmann thrombasthenia patients: data from the international Glanzmann Thrombasthenia Registry. *Haemophili* 2017;23 (Suppl 2):120 (European Association for Haemophilia and Allied Disorders and the Hemostasis & Thrombosis Research Society Xth Congress, Paris Feb 1-3, 2017 (Abstract P151)
- 269 \*Vijay A, Lee A, Vijayakumar N, **Poon M-C**. Low Dose prophylaxis in children with Hemophilia in Aluva, India: Outcome audit at 1 year. University of Calgary Department of Medicine Research Day, Calgary, Canada, May 17, 2917
- 270 \*Shivji S, Hews-Girard J, Goodyear D, Rydz N, Lee A, **Poon M-C**. A Case of Inhibitor Development After A FVIII Product Switch. Association of Hemophillia Clinic Directors of Canada Annual Meeting, Toronto, ON May 27, 2017
- 271 \*Wong A, Hews-Girard J, Fung T, Lee A, Goodyear D, Rydz N, **Poon M-C**. Prevalence of postpartum hemorrhage in Von Willebrand disease patients with adequate Von Willebrand factor activity: a quality improvement retrospective review of 52 pregnancies. Association of Hemophillia Clinic Directors of Canada Annual Meeting, Toronto, ON May 27, 2017
- 272 Lee A, Rayond D, Burt L, Jackson S, McKay H, Boyd S, Kline G, **Poon M-C**. Compartmental high resolution 3D imaging by HR-pQCT reveals low bone mineral density in hemophilia patients is attributed to loss of trabecular bone. XXVI Congress of the International Society on Thrombosis and Haemostasis, Berlin, Germany, July 10-13, 2017 (Poster 204-PB, DOI 10.3252/pso.eu.ISTH2017.2017)
- 273 Hua BL, Lee A, Fan LK, Li KX, Zhang YH, **Poon M-C**, Zhao YQ. Low-dose Factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption. XXVI Congress of the International Society on Thrombosis and Haemostasis, Berlin, Germany, July 10-13, 2017
- 274 **Poon M-C**, Card RT. First successful treatment of hemophilia with blood transfusion – could this also be the first successful bypassing therapy on record? Association of Hemophillia Clinic Directors of Canada Annual Meeting, Quebec City, PQ. June 2, 2018 (poster presentation)
- 275 Card TR, **Poon M-C**. First Successful Blood Transfusion of a Hemophiliac: a Collaboration between Samuel Armstrong Lane and James Blundell in London (1840). Why did it take more than 100 years before this became accepted practice? / La première transfusion sanguine d'un hémophile : une collaboration entre Samuel Armstrong Lane et James Blundell à Londres (1840). Pourquoi a-t-il fallu 100 ans avant que la pratique ne soit acceptée? Canadian Society for the History of Medicine Annual Meeting. May 25-28, 2018 (oral presentation)

- 276 Hews-Girard J, **Poon M-C**. DDAVP responsiveness and clinical outcomes: A Canadian single center experience. 2018 World Federation of Haemophilia Congress, Glasgow, UK May 20-24, 2018 (abstr W-FPR-003(57), oral presentation) *Haemophilia* 2018;24(Suppl S5): 55-56 (Oral presentation – competition for Christine Lee prize for early career investigators)
- 277 Anthony S, Goodyear D, **Poon M-C**, Hews-Girard J. Physiotherapy assessment following emergency department visits by patients with hemophilia: a Canadian, single-centre experience. 2018 World Federation of Haemophilia Congress, Glasgow, UK May 20-24, 2018 (poster presentation)
- 278 Rand M, Bowman M, Cloutier S, Jackson S, **Poon M-C**, James P. Intrinsic Dysfunction in Platelets from Patients with von Willebrand Disease Type 2B,(VWD2B). Association of Hemophilia Clinic Directors of Canada Scientific meeting, Montreal, Canada May 25, 2019
- 279 Rand M, Bowman M, Cloutier S, Jackson S, **Poon M-C**, James P. Insights into defects in Ca<sup>2+</sup>-mobilization in platelets from patients with von Willebrand disease type 2B (VWD2B). 2019 XXXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne July 6-10, 2019 Abstr PB0434, (poster presentation)
- 280 Chitlur M, Carcao M, Cooper D, Jain S, Kavakli K, Kerlin B, Peltier S, **Poon M-C**, Saad H, Shapiro A. An update on rFVIIa use in females with rare bleeding disorders. American Society of Hematology Annual Scientific Meeting, Orlando, FL, December 7-10, 2019 (poster presentation #1119)
- 281 \*Li Z, Chen ZP, Cheng XL, Wu XY, Gang L, Zhen YZ, Cai SY, Poon M-C, Wu RH. Low-dose immune tolerance induction for hemophilia A children with poor-risk high-titer inhibitors. American Society of Hematology Annual Scientific Meeting, Orlando, FL, December 7-10, 2019 (poster presentation #1122)
- 282 Yang R, **Poon M-C**, Luke KH, Zhao Y, Sun J, Wang X, Wu R, Chen L, Zhang X, Wu J. Building a network for hemophilia care in China: 5 years achievement of the Hemophilia Treatment Center Collaborative Network of China (HTCCNC). American Society of Hematology Annual Scientific Meeting, Orlando, FL, December 7-10, 2019 (Global Capacity-Building Showcase poster presentation)
- 283 Lee A, Chow L, Nicholas J, Skeith L, Poole AW, **Poon M-C**, Agbani EO. (2020). Platelet Procoagulation and Microthrombi in Preeclampsia: BSHT- British Society of Haemostasis and Thrombosis Annual Scientific Meeting. Birmingham, England, January 23-24, 2020.
- 284 \*Li Z, Chen Z, Cheng X, Wu X, Li G, Zhen Y, Cai S, **Poon M-C**, Wu R. Successful inhibitor eradication for hemophilia A children with poor-risk high-tier inhibitor using low-dose immune tolerance induction strategy [ISTH 2020 Congress abstract PB1077] *Res Pract Thromb Haemost* 2020;4 (Suppl 1). <https://abstracts.isth.org/abstract/successful-inhibitor-eradication-for-hemophilia-a-children-with-poor-risk-high-titer-inhibitor-using-low-dose-immune-tolerance-induction-strategy/>
- 285 Matino D, Iorio A, Keepanasseril A, Germini F, Birkegard AC, Cailaud A, Carcao M, Hews-Girard J, Iserman E, James P, Lee A, Phua C, Sun H, Teitel J, **Poon M-C**. A Canadian, multi-center, retrospective, non-interventional study of clinical outcomes from early use of N9-GP compared with previous treatment in patients with hemophilia B in a real-world setting [ISTH 2020 Congress abstract PB0905] *Res Pract Thromb Haemost* 2020;4 (Suppl 1). <https://abstracts.isth.org/abstract/a-canadian-multi-center-retrospective-non-interventional-study-of-clinical-outcomes-from-early-use-of-n9-gp-compared-with-previous-treatment-in-patients-with-hemophilia-b-in-a-real-world-setting/>
- 286 Gregory AJ, Walker AM, Dobson G, **Poon M-C**, Hollenberg M, Poole AW, Agbani EO. Platelet procoagulant membrane dynamics in cardiac surgery with cardiopulmonary bypass: outcomes of a pilot study [ISTH 2021 Congress abstract PB0435] *Res Pract Thromb Haemost* 2020;4 (Suppl 1). <https://abstracts.isth.org/abstract/platelet-procoagulant-membrane-dynamics-in-cardiac-surgery-with-cardiopulmonary-bypass-outcomes-of-a-pilot-study/>
- 287 Rand M, James P, Wang H, Bang KWA, Bowman M, Cloutier S, Jackson S, **Poon M-C**. Variability in platelet function among patients with von Willebrand disease type 2B (VWD2B): Focus on patients with

- historically diagnosed with Montreal Platelet Syndrome (Historic-MPS) [ISTH 2020 Congress abstract PB1672] *Res Pract Thromb Haemost* 2020;4 (Suppl 1). <https://abstracts.isth.org/abstract/variability-in-platelet-function-among-patients-with-von-willebrand-disease-type-2b-vwd2b-focus-on-patients-historically-diagnosed-with-montreal-platelet-syndrome-historic-mps/>
- 288 Lee A, Germini F, **Poon M-C**, Keepanasseril A, Ibrahim Q, Shang A, Nissen F, Meier O, Sima CS, Matino D, Iorio A. Anaanalysis of hemophilia A outcomes and treatment patterns using real-world data from the Canadian Hemophilia Bleeding Disorder Registry. American Society of Hematology 62nd Annual Scientific Meeting (Virtual), December 2-10, 2020 (poster presentation #1793) *Blood* (2020) 136 (Supplement 1): 37–38.
- 289 Lee A, Chow L, Nicholas J, Skeith L, Poole AW, **Poon M-C**, Agbani EO. Platelet membrand procoagulation in preeclampsia. American Society of Hematology 62nd Annual Scientific Meeting (Virtual), December 2-10, 2020 (poster presentation #2665) *Blood* (2020) 136 (Supplement 1): 7. (oral poster presentation)
- 290 \*Cusano E, Hows-Girard J, **Poon M-C**, Lee A. Case series: outcome and cost analysis of Rituximab versus non-targeted immunosuppression as first line inhibitor eradication in acquired hemophilia A. American Society of Hematology 62nd Annual Scientific Meeting (Virtual), December 2-10, 2020 (poster presentation #)
- 291 **Poon M-C**, d’Oiron R, Baby S, Zotz R, Di Minno G. The Glanzmann’s Thrombasthenia Registry (GTR): Safety of platelet therapy in patients with Glanzmann’s thrombasthenia, with a focus on changes in alloimmunization status. [ISTH 2021 Congress abstract PB0893] *Res Pract Thromb Haemost*. 2021;5 (Suppl 1). <https://abstracts.isth.org/abstract/the-glanzmanns-thrombasthenia-registry-gtr-safety-of-platelet-therapy-in-patients-with-glanzmanns-thrombasthenia-with-a-focus-on-changes-in-alloimmunization-status/> (poster presentation)
- 292 Bowman M, Grabell J, Paterson AD, **Poon M-C**, Jackson S, Lillicrap D, Haller G, Sadler B, James P. Enrichment of variants in platelet genes in patients with bleeding of unknown cause. [ISTH 2021 Congress abstract LPB0082] *Res Pract Thromb Haemost*. 2021;5 (Suppl 2). <https://abstracts.isth.org/abstract/enrichment-of-variants-in-platelet-genes-in-patients-with-bleeding-of-unknown-cause/> (oral poster presentation)
- 293 \*Li Z, Chen Z, Liu G, Cheng X, Yao W, Huang K, Li G, Zhen Y, Wu X, Cai S, **Poon M-C**, Wu R. The efficacy and prognosticator for inhibitor eradication in hemophilia A boys with high-titer inhibitors using a low-dose immune tolerance induction strategy (with or without immunosuppressants): data from the National Center for Children’s Health of China [ISTH 2021 Congress abstract PB0520] *Res Pract Thromb Haemost*. 2021;5 (Suppl 2). <https://abstracts.isth.org/abstract/the-efficacy-and-prognosticator-for-inhibitor-eradication-in-hemophilia-a-boys-with-high-titer-inhibitors-using-a-low-dose-immune-tolerance-induction-strategy-with-or-without-immunosuppressants-dat/> (poster presentation)
- 294 Sale T, Roessner C, Goodyear D, Lee A, **Poon M-C**, Rydz N. Increasing and optimizing the use of disease modifying interventions in the sickle cell disease opulation within the Southern Alberta Rare Blood and Bleeding Disorders (SARBVD) Comprehenisve Care Program: a quality assessment and improvement initiative. 49th Sickle Celle Disease Association of America (SCDAA) Annual National Convention (Virtual), October 12-16, 2021 (oral presentation)
- 295 Sale T, Roessner C, Goodyear D, Lee A, **Poon M-C**, Rydz N. Identification of knowledge gaps in red blood cell transfusion support in the sickle cell disease population within the Southern Alberta Rare Blood and Bleeding Disorders (SARBBD) Comprehensive Care Program: a quality assessment and improvement initiative. 49th Sickle Celle Disease Association of America (SCDAA) Annual National Convention (Virtual) October 12-16, 2021 (oral presentation)
- 296 **Poon M-C**, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Nissen F, Sanabria F, Santos M, Iserman E, Matino D, Iorio A. Emicizumab outcomes in hemophilia using real-world data from the Canadian

- Hemophilia Bleeding Disorder Registry. 63rd American Society of Hematology (ASH) Annual Scientific Meeting, Atlanta, GA, USA. Dec 11-14, 2021 (Abstr 347, oral presentation)
- 297 Roesner C, Sale T, **Poon M-C**, Goodyear D, Lee A, Rydz N. A Pharmacist-Managed Protocol Improves Hydroxyurea Uptake and Optimization among Patients with Sickle Cell Disease within The Southern Alberta Rare Blood and Bleeding Disorders (SARBBDD) Comprehensive Care Program. 63rd American Society of Hematology (ASH) Annual Scientific Meeting, Atlanta, GA, USA. Dec 11-14, 2021 (Abstr 1896, poster presentation)
- 298 Agbani E, Chaturvedi S, Lee A, Schneider P, Barber RW, Yamaura L, Main K, Garven A, Mahe E, Dufour A, Clarke AE, Choi MY, **Poon M-C**, Poole AW, Skeith L. Spleen tyrosine kinase activation drives platelet procoagulation in antiphospholipid syndrome during pregnancy. [abstract OC 51.4]. <https://abstracts.isth.org/abstract/spleen-tyrosine-kinase-activation-drives-platelet-procoagulation-in-antiphospholipid-syndrome-during-pregnancy/> ISTH 2022 Congress July 9-13, 2022 (London) (Oral presentation)
- 299 \*Li Z, Liu G, Yao W, Chen Z, **Poon M-C**, Wu R. Eradication of FIX inhibitor in haemophilia B children: a retrospective study from haemophilia pediatric comprehensive care center of China <https://abstracts.isth.org/abstract/eradication-of-fix-inhibitor-in-haemophilia-b-children-a-retrospective-study-from-haemophilia-pediatric-comprehensive-care-center-of-china/> [abstract VPB1166] ISTH 2022 Congress July 9-13, 2022 (London) (poster presentation)
- 300 **Poon M-C**, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Nissen F, Moreno K, Santos M, Iserman E, Matino D, Iorio A. Real-world outcomes of emicizumab in hemophilia A with or without FVIII inhibitors from the Canadian Hemophilia Bleeding Disorder Registry. American Society of Hematology 64nd Annual Scientific Meeting, December 10-13, 2022 (poster presentation, abstract #3796)
- 301 \*Cusano E, Sun HL, Goodyear MD, **Poon M-C**, Seal D, McClure RS, Rydz N. Comparison of activated clotting time to Hepcon protamine titration for anticoagulation management during cardiopulmonary bypass surgery in a patient with severe hemophilia A on Emicizumab prophylaxis. American Society of Hematology 64nd Annual Scientific Meeting, December 10-13, 2022 (poster presentation, abstract #1169)
- 302 \*Li Z, **Poon M-C**, Liu G, Li Z, Sun J, Wu R. Shorter time interval from inhibitor detection to starting low-dose immune tolerance induction therapy is associated with better inhibitor eradication outcomes in severe hemophilia A children with high-titer inhibitors in China. American Society of Hematology 64th Annual Scientific Meeting, December 10-13, 2022 (poster presentation, abstract #1168)
- 303 \*Chandrakumaran P, Hews-Girard J, **Poon M-C**. Desmopressin use in patients with von Willebrand disease: a single-centre retrospective review of test response and clinical outcomes. 16<sup>th</sup> Congress of the European Association for Haemophilia and Allied Disorders, Manchester, UK, February 7-10, 2023. (poster presentation PO216, abstract #1540) *Haemophilia* 2023;29(suppl 1):145
- 304 Skeith L, James P, Kouides P, \*Uminski K, Duffett L, Jackson S, Sholzberg M, Ragni MV, Cuker A, O'Brien M, \*Rubinstein S, Hews-Girard JC, Rydz N, Goodyear D, Baxter J, James A, Garcia P, Vesely, SK, **Poon M-C**. A multicentre cohort study evaluating pregnancy loss in patients with von Willebrand disease and unspecified bleeding disorders. [abstract OC25.3] ISTH 2023 Congress Jun 24-28, 2023 Montreal) (oral presentation)
- 305 Hews-Girard, JC, **Poon M-C**. To Test or Not to Test: Do all individuals with non-severe hemophilia A need DDAVP response testing? [abstract PB0697] ISTH 2023 Congress Jun 24-28, 2023 Montreal) (poster presentation)
- 306 Agbani EO, \*Young D, Shen SA, Smith S, Lee A, Poole AW, Dufour A, **Poon M-C**. Membrane Procoagulation and N-Terminomics/TAILS Profiling in Montreal Platelet Syndrome Kindred with VWF p.V1316M mutation [abstract PB0864] ISTH 2023 Congress Jun 24-28, 2023 Montreal) (poster presentation)



- 307 Wang Z, Wang N, Ouyang J, Ma J, Poon M-C, Chen A, Cheng Z, Wu R. Long-term eltrombopag in children with chronic immune thrombocytopenia: A single extended real-life observational study in China. American Society of Hematology 65<sup>th</sup> Annual Scientific Meeting, December 9-12, 2023, San Diego (poster presentation, abstract #2590)
- 308 Li Z, Poon M-C, Wu R. Low-dose immune tolerance induction therapy for severe hemophilia A inhibitor patients: Immunosuppressants improve outcomes but are generally not necessary for inhibitor titers below 200 BU/mL. American Society of Hematology 65<sup>th</sup> Annual Scientific Meeting, December 9-12, 2023, San Diego (poster presentation, abstract #3988)
- 309 Poon M-C, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Polito L, Moreno K, Santos M, Iserman E, Matino M, Iorio A. Experience with emicizumab among people with hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry. American Society of Hematology 65<sup>th</sup> Annual Scientific Meeting, December 9-12, 2023, San Diego (poster presentation, abstract #1240)
- 310 **Poon M-C**, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Polito L, Moreno K, Santos M, Iserman E, Matino D, Iorio A. Long-term effectiveness and safety of emicizumab in people with hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry. International Society for Thrombosis and Haemostasis 2024 International Congress June 22-27, Bangkok Thailand (poster presentation, abstract #PB0202)
- 311 Xu Y, Wang Y, Wu R, Zheng C, Zhang L, Xu W, Feng X, Wang H, Cao X, He L, Xue T, Jin M, Xie B, Ling J, Sun L, **Poon M-C**, Liu W, Zhang L, Xue F, Yang R. Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicenter real-world study in China. International Society for Thrombosis and Haemostasis 2024 International Congress June 22-27, Bangkok Thailand (poster presentation, abstract #PB0265)
- 312 Pardy N, Teitel J, St-Louis J, Strike K, Lalonde K, Isler M, Iorio, A, Decker K, Thibault, **Poon, M-C**. A Canadian roundtable discussion of the peri-operative use of nonacog beta pegol (N9-GP) for persons with moderate to severe hemophilia B. International Society for Thrombosis and Haemostasis 2024 International Congress June 22-27, Bangkok Thailand (poster presentation, abstract #PB0547)
- 313 Mao Q, Chen Z, Liu G, Li G, Zhen Y, Cheng X, Li Z, Yao W, Ai D, Li Z, Wang N, **Poon M-C**, Wu R. Real-world use of emicizumab in Chinese children with hemophilia A: retrospective data from a comprehensive care center. International Society for Thrombosis and Haemostasis 2024 International Congress June 22-27, Bangkok Thailand (poster presentation, abstract #PB0613)
- 314 Li, Z, Li Z, Cheng X, Zhang H, Yang C, Xu Q, Chen Z, Zhen Y, Li G, Liu G, Yao W, Zhou M, Jin J, Huang J, Fang Y, Xie L, **Poon M-C**, Wu R. Intermediate-dose immune tolerance induction is more cost-effective: a multicenter randomized clinical trial (LOME). International Society for Thrombosis and Haemostasis 2024 International Congress June 22-27, Bangkok Thailand (oral presentation, abstract #OC61.3)
- 315 Cusano E, Hews-Girard J, Basharat M, Cowley L, Grabell J, Hodgson N, Pittman K, Rupnaraine A, Thillaye-Kerr R, Lethebe CB, James P, Khalifé R, Pardy N, Phua CW, Prokopchuk-Gauk O, Sholzberg M, Sun HL, **Poon M-C**, Goodyear D. Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia A. American Society of Hematology 66<sup>th</sup> Annual Scientific Meeting, December 7-10, 2024, San Diego, CA (oral presentation, abstract #)

